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Abstract
Streptococcus pneumoniae is the most common bacterial cause of
community-acquired meningitis world-wide. Despite optimal antibiotic
therapy and supportive care, the mortality of this condition remains very
high at over 60% in under-resourced hospitals. There is an urgent need
for more information about the mechanismsofbrain damage and death in
pneumococcal meningitis so that new treatments can be designed.
Using proteomic techniques and bioinformatics the protein content
of cerebrospinal fluid was examined in great detail. A significant
difference in the level of protein in normal CSF andclinically diagnosed
meningitis was observed. 34 proteins were found to have an association
with survival. Mass spectrometry allowed identification of these proteins.
A subset of these identified proteins was validated using Western blot. In
this thesis it has been observedthat transferrin shows increased levels in
CSF from non-survivors and complement C3 appears to show reduced
levels in CSF from non-survivors in a larger sample size.
Animal models have added greatly to our knowledge of possible
mechanisms of cell death and shown that hippocampal apoptosis and
cortical necrosis are distinct mechanisms of neuronal death. The
contribution of these pathways to human disease is unknown. Specific
targets were selected from neuronal death pathways and from known
pneumococcal proteins for confirmation in CSF using Western blot. In
this study I will show that proteins associated with apoptosis are absent
from CSF and there is low expression levels of proteins indicative of
necrosis. In addition pneumococcal proteins remain at high
concentrations in CSF after treatment. This information couldleadto the
design of novel therapies to minimise brain damage and lower mortality.
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CHAPTER1
GENERAL INTRODUCTION
Upali R. Goonetilleke Chapter 1
1.1 The Clinical Problem of Meningitis
Streptococcus pneumoniae is the most commonpathogenassociated
with bacterial meningitis beyond the neonatal period (1). Pneumococcal
meningitis has a high fatality rate of 19 — 37% even with optimal
treatment and is much worse in under resourced nations (2). For example
pneumococcal meningitis in Malawi has a high fatality rate of 61% (3).
Survivors of the infection often develop long-term neurological sequelae,
including hearing loss and other focal neurologicaldeficits (4).
Pneumococci are able to colonise the nasopharynx without
developing any serious consequences. Pneumococcal carriage rates in
youngchildren vary from over 40% in developed nations such as USA.to
87% in developing nations such as Gambia (5;6). Pneumococcalcarriage
rates in adults vary from approximately 10% in developed nations such as
USA. to 51% in developing nations such as Gambia (7). When
pneumococcispread to the sinuses, ear, lung and blood stream,diseases
such as sinusitis, Otitis media, pneumonia and septicaemia can result
(Figure 1.1).
1.2 The Pneumococcus
1.2.1 History ofthe Pneumococcus
Streptococcus pneumoniae is an ovoid gram-positive bacterium
which was identified more than one hundred years ago as the causative
agent of pneumonia (8). It is responsible for millions of deaths
worldwide, in particular, across the African ‘meningitis belt’ (an area
which stretches from Ethiopia through to Senegal). This hyper-endemic
area is characterised by particular climate andsocial habits.
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Figure 1.1 Outcome of pneumococcal invasion. When pneumococci
spread to the sinuses, ear, lung and blood stream, diseases such as
sinusitis, Otitis media, pneumonia and septicaemia can result. Invasion of
the central nervous system (CNS) by colonising pneumococci follows an
alteration in the balance between the virulence of the bacteria and the
defences of the patient. Factors such as common colds or other upper
respiratory virus infections alter the lining of the respiratory tract and
allow bacteria to enter the bloodstream. Pneumococci then actively
translocate across intact endothelial layers by means ofspecific receptor
binding andtranslocation. Endothelial cells normally separate the blood
from neuronaltissueforming a protective blood-brain barrier (BBB). The
integrity of the BBB is compromised by apoptosis of endothelial cells.
The BBB breakdownallowsfurther invasion ofcerebrospinalfluid (CSF)
(9).
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1.2.2 Pneumococcal Serotypes
Pneumococci have a highly developed capsule of great variation in
chemical composition and of type specific capsular polysaccharides.
Consequently pneumococci have at least 91 serologically distinguishable
capsular polysaccharide types which comprise 48 cross-reactive groups
(10).
The serotyping scheme for pneumococci has been updated many
times, and the 91 currently recognized serotypes probably represent a
high proportion of the total capsule diversity in the species, although a
variant within serogroup 6 (serotype 6C) has been reported (11).
Amongthe 91 different pneumococcal serotypes, only a few account
for the majority of invasive pneumococcal diseases and their relative
frequency depends on age and sex and varies geographically (12).
Regional differences in the prevalence of specific serotypes highlight the
importance of knowingthe serotypes for each geographicarea(13).
These capsules are hydrated, negatively charged shells (except 7F,
7A, 14, 33F, and 37 species) which control diffusion, adherence and
formation of biofilms and microcolonies.
1.3 Pathogenesis of Pneumococcal Meningitis
1.3.1 Signs and Symptoms ofPneumococcal Meningitis
As with other forms of bacterial meningitis, pneumococcal
meningitis is characterised by headache, fever, nuchalrigidity and altered
mental status. The petechial rash associated with meningococcal
meningitis, however, is absent in pneumococcal meningitis. Few patients
haveall the symptoms but almostall patients (95%) have at least two of
the four symptoms(4).
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1.3.2 Pneumococcal Invasion
Pneumococci colonise the nasopharynx and attach to the
nasopharyngealcells of the upper and lowerrespiratory tract (14). This is
facilitated by the presence of choline binding protein A (CbpA or
pneumococcal surface protein C, PspC) on the cell wall of the
pneumococcus (15). Invasion by colonising pneumococci follows an
alteration in the balance between the virulence of the bacteria and the
defencesofthe patient (16). Factors such as commoncoldsor other upper
respiratory virus infectionsalter the lining of the respiratory tract and aid
pneumococcal translocation across intact epithelial layers (17). This 1s
achieved by means of specific receptors such as the polymeric
immunoglobulin receptor and platelet activating factor receptor
(16;18;19).
1.3.3 Translocation ofPneumococci into the CNS
Endothelial cells normally separate blood from neuronal tissue
forming a protective blood-brain barrier (BBB). Theintegrity of the BBB
is compromised by apoptosis of endothelial cells. The BBB breakdown
allows further invasion of cerebrospinal fluid (CSF) (20-22). It has been
observed in somechildren, that bacteria can translocate directly from the
nasopharynx into the CNS via olfactory neurones (23). A non-
haematogenousroute has also been demonstrated in animal models(24).
1.3.4 Outcome ofCSFHost Inflammatory Response
Theinitial host inflammatory response is initiated by pneumococcal
capsular polysaccharides and surface proteins, such as pneumolysin and
PspA (25;26). Most of the tissue damage associated with meningitis is
caused by host response. This may include the action of phagocytes,
secreted granular toxins, cytokines, leukotrienes, matrix
metalloproteinases and the direct pressure effect of cerebral oedema
causing ischaemia (27).
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1.3.5 Neuronal Cell Death and Meningitis
Pneumococcal proteins have been shown to contribute to neuronal
cell death in animal models (28). For example pneumolysin can induce
apoptosis of microglial and hippocampal neurones in a rat model at
concentrations as low as 0.1 gm’! (29). Neuronal cell death has been
determined to occurvia three distinct pathways(30);
(i) Classic caspase-3—dependent cell death which leads to
apoptosis or programmedcell death.
(ii) Caspase-3-independent cell death which leads to pyknosis
(irreversible condensation of chromatin in the nucleusofa cell
undergoing programmedcell death or apoptosis).
(iii) Necrosis, the unnatural death of cells and living tissue through
cell swelling, chromatin digestion, and disruption of the
plasma membraneand organelles.
Neuronal Cell Death in the Hippocampus
Animal models have been used to determine the mechanism of
pneumococcal related neuronal apoptosis. In the rabbit model of
pneumococcal meningitis hippocampal apoptosis was found to be the
predominant form of neuronal damage (31;32). Inhibition of
phosphorylcholine synthesis in mitochondria of neurons in the
hippocampal dentate gyrus leads to mitochondrial release of apoptosis
inducing factor (AIF) which in turn causes pyknosis of the hippocampus.
In an adult mouse model both caspase-dependent and independent forms
of neuronalcell death have been described in the dentate gyrus of adult
mice (33). Bacterial cell wall products initiate mitochondrial release of
cytochrome c leading to classic toll-like receptor (TLR) dependent-
caspase-3 mediated apoptosis occurring more widely in the brain. Infant
rat models of pneumococcal meningitis showed similar neuronal damage
patterns to humandisease (34:35). Also in the infant rat meningitis model
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apoptosis and pyknosis of neurons have been identified in the dentate
gyrus of the hippocampus. In humans evidence of apoptosis has been
observed in the dentate gyrus. The location of the dentate gyrus in the
human brain is shown in Figure 1.2 (36). Apoptosis primarily affects the
subgranular zone containing recently divided immature neurons.
Pyknosis occurs throughout the dentate granularcell layer. Both mature
and immature neuronsare affected as a result (34).
Neuronal Cell Death in the Cortex by Necrosis
A feature of severe pneumococcal meningitis is ischemic damage of
neurons in the ischemic core of the cortex which results in necrosis in
addition to caspase-3 dependent cell death (34;37;38). Inflammation of
the meninges leads to oxygen and glucose deprivation of neuronal cells.
The release of excitatory neurotransmitters from glutamatergic neurons
lead to glutamate receptor overactivation. This leads to Ca’* influx,
subsequent injury and eventually neuronal necrosis (39). Energy
depletion is a potent trigger of necrosis. During ischemic and
hypoglycaemic episodes, lack of oxygen or essential nutrients leads to a
shortage of energy to sustain the membrane potential (40). Necrosis has
been commonly thoughtof as a passive process but neuronal necrosis and
neuronal apoptosis may share a final commonpath i.e. the mitochondrial
pathwayasillustrated in Figure 1.3 (41;42).
Creatine kinase brain type (CKBB) mayact as a marker of neuronal
cell death by necrosis. The small size of the dimeric enzyme meansit can
leak out of cells under ischemic episodes or injury to the brain. CKBB in
the CSF originates from neurons and astrocytes (43). CKBBactivity in
CSF has been shown to be elevated in neurological diseases including
infectious conditions (44).
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Figure 1.2 Potential cell death regions of the human brain. The
hippocampus is a part of the forebrain, located in the medial temporal
lobe. The hippocampus is used in storing and processing spatial
information. In the rabbit model of pneumococcal meningitis,
hippocampal apoptosis was found to be the predominant form of
neuronal damage. In humans apoptosis andpyknosis have been identified
in the dentate gyrus of the hippocampus. Apoptosis primarily affects the
subgranular zone containing recently divided immature neurons.
Pyknosis occurs throughout the dentate granular cell layer (9)
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Figure 1.3 Pathways leading to cell death. A The cell wall of S.
pneumoniae has a diverse protein population. Proteins such as
pneumolysin at a concentration of 0.lugml' can trigger apoptosis on
entering cells by targeting mitochondria. In addition oxidising
components such as hydrogen peroxide can trigger apoptosis and
necrosis. B The adaptor protein FADD activates caspase-8 to form a
signal complex to directly activate caspase-3. The mitochondrial stress
pathway is initiated when proapoptotic proteins in the cytoplasm
stimulate the rupture of the mitochondria. In the caspase dependant
pathway, cytochrome c releasedfrom the mitochondria forms a complex
in the cytoplasm with ATP and apoptotic protease activating factor -1
(Apaf-1) and activated caspase-9 called an apoptosome which activates
caspase-3. The caspase independent pathway (pyknosis) is as a result of
apoptosis inducing factor (AIF). The necrotic pathway is activated in
severe meningitis. Alterations in the concentration of cytoplasmic
calcium could signal the mobilisation ofexecutioner cathepsin proteases
andother hydrolases, through calpain activation (9).
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1.3.6 Host and Pathogen Proteins
Proteomic comparisonsof infected and normal CSF can be expected
to differ in the concentration of both pneumococcal proteins and host
proteins. Identification of pneumococcal proteins associated with poor
outcome may suggest either therapeutic possibilities or vaccine
candidates. Host proteins associated with poor outcome may suggest
pathways amenable to immunomodulation or therapeutic intervention.
Pathogen Proteins
Proteins associated with pneumococci may be found in the
pneumococcalcapsuleor the cell wall.
Capsule
Pneumococci have developed a unique survival mechanism in order
to evade the immune system. The capsule functions to protect the
pneumococcus from phagocytosis by polymorphonuclear leukocytes, by
physically shielding the inner structures from antibodies, separating
bound antibodies and complementreceptors on phagocytes (45;46).
Pneumococci which lack the capsule are normally avirulent and
antibodies to the capsular polysaccharides are protective (47). The
capsule as such does not cause inflammation (48). Oxygen levels were
discovered to affect the opaque (O) and transparent (T) phase variants
differently (17). Greatly enhanced production of capsular polysaccharide
in O variants in conditions of reduced oxygen such as the blood
circulatory system where discovered, whereas synthesis of capsular
polysaccharide in T variants remain comparatively low, under both
aerobic and anaerobic conditions such as the nasopharynx (17).
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Cell Wall and Cell Wall Polysaccharide
Pneumococci produce the antigenic polysaccharides teichioic acid
and lipoteichioic acid (Forssman antigen). These structures are unique
because they possess identical repeat and chain structures, unlike other
gram positive bacteria, in which they are different in both structure and
synthesis (49). Choline present within the structural cell wall plays a key
role in many ofthe functions of the organism. Replacementofthe choline
residues with the structural analog ethanolamine causes dramatic changes
in the cell physiology such as growth in long chains, loss of competence
for transformation, resistance to lysis etc. The exposed phosphocholine
acts as an adhesion ligand for pneumocytes and peripheral endothelial
cells. This also involves the platelet-activating-factor receptor which
enhancesadherence andpenetration ofhostcells (49).
PneumococcalProteins
The cell wall of S. pneumoniae has a diverse protein population,
and pathogenic expression of pneumoccal proteins are associated with
adherence to and colonisation of mucosal surfaces, resistance to specific
and non-specific host defences, penetration and invasion ofhosttissues,
and generation of tissue damage mediated either directly by toxins or
indirectly via inflammatory responses as summarised in Table 1.1. All the
proteins listed in Table 1.1 have been described in experimental studies
including animal models of meningitis and have been found to exhibit an
effect on inflammation and toxicity e.g. N-acetylmuramoyl-L-alanine-
amidase (LytA)is an autolytic enzyme required during cell division. Its
role in pneumococcal meningitis is unknown but has been shown in
various animal models to mediate toxicity and inflammation (50).
Proteins such as pneumolysin can stimulate the host response and
also enter cells though pore formation. It has the ability to trigger
apoptosis on entering cells by destruction of the mitochondria (50). In
11
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Table 1.1 Pneumococcalproteins associated with infection
 
Protein Description Action References
Enzynie required during cell Hydrolyses amide bonds between
LytA - .. 8 muramic acid and L-Alanine (50;51)division :residues
Anchored to th ter layer ofPspA outer ay Inhibits complementactivation (52)the plasma membrane
pneumococcal Novelfamily of cell surface- lnduines alifibedies capable aere : : protecting mice against (53;54)histidine triad (Pht) exposed proteins :pneumococcal sepsis and death
Pspc Surface protein Mediatesinvasion across human (15;55)
nasopharyngeal epithelial cells
Neuraminidasese.g. Cleaves terminal sialic acid
NanA and NanB residues Unanolr (Bes7)
A highl d set PHeatishock proteins ig y conserve set of roduced asa result of (58)
proteins temperatureshift
hyaluronatelyase Covalently linked to the cross- Degrades essential components
" (Hyal) ¥ bridges ofthe cell wall of the host's extracellular matrix (59)
¥ peptidoglycan (ECM)
34.5 kDa protein covalently Belongs to an ATPbindingpneumococcal surface. anchoredtothecell cassette (ABC)-type transport (60)antigen A (PsaA) membrane system
Induces leakage of solutes after
wearaaltn insertion into the lipid bilayer
felernsl once Ply) 53-kDa protein leading to membrane (61)
¥ ¥ destablisation altering the
membranepotential of the cell
. Catalyse the polymerisation of
polite ibid? S. pneumoniaecarry a .penicillin-binding : : . glycan chains and. relatively simple set of six ices sy2 (62)proteins (PBPs) PBPs transpeptidation of pentapeptidic
moieties
pneumococcal iron Lipoprotein components ofuptake (Piu) and iron Pop P Essential for iron uptake (63)
acquisition (Pia) iron ABC transport systems
 
The Pneumococcal proteins above have been identified as being
important contributors to the progression ofpneumococcal disease and
in particular in animal models ofmeningitis.
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addition oxidising components such as hydrogen peroxide can also
trigger apoptosis and necrosis. Both pneumolysin and autolysin have
been shown to play a crucial role in the pathogenesis of pneumococcal
meningitis in an adult rat model of meningitis (64).
Neuraminidases are a group of enzymes which can cleave terminal
sialic acid residues from a wide variety of glycan structures (56). The
pneumococcus produces two distinct neuraminidases, -acetylneuraminic
acid (NanA) and endo-B-1, 4-N-acetylglucosaminidase (NanB) (65;66).
There are several conflicting publications on the precise role of NanA in
pneumococcal disease, however an Otitis media chinchilla model
revealed NanA-deficient pneumococci are significantly less able to
colonise and persist in the nasopharynx and middle ear than NanA-
sufficient wild-type pneumococci (57). The relative contribution ofNanB
to disease has not been reported in either a sepsis or pneumonia model.
Host Defence Proteins
The host immuneresponse will most likely make up the majority of
proteins present in the CSF because these proteins will include host
immune response factors such as complement and cytokines, as well as
specific immunoglobulins and proteins from serum leaking to the CSF as
a result of the blood brain barrier breakdown (Table 1.2). Host proteins
that this thesis will aim to find include:
Complement Cascade Proteins
In the absence of specific antibodies, activation of the complement
cascade is imperative for the clearance of pneumococci. Many pathogenic
serotypes are able to resist phagocytosis by being pooractivators of the
alternative complement pathway and by degrading the deposited C3b into
opsonically less active components(67;68). The alternative pathway may
13
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Table 1.2 Selected Proteins Associated with the Host Immune
Response
 
Protein Description Action References
Complement
components
e.g. C3b, iC3b,
or C4b (CR1,
CR3).
IL-6
Interleukin-1
(IL-1)
IgG
Consists of a numberof
small proteins found in
the blood, normally
circulating as inactive
zymogens
A pro-inflammatory
cytokine.
A superfamily consisiting
of IL-1a, IL-1B, and the
IL-1 Receptor antagonist
(IL-LRA)
The most abundant
immunoglobulin. Equally
distributed in blood and
in tissue liquids.
Help clear pathogens from
an organism.
Secreted by T cells and
macrophagesto stimulate
immune responseto
trauma, leading to
inflammation.
They control lymphocytes.
IL-1a and IL-1B are
produced by
macrophages, monocytes
and dendritic cells
Activates complement
(classic pathway),
opsonization for
phagocytosis and
neutralisation of their
toxins.
(46)
(69)
(70)
(71)
 
Host immune responsefactors such as complement and cytokines, as well
as specific immunoglobulins andproteins from serum leaking to the CSF
have all been described as having an association with survival in
meningitis. The table above shows 4 proteins selectedfrom the immune
response which have beenidentified in analyses ofthe CSF samples used
in this study.
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be triggered by the capsular polysaccharides of some serotypes and by
capsular polysaccharides.
C-reactive protein (CRP) is an acute phase protein which may
interact with phosporylcholine residues of the capsule polysaccharide and
activate the classical pathway of complement. In exponentially growing
bacteria, the potential deposition of C3b to the cell wall excludes it from
interacting with phagocytes since capsular polysaccharide is concealed by
the capsule. Therefore phagocytosis of serotypes which lack
phosphorylcholine in their capsule is not enhanced by a capsular
polysaccharide or CRP mediated complement cascade. Transparent and
opaque phenotypes may differ in this respect, as suggested by the
enhanced phagocytic killing of the transparent but not opaque variant of
type 6B bacteria in the presence of increasing concentrations of CRP
(72).
Activation of complement generates not only opsonins to facilitate
phagocytosis but also the biologically active fragments C5a and C3a.
This increases vascular permeability and activates mast cells to release
inflammatory mediators. This attracts both polymorphonuclear
leukocytes (PMNL) and monocytes to the site of infection which induce
cytokine release from the phagocytes.
Whether complement is activated by classical, alternative, or the
mannan-binding lectin pathway, by antibody, CRP, pneumococcal
polysaccharide or lectins, the outcome is deposition of opsonising
complement proteins (C3b, iC3b, or C4b) on the capsule, alongside
specific IgG. Since phagocytic macrophages and PMNLconstitutively
express receptors for IgG (FcyRII, III) and complement components C3b,
iC3b, or C4b (CR1, CR3), these molecules act in concert to facilitate
phagocytosis, and are essential for pneumococcal clearance. The
importance of opsonisation is strongly supported by the finding that the
15
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impairment of either phagocytic system or opsonin production
predisposes the host to pneumococcaldisease.
Cell Death Proteins
These will include signalling molecules such as tumour necrosis
factor alpha (TNF-a (73), Fas and Fas-associated death domain protein
(FADD) as shown in Table 1.3 (74). These proteins can lead to apoptosis
through activation of transmembrane death receptors such as Fas which
causes receptors to aggregate together on the cell surface. This in turn
activates the adaptor protein Fas-associated death domain protein
(FADD) which then activates caspase-8, an initiator protein, to form a
signal complex. This complex is now able to directly activate caspase-3,
an effector protein, to initiate degradation of the cell. Active caspase-8
can also cleave BID protein to tBID, which acts as a signal on the
membrane of mitochondriato facilitate the release of cytochromec in the
intrinsic pathway.
The mitochondrial stress pathwayis initiated whena stress signal is
activated, proapoptotic proteins in the cytoplasm, BAX and BID,
stimulate the rupture of the mitochondria. The release of mitochondrial
content is aided by the protein BAK.In the caspase dependant pathway,
cytochrome c released from the mitochondria forms a complex in the
cytoplasm with adenosine triphosphate (ATP) and apoptotic protease
activating factor-1 (Apaf-1). This complex activates caspase-9, an
initiator protein. In return, the activated caspase-9 works together with
the complex of cytochrome c, ATP and Apaf-1 to form an apoptosome,
which in turn activates caspase-3, the effector protein that initiates
degradation (75).
The other cell death proteins include; caspase independent pathway
(pyknosis) whichis a result of apoptosis inducing factor (AIF). The
16
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Table 1.3 Selected Proteins Directly Associated with NeuronalCell
Death
 
Protein
Cytochrome
C (Cyt C)
Tumour
necrosis
factor (TNF-
a)
Caspases
Fas
FADD
BAX
Apoptosis
inducing
factor(AIF)
Creatine
kinase BB
(CKBB)
Description
A small hemeprotein found
loosely associated with the
inner membraneof the
mitochondrion.
TNF acts via the TNF Receptor
(TNF-R) andis part of the
extrinsic pathwayfor triggering
apoptosis.
Proteases, which exist as
inactive proenzymes
Ligand which Associated with
the Formsthe Death Inducing
Signalling Complex (DISC) upon
ligand binding.
An adaptor molecule that
bridges the Fas-receptor, and
other death receptors, to
caspase-8 throughits death
domain
A pro-apoptotic memberof the
Bcl-2 protein family
A flavoprotein foundin the
mitochondrial intermembrane
spacein healthy cells
Catalyse the reversible transfer
of a high-energy phosphate
group between
phosphocreatine (PCr) and ADP
to maintain intracellular ATP
levels in cells of high and
fluctuating energy demands
Action
CauseERcalcium release leading to
caspase 9 activation
Associates with procaspases through
adapter proteins (FADD, TRADD,etc.)
Play essential roles in apoptosis
(programmedcell death) and
inflammation
Fas pathwayis sufficient to induce
complete apoptosisin certain cell
types through DISC assembly and
subsequentcaspase-8 activation
Formsthe death inducingsignalling
complex (DISC) during apoptosis
Activated Bax formsan oligomeric
pore in the outer membrane
Essential for nuclear disassemblyin
apoptoticcells
Essential for storing, buffering and
intracellular transport of “energy-
rich” phosphate compoundsin
tissues with fluctuating high energy
demandsuch as muscle, brain and
othertissues and cells where CKis
expressed
References
(76)
(77)
(21)
(74)
(74)
(21)
(21)
(44)
 
Proteins associated with the apoptotic pathway may be released into
CSF. The levels of these proteins might increase during pneumococcal
meningitis as a result of both the inflammatory response and the release
ofpneumococcalproteins. The table above showsproteins selectedfrom
the cell death cascade which have been identified in animal models of
cell death and identified in the analyses of the CSF samples used in this
study.
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necrotic pathway is activated in severe meningitis. Alterations in the
concentration of cytoplasmic calcium signal the mobilisation of
executioner cathepsin proteases and other hydrolases, through calpain
activation. Calpains have been implicated in the activation of pro-
apoptotic caspase proteases; hence the later steps of necrosis correlate
with the later steps of apoptosis.
1.4 Current Treatment
1.4.1 Antibiotic Treatment
Pneumococci can be killed with antibiotics such as ceftriaxone or
cefotaxime. The choice of antibiotic depends on local patterns of
epidemiology and patterns of resistance. The emergence of penicillin
resistant isolates of pneumococci has hampered the use of B-lactam
antibiotics for the treatment of pneumococcal infection. Monotherapy
with penicillin can only be considered in areas with very low penicillin
resistance rates (< 1%), although many experts recommend combination
therapy forall patients (78).
In studies conducted in Egypt an association between mortality and
penicillin resistance was reported by several studies at different time
intervals, with an increase in the pattern of resistance overtime (79).
In light of this emergence of penicillin-resistant strains (78), more
advanced f-lactam antibiotics (cephalosporins) are commonly used in
combination with other drugs such as vancomycin to treat meningitis
(80). Delay in the initiation of antimicrobial therapy can result in poor
outcomein this disease (4). A major problem with antibiotic therapy is
that dead bacterial particulate matter can still stimulate inflammation.
Steroid co-treatment is often used as aresult.
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1.4.2 Steroid Therapy
The benefit of steroid therapy is still not completely known. In
developed nations, steroid adjuvant therapy has been shown to reduce
deaths in someadults, particularly in patients with mild pneumococcal
meningitis (81). Howevera large paediatric trial in Malawi demonstrated
no benefit from steroids in children with bacterial meningitis (82).
1.4.3 Trial ofDexamethasonein Adults in Malawi
A double blind, randomised, placebo controlled trial of
dexamethasone adjuvant therapy in adults with bacterial meningitis in
Malawi showed no advantage after 40 days of treatment (2). The
difference seen between Europe and Malawiis likely to have resulted
from differences in the severity of the cases. There remains an urgent
need for novel adjuvant therapy in the treatment on pneumococcal
meningitis worldwide.
1.4.4 Pneumococcalvaccinesfor meningitis
Current pneumococcal vaccineselicit immune responsesto cell-wall
polysaccharides of pneumococci. The older 23-valent pneumococcal
polysaccharide vaccine contains capsular polysaccharides of 23 serotypes
responsible for about 90% of invasive pneumococcalinfections (83). The
vaccine is poorly immunogenicin certain groups whoare at highrisk for
invasive pneumococcal infection, especially children younger than 2
years old (with relatively immature B cells), elderly people, and
immunocompromised patients. The immune response in infants and
young children can be improved by conjugation of pneumococcal
polysaccharides to carrier proteins that enable activation of T cells,
thereby enhancing antibody production and immunological memory (1).
In regions where the 23-valent vaccine is used, administration of the
vaccine is recommendedearly in the course ofHIV disease.
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Pneumococcal conjugate vaccines offer an alternative approach to
preventing pneumococcaldisease. The 7- and 9-valent conjugate vaccines
have been shown to be highly efficacious. Such vaccines are effective at
preventing invasive pneumococcal disease in HIV-infected children,
although with a lower efficacy and duration of effect than in children
without HIV infection (84;85).
1.4.5 Potentialfor New Therapy
Critical pathways for new therapy could potentially target the
apoptotic and necrotic pathways. For example; citicholine has been
shown to prevent neuronal damage when given before and after bacterial
infection in animal models of meningitis regardless of the route of
infection (86;87). Alternatively matrix metalloproteinase inhibitors could
prevent blood brain barrier damage. Matrix metalloproteinase’s (MMP)
are a family of zinc-dependent endopeptidases that show affinity to
different componentsofthe extracellular matrix. They have been shown
to play a role in the breakdown of the blood-brain barrier and the
facilitation of neuroinflammation in bacterial meningitis (88). In bacterial
meningitis MMPs may contribute to the development of brain injury by
both their proteolytic activity on the extracellular matrix and their ability
to increase the levels of soluble TNF-a, a pivotal element in the
meningeal inflammatory process. TNF-a is a strong stimulus for the
release and activation of MMPsinthe brain (89;90).
1.4.6 Critical Gaps in Knowledge
There are critical gaps in knowledge that need to be addressed
before new therapies can be implemented in meningitis. In particular
there is insufficient data to link human death in meningitis with the
mechanisms observed in animal models. High levels of CSF apoptosis
proteins in patients with neurological damage or death would provide a
basis for trials of citicholine. Alternatively, high levels of MMP and
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MMP-related damage would provide a case for the use of MMP
inhibitors. Proteomics methods provide a modern means of obtaining
these pivotal data.
1.5 Current Genomic Data Available for the Pneumococcus
The complete genome sequence of a capsular serotype 4 isolate of S.
pneumoniae [designated TIGR4; TIGR indicates The Institute for
Genomic Research] was determined by the random shotgun sequencing
strategy (Gen- Bank accession number AE005672; see www.
tigr.org/tigr-scripts/CMR2/CMRHomePage.spl). The 2,160,837 — base
pair genome sequence of this pneumococcal isolate contains 2236
predicted coding regions; of these, 1440 (64%) were assigned a
biological role. Approximately 5% of the genome is composed of
insertion sequences that may contribute to genome rearrangements
through uptake of foreign DNA. Several surface-exposed proteins that
may serve as potential vaccine candidates were identified. Comparative
genome hybridization with DNA arrays revealed strain differences in S.
pneumoniae that could contribute to differences in virulence and
antigenicity (91).
There are nine further S. pneumoniae genomes available for
analysis, although some of these are in the process of completion.
Information generated form the comparative analysis of these sequences
will provide insights into the evolution of these genomes, and will serve
as a building block to understand the complexity of a species such as the
Pneumococcus(92).
1.6 The Proteome and Proteomics
The proteomerefers to the entire quota of protein expressed by the
genome of an organism or cell type. This quota of proteins varies with
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time. Proteomicsis the quantitative analysis of expressed proteins present
in cells, tissues or organisms at a certain time and under different
conditions; like genomics, it takes a global, system-wide view of the
organism (93). Serum proteomics provide a pattern-based diagnosis,
because multiple peptide and protein signals are detected simultaneously
in a single mass spectrum. Furthermore, disease states seem to be
characterised by raised levels of cleavage products of abundant serum
proteins (94).
1.6.1 Application ofProteomics to Pathogenic Diseases
Proteomics is a technique which has previously been applied to
different pathogenic diseases with successful outcomes. Rao ef a/ used
proteomics to study host immune response to Pseudomonas aeruginosa
in patients with cystic fibrosis (95). In this study proteomics was applied
to serum. It was observed that the outer membrane protein L (OprL), a
non-typeIII secretion system protein, were an early immunogenicprotein
duringthe initial P. aeruginosa infection of patients with cystic fibrosis.
Another study with a successful outcome from proteomic analysis
was from Agranoff ef al (96). In this study, sera were studied from
patients with active tuberculosis with proteomics. They were able to
discriminate the proteomic profile of patients with active tuberculosis
from that of controls with overlappingclinical features.
1.6.2 Cerebrospinal Fluid Proteomics
Cerebrospinal Fluid
Cerebrospinal fluid is a clear bodily fluid which resides in the
subchranoid space between the arachnoid and pia mater layers of the
meninges. It is a saline solution with microglia and one of its main
actions is to act as a buffer for the cortex. It is produced by specialised
ependymalcells of the choroid plexus located within the brain (97). CSF
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thus provides an ideal proteome for qualitatively comparing the quota of
proteins present in CSF as a consequence of meningitis, leakage of the
blood brain barrier or from bacteria.
Background to Patient CSF Used In This Thesis
CSF used in this thesis was collected as part of a clinicaltrial into
the use of corticosteroids for the treatment of bacterial meningitis in
adults (2). As part of this study CSF was collected by lumbar puncture
from 465 patients. A second lumbar puncture was taken from patients
whom survived after 48hrs if a) they were conscious and able to consent
or b) there was a
clinical imperative to repeat the LP (such as deterioration or failure to
improve despite appropriate therapy, diagnostic uncertainty, intracranial
pressure control). The majority of these patients also had HIV co-
infection. Patients were randomly assigned to receive dexamethasone
(233 patients) or placebo (232 patients) plus intramuscular ceftriaxone
(230 patients) or intravenousceftriaxone (235 patients). The study design
and data collection were conducted by members of the University of
Malawi, College of Medicine.
1.7 Proteomic Methods Applicable to CSF Analysis
Proteomic techniques applicable to CSF are either a “shotgun”
approach (complex peptide mixtures from multiple proteins are analysed
with mass spectrometry at once) or the identification of specific proteins,
extracted from polyacrylamide gels, from the peptide spectra of digested
protein based off the characteristic peptide spectra of that protein (a
peptide mass fingerprint, PMF) (98;99). Protein identification in this
thesis utilised the latter method for the analysis of proteins in the CSF
samples obtained from the clinical trial of dexamethasone described
previously (2).
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The applications of proteomics to CSF samples have allowed the
presence or absence of proteins to be associated with neurological
damage and death in meningitis. Proteomics approaches allow the
analysis of a large spectrum of host and pathogen proteins but cannot yet
be applied to the bacterial cell wall components such aslipoteichioic acid
(LTA) of pneumococcus.
As discussed, these methods have already been applied in malaria
and tuberculosis. This thesis is the first application of proteomics to the
investigation of pneumococcal meningitis (58;100). In this thesis we have
used a numberof proteomic techniques to analyse CSF. The rationale for
using these techniques are discussed below andthe detailed methodology
in the methods section. In support of the use of proteomics, add
something to indicate that this technology has been use successfully with
other bacteria (a summary table, or at least a brief paragraph with a few
references).
1.7.1 The Bradford Assay
To account for variability in the amount of protein loaded, protein
concentration was determined using the Bradford assay. The Bradford
Assay is a dye-binding assay in which a differential colour change of a
dye occurs in response to various concentrations of protein. The
absorbance maximum for an acidic solution of Coomassie” Brilliant Blue
G-250 dye shifts from 465 nm to 595 nm whenbindingto protein occurs.
The Coomassie blue dye binds to primarily basic and aromatic amino
acid residues, especially arginine (101).
The advantages of the Bradford assay include; ease of use,
sensitivity and low cost of reagents. Also for microplate-based assays the
reagent volumescan be decreased to a volumeas low as10 ul. This was
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useful in preserving the CSF samples whilst obtaining a reproducible
protein concentration for use in the analysis.
The accuracy of quantification with Bradford reagent is dependent
on the amino acid sequenceofthe protein (101). Thus a suitable positive
control/calibration protein was needed. Bovine serum albumin was used
as the positive control. However it has been noted to give low protein
concentrations. This had no effect on the outcome of any experiments
undertakenin this thesis as all expression data was normalised. Thus the
method and the amount of protein loaded were kept constant for all
experimental analyses.
1.7.2 Polyacrylamide Gel Electrophoresis (PAGE) ofProteins
Gel Electrophoresis
Gel electrophoresis is a technique that separates macromolecules on
the basis of size, electric charge, and other physical properties (102). In
gel electrophoresis proteins are separated according to molecular weight.
Polyacrylamide acts as a molecular sieve allowing smaller proteins to
reach the bottom of the gel before the larger proteins. Protein on
polyacrylamide gels can then be visualised by staining ortransferred to a
membrane(Western blot).
Protein Denaturation and Solubilisation
Protein denaturation is essential to separate proteins. Before
separating the proteins, they are treated with sodium dodecyl sulfate
(SDS). Protein denaturation allows attachment of a number of SDS
molecules roughly proportionalto the protein's length. A protein's length
when unfolded is roughly proportional to its mass. This is equivalent to
saying that it attaches a number of SDS molecules roughly proportional
to the protein's mass. Since the SDS molecules are negatively chargedall
of the proteins will have approximately the same mass-to-chargeratio as
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each other. The problem imposed by this compoundis that the negative
charge can affect the movement of the protein within the gel. This was
counteracted by the addition of the zwitterionic detergent: 3-[(3-chlor-
amidopropyl)-dimethyl ammonio-1-propane sulfonate (CHAPS).
Other denaturing agents, such as iodoacetamide, help break down
disulphide bonding within the protein. In addition a high concentration of
urea and the reducing agent dithiothreitol was used in order to further
denature the proteins. These compoundsalso aid solubilisation of certain
types of protein, in particular hydrophobic proteins, which can affect the
results of the gel separation.
2D PAGE
The technique of 2-dimensional PAGEis a modified form of SDS-
PAGEin which separation of macromolecules depends upon two forces:
charge and mass (103). The first dimension separates protein molecules
according to protein isoelectric point (pl). Proteins can carry positive,
negative or zero charge depending on their local pH, and for every
protein there is a specific pH at which its net charge is zero;thisisits pl.
Commercial immobilized pH gradient (IPG) strips improve the
resolution of 2D PAGEand allow a higher level of sample load (104).
Protein pl's generally fall in the pH range 3 - 12, with most being around
4 - 7. In this analysis the majority or proteins fell within the pH 4 — 7
region (105).
The second dimension separates proteins based on their molecular
weight. The second dimension is usually performed using a standard
SDS-polyacrylamide gel. Here an electric potential is again applied, but
at a 90° angle from the first field. The proteins are attracted to the
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negative side of the gel proportionally via their mass-to-charge ratio
(103).
Staining
Standard SDS-PAGEgels were stained using colloidal Coomassie
blue (CBB) stain and 2D gels were stained using silver stain. Colloidal
Coomassie blue stain can detect protein quantities up to 100 ng.
The use ofsilver staining allowed protein quantities as low as 5-7 ng
to be detected (106). The silver nitrate bonds to cysteine groups within
the protein. The silver is darkened by exposure to ultra-violet light. The
darkness of the silver can be related to the amount of silver and therefore
the amountof protein at a given location on the gel (107).
Excessive staining effects can be a problem with the methodbutthis
has been resolved using computational methods for gel matching as spot
normalisation will remove most of this effect as discussed in chapter 3
(108).
1.7.3 Mass Spectrometry
Mass spectrometry is a powerful analytical technique which is used
to analyse small molecules and complex biomolecules, such as DNA,
lipids, carbohydrates and proteins. The technique involves the study of
the mass-to-charge ratio (m/z) of atoms, molecules or fragments of
molecular ions. Mass spectrometry is a destructive method of analysis as
it forms and utilises ions rather than molecules thus conversion back to
the starting material is impossible (109). All mass spectrometers have the
same 4 sections; an inlet system; an ion source; a mass analyser, and a
detector.
Mass spectrometry only works for charged species and in orderto
obtain a mass spectrum, gaseous molecules or species desorbed from
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condensed phases must first be ionised. There are various techniques
available for ionisation depending on the ion source. Direct ion sources
exist as two types: liquid-phase ion sources and solid-state ion sources.
Depending on the method ofionisation there are different inlet systems
available. The purpose of the inlet system is to permit introduction of a
representative sample into the ion source with a minimalloss ofpressure.
Onceions have been generated they are separated according to their
mass-to-charge ratio using a mass analyser. Instruments with several
analysers in sequence are used for tandem mass spectrometry (MS/MS)
(110). There are three main characteristics of a mass analyser: the upper
mass limit, the transmission and the resolution. The mass limit
determines the highest value of m/z (in Th or atomic mass units (amu),
where z = 1) that can be measured. Transmissionis the ratio between the
numberof ions reaching the detector and the numberof ions produced in
the source. Resolving poweris the ability to produce distinct signals for
two ions with a small mass difference.
MALDI-TOF
MALDIIonisation
Matrix assisted laser desorption/ionisation-time of flight (MALDI-
TOF)is a mass spectrometry methodutilising a solid-state ion source in
whichthe analyte is in an involatile deposit (a matrix). In this analysis the
matrix used was alpha-cyanao-4-hydroxycinnamic acid. The peptide
digest mixture molecules are embedded throughout the matrix (isolated
from each other). Bulk portions of the solid solution were ablated by
intense pulses of laser for a short duration. This induces rapid heating of
crystals through excitation of matrix molecules causing localised
sublimation and expansion into the gas phase. Ionisation of the analyte
may occur at any time during this process(111).
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Three different types of fragmentation in MALDI can occur;
fragmentation at the sample surface (prompt fragmentation),
fragmentationin the source, after desorption, but before acceleration(fast
fragmentation) and after acceleration (post-source decay, PSD
fragmentation) (112). The first two are always apparent in MALDI
spectra; the last method is only seen undercertain conditions.
Time ofFlight Mass Analyser
MALDIutilises a Time-of-flight (TOF) mass analyser to detect the
short-lived ions signals. Positive ions that are formed are accelerated by
an electric field pulse which has a similar frequency but slightly lags
behind the ionisation pulse.
Accelerated ions pass into a region containing no external field
known as a drift tube. Assuming all ions have the same kinetic energy
then their velocities will depend upon their masses. Heavier ions will
arrive at the detector up to 30 usafter lighter ones (113). The detector is
set up so that we may have an instantaneous display of the mass
spectrum. Time resolution increases with increasing distance, d, and
deceases with an increase in voltage.
In principle, upper mass range of TOF has no limit, which is very
good for soft ionisation techniques. These instruments also have high
transmission efficiency, whichleads to high sensitivity e.g. 100-200 amol
of cytochrome c can be observed. In principle, all ions formed are
analysed (114).
One major drawback of TOF is poor mass resolution caused by
factors including; length of ion formation pulse (time distribution), size
of volume where ions are formed (space distribution), and variation in
kinetic energy of ions (KE distribution). Mass resolution is improved by
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using an electrostatic reflector, known as a reflectron. The reflectron
creates a retarding field that acts as an ion mirror. It deflects ions and
sends them back throughtheflight tube effectively increasing d. The term
reflectron TOF is used to differentiate this method from a linear TOF.
The reflectron corrects for KE dispersion at the reflecting point,
increasing mass resolution. However, there is a loss of sensitivity and
also the mass range is limited to maximum of 3500 Da.
The spectra generated from MALDI-TOF provide a peptide mass
fingerprint (PMF) of the protein as shown in figure 1.4. The peptide
sequencescanbesearchedin silico using online protein databases (94).
Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS)
This method of mass spectrometry involves electrospray ionisation.
This method ofionisation utilises a liquid-phase ion source. The peptide
mixture is in solution and the sample is directly injected into the mass
spectrometer via a liquid chromatography machine. This solution is
introduced, by nebulisation, as droplets into the mass spectrometer.
Liquid Chromatography (LC)
In Liquid Chromatography a liquid sample is applied to a narrow
cross section of a column which is filled with a particular packing. A
solvent is passed through a column sweeping the sample from theinlet to
the outlet.
The mobile phaseis typically a solvent moving through the column
which carries the mixture to be separated (115,116). The mobile phase
can be adjusted to improve the separation; solvents can be changed as
well as their ratios.
The stationary phaseis located within a column. Different stationary
phases may be employedsuch as; normal(or adsorption/displacement),
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Figure 1.4 Representative PMF generated by MALDI-TOF. A
Representative PMF mass spectrum generated by MALDI-TOF mass
spectrometry. B Peaks correspond to specific peptides shown in red.
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reversed (lipophilic), ion exchange, size exclusion or bioaffinity. The
phases are chosen such that components of the sample have differing
solubility’s in each phase. A component which is quite soluble in the
stationary phase will take longer to travel through it than a component
which is not very soluble in the stationary phase but very soluble in the
mobile phase. As a result of these differences in mobility’s sample
components will become separated from each otheras they travel through
the stationary phase (115;116).
There are many different kinds of detectors available for LC and
most commonly they use the optical properties of the analytes e.g.
absorption (UV/Vis detectors) or fluorescence (spectrofluorometric
detectors).
Electrospray Ionisation
Along with MALDI the other major ionisation technique for
biomolecular analysis is electrospray ionisation (ESI). ESI is an
atmospheric pressure ionisation source. ESI is important for biomolecular
analysis (such as proteins and oligonucleotides) as they can be analysed
using mass analysers with a relatively low m/z range. ESI allows very
high sensitivity to be reached andis easily coupled to LC (114).
Anelectrospray is produced by applying a strong electric field under
atmospheric pressure to a liquid passing through a capillary tube with a
weak flow (typically 1 — 10 ulmin’'). The Field induces charge
accumulation at the surface of the liquid at the end of the capillary.
Liquid breaks to form highly charged droplets. The Spray starts at a
voltage (onset voltage) that for a given source depends upon the surface
tension of the solvent (114) with formation of a “Taylor cone” (117) as
shown in figure 1.5. Solvent contained in the droplets evaporate causing
them to shrink to a point whererepelling coulombic forces(the
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Figure 1.5 ESI ion formation. Generation of ions during electrospray
ionisation with generation ofa Taylor cone.
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electrostatic interaction betweenelectrically charged particles) are close
to cohesion forces. Due to the strength of the field a cascade of ruptures
occur generating highly charged droplets. When the electric field at the
surface is large enough desorption of ions occurs. Desorption of charged
molecules occurs from the surface thus sensitivity is higher for
compounds formed in higher concentrations at the surface i.e. more
lipophilic.
ESIis sensitive to concentration rather than total amount of sample.
Reducing flow rates (thus increasing concentration) increases sensitivity.
At the lower limit this is nanolitre per min (nl min’', nanoelectrospray,
nESI) as usedin this analysis (118).
Ion Trap Mass Analyser
The mass analyser used in this analysis was an ion trap mass
analyser. An ion trap is a combination of electric or magnetic fields that
captures ions in a region of a vacuum system ortube. Ions with different
masses are present together within the ion-trap and then expelled
according to their masses to obtain spectrum. As ions in the trap expel
each other, their trajectories expand as a function of time. Following
injection ions of different mass are stored together. By applying a RF
voltage of selected frequency and variable amplitude it is possible to
select ions according to their m/z. Tandem MS was time-dependent in the
trap. A sequence of events takes place to allow MS". Ions of one m/z are
selected by expelling all the others from the ion-trap.
MS/MSspectra are informative about the composition and the order
of amino acids in a peptide sequence as it can reveal the molecular
weights of the peptide’s breakdowns. Several bonds along the backbone
of a peptide can be inducedby collisions. If the charge is retained on the
N-terminal fragment, the ionis classified as a, b or c, and if the charge is
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retained on the C-terminal, the ion is classified as x, y or z as shownin
figure 1.6. It has been observed that in a typical MS/MSspectral dataset,
the majority of the N- and C-terminalions are b andy ions, respectively,
and each of these ion types contains the derivatives of neutral loss of
water or ammonia(119).
1.8 Mascot
Mascotis a powerful search engine that uses mass spectrometry data
to identify proteins from primary sequence databases. This search engine
uses the MOWSEstatistical algorithm to confirm the identity of proteins
from peptide mass spectrometry data.
1.8.1 Mowse Probability Score
Peptide massfingerprints and MS/MSfingerprints have been used to
confirm protein sequences allowing the detection of translation errors,
mutation or insertion, characterize post-translational modifications or
processing events, and assign disulphide bonds. Such peptide-mass
information can provide a distinctive fingerprint signature, which is
sufficiently discriminating to allow the unique andrapid identification of
unknown sample proteins. The Mowse scoring algorithm was developed
by Pappin in 1993 (120). Mowse databases comprise calculated
molecular weights ofall peptide fragments derived from a set of specific
enzymeor reagent cleavagerules. The first stage of a Mowsesearch is to
compare the calculated peptide masses for each entry in the sequence
database with the set of experimental data. Mascot incorporates a
probability based implementation of the Mowse algorithm. Rather than
just counting the number of matching peptides Mowse uses empirically
determined factors to assign a statistical weight to each individual peptide
match.
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Figure 1.6 Representative spectra generated by MS/MS. A
Representative MS/MS spectra generated by peptide spectra. B This
spectra is analysed against protein databases which are represented by
red sequences.
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1.8.2 Important Search Fields
Database
In this analysis SwissProt or MSDB databases were used to analyse
the PMF and MS/MSdata because of the high quality of the protein
sequence data. The databases available on this Mascot are shown in table
1.4,
Taxonomy
The taxonomy of the species under analysis can be changed to
include all species or specific species. Analysis of smaller genomic
organism’s results in an increase in the possibility of false positives
therefore it is necessary to increase the number of searches to avoid the
possibility of false positives. In this analysis the spectra were compared
to Homo sapiens, Streptococcus pneumoniae, all mammalian,all bacteria
andall species.
Enzyme
As a result of the varying cleavage specificity of the enzymes used
for digestion as shown in table 1.5 it was necessary to specify the reagent
used for protein digestion. Trypsin wasused in all digestion experiments.
Modifications
Mascot supports two types of modification; fixed modifications are
applied universally, to every instance of the specified residue(s) or
terminus. There is no computational overhead associated with a fixed
modification it is simply equivalent to using a different mass for the
modified residue(s) or terminus e.g. selecting carboxymethyl (C) means
that all calculations will use 161 Da as the massofcysteine.
Variable modifications are those which may or may notbe present.
Mascottests all possible arrangements ofvariable modificationsto find
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Table 1.4 Non-redundant Databases Available on Mascot
 Database Comment
EST EST divisions of Genbank,(currently
EST_human, EST_mouse, EST_others)
MSDB Comprehensive, non-identical protein
database
NCBI nr Comprehensive, non-identical protein
database
SwissProt High quality, curated protein database
 
SwissProt and MSDB were mostly used in this thesis for their high
quality protein databases.
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Table 1.5 Enzyme Reagents Which Can Used with Mascot
 
Enzyme Name Cleave Don't cleave
Trypsin KR P CTERM
Arg-C R P CTERM
Asp-N BD NTERM
Asp-N_ambic DE NTERM
Chymotrypsin FYWL P CTERM
CNBr M CTERM
Formic_acid D CTERM
Lys-C K Pp CTERM
Lys-C/P K CTERM
PepsinA FL CTERM
Tryp-CNBr KRM P CTERM
TrypChymo FYWLKR P CTERM
Trypsin/P KR CTERM
V8-DE BDEZ P CTERM
V8-E EZ P CTERM
M
CNBr+Trypsin CTERMKR P
None - = =
Semitrypsin - = =
 
The enzyme usedfor this analysis was trypsin. Trypsin cleaves between
arginine and lysine except when next to proline.
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the best match e.g. if oxidation (M) is selected and a peptide contains 3
methionines. Mascot will test for a match with the experimental data for
that peptide containing 0, 1, 2, or 3 oxidised methionine residues.
Variable modifications can be a very powerful means of finding a
match, but there are also dangers to be aware of. Even a single variable
modification will generate many possible additional peptidesto be tested.
More than one variable modification causes the numberof arrangements
to increase geometrically. This means that a search can take dramatically
longer than the same search with fixed modifications. More importantly,
testing all possible arrangements of modifications generates many more
random matches, so that discrimination can be sharply reduced.
Peptide andMS/MS Tolerance (+)
The peptide tolerance is the error window on experimental peptide
mass values which takes into account isotopic variation. The MS/MS
tolerance is error window for MS/MSfragment ion massvalues.
Mass Values
Specifies whether experimental peptide mass values in a peptide
mass fingerprint search include the mass of the chargecarrier, MH’ or M
H, or whetherthey correspond to a neutral Mrvalue.
Peptide Charge
The peptide charge is used to specify the precursor peptide charge
state in a sequence query or an MS/MSions search. The peptide mass
value supplied in an MS/MSdatafile is usually an observed m/z value.
The charge state field is used to calculate the relative molecular mass
(Mr) of the precursor from the observed m/z unlessthe data file explicitly
specifies a different chargestate.
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Missed Cleavages
Setting the number of allowed missed cleavage sites to zero
simulates a limited digest. This setting assumesthe digest is perfect with
no partial fragments present. This will give maximum discrimination and
the highest score.
Digest mixtures usually include partial digestion 1.e. peptides with
missed cleavage sites. Therefore a setting of 1 was chosen. A higherlevel
of missed cleavages increases the numberof calculated peptide masses to
be matched against the experimental data. If the actual digest does not
contain extended partials, this simply increases the number of random
matches, and so reduces discrimination.
Instrument
Variations in the mass analyser effect which fragment ionseries will
be used for scoring. For ion trap mass analysers the standard fragments
include; 1* fragments, 2* fragments (if precursor 2” or higher), b series
ions, b-NH; (if fragment includes RKNQ), b-H2O (if fragment includes
STED), y series ions, y-NH;(if fragment includes RKNQ)and y-H20 (if
fragment includes STED).
1.9 Gene Ontology
Gene Ontology (GO) provides a structured, precisely defined,
common, controlled vocabulary for describing the roles of genes and
gene products in any organism (121). The vocabulary consists of three
groups; molecular function, biological process and cellular component.
1.9.1 Molecular Function
GO molecular function terms represent activities rather than the
entities (molecules or complexes) that perform the actions, and do not
specify where or when, or in what context, the action takes place.
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Molecular functions generally correspond to activities that can be
performed by individual gene products, but someactivities are performed
by assembled complexes of gene products.
1.9.2 Biological Process
GO biological process is a series of events accomplished by one or
more ordered assemblies of molecular functions. It can be difficult to
distinguish between a biological process and a molecular function, but
the general rule is that a process must have more than onedistinct step.
1.9.3 Cellular Component
GO cellular component refers to the place in the cell where a gene
productis active.
1.10 ClustalW
ClustalW is a general purpose multiple sequence alignment program
for DNA or proteins. It produces biologically meaningful multiple
sequence alignments of divergent sequences. It calculates the best match
for the selected sequences and lines them up so that the identities,
similarities and differences can be seen. Evolutionary relationships can be
seen via Phylograms. The basic information they provide is very useful in
designing experiments to test and modify the function of specific
proteins, in predicting the function and structure of proteins and in
identifying new membersofprotein families (122)
ClustalW uses a computer generated pairwise alignment of protein
sequences. Using the alignments of the protein sequences being
compared an evolutionary distance is computed. This distance is
calculated by looking at the non-gapped positions and the number of
mismatches between the two sequences. This value is then divided by the
number of non-gapped pairs to calculate the distance. Onceall distances
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for all pairs are calculated they go into a matrix. ClustalW constructs a
similarity tree using this matrix and Neighbour-Joining.
1.11 Western Blot
The Western blot (immunoblot) is an analytical technique used to
detect specific proteins in a given sample of tissue homogenate or extract.
Protein separated using SDS PAGEwastransferred to a membrane made
of nitrocellulose or Polyvinylidene Fluoride (PVDF). The membranesare
probed using antibodies specific to the target protein. Nitrocellulose and
PVDFare used for immobilisation of proteins in Western blots for their
non-specific affinity for amino acids.
1.11.1 Western Blot Image Development
Alkaline phosphatase (AP) and horseradish peroxidase (HRP) are
the two enzymesused most extensively as labels for protein detection. An
array of chromogenic, fluorogenic and chemiluminescent substrates are
available for use with either enzyme. Alkaline phosphatase offers a
distinct advantage over other enzymesin that its reaction rate remains
linear allowing sensitivity to be improved by simply allowing a reaction
to proceed for a longertime period. Unfortunately, the increased reaction
time often leads to high backgroundsignal resulting in low signal:noise
ratios. HRP conjugated antibodies are considered superior to antibody-
AP conjugates with respect to the specific activities of both the enzyme
and antibody due the smaller size of HRP enzyme and compatibility with
conjugation reactions. In addition the high activity rate, goodstability,
low cost and wide availability of substrate makes HRP the enzyme of
choice for most applications.
BCIP/NBTreacts with alkaline phosphatase forming Formazan as
an insoluble purple precipitate. DAB tetrahydrchloride reacts with HRP
in the presence of hydrogen peroxide (H,O2) forming DAB as an
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insoluble brown precipitate. ECL reacts with HRP in the presence of
H,0O, to form an unstable compound which emits chemiluminescence.
Detection may be documented with x-ray film. Of these detection
methods, x-ray film is the most sensitive method.
1.12 Thesis Aims and Project Hypothesis
The aims ofthis thesis are to (1) compare the 2D PAGEpattern of
proteins found in the CSF obtained at admission from groups ofpatients
with pneumococcal meningitis in Malawi. (2) Formally identify proteins
found to be distinguishable between non-survivors and survivors using
mass spectrometry. (3) Relate these proteins to known mechanisms of
pneumococcal meningitis in order to generate hypotheses. (4) Validate
the identity of selected proteins from the list obtained and confirm the
expression of specific proteins from host and pneumococci present in
CSF.
This thesis will test the general hypotheses; (1) Proteins present in
CSF of patients with pneumococcal meningitis are different to those
proteins present in normal CSF. (2) Host and pneumococcal proteins in
CSF havean association with clinical outcome.
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2.1 Introduction
The aim of this chapter is to provide information on the samples
used and on the experimental techniques which have been utilised to
provide the information in this thesis. This chapter will provide a
comprehensive step-by-step methodology of the general techniques used
in this thesis allowing easy reproducibility.
2.2 Patient Information
2.2.1 BackgroundofPatients and CSFsamples
CSF used for the experimental analysis was chosen from patients
whohad an excellent recovery and short clinical course. These subjects
all survived with no neurological impairment (median duration of
symptomsetc).
As discussed in the introduction patients were recruited to a double
blind, randomised, placebo controlled trial of dexamethasone adjuvant
therapy. The study was conducted in adults with bacterial meningitis
presenting at the Queen Elizabeth Central Hospital in Blantyre, Malawi
between May 2002 and Jan 2005 in (2). The study was approved by the
research ethics committees of the University Of Malawi College Of
Medicine and the Liverpool School of Tropical Medicine. Patients or
their legal guardians provided written informed consentor, if they were
unable to read or write, they provided independently witnessed verbal
consent before recruitment. Patients were treated in hospital for a
minimum of 10 days and were evaluated at 40 days and at 6 months.
Clinically evident adverse events were recorded systematically
throughout the trial period. At follow-up, patients had a standardized
neurologic examination and a hearing assessment. Patients who did not
return for follow-up appointments were visited at home. No other
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underlying diseases were specifically
looked for other than HIV and malaria. However, some patients
volunteered a past medical history. Patients in Malawi have basic medical
care as described previously (2).
The eventual cause of death was often not known. However we have
initiated a new study (2010 — 2012) to determine causes of death in a new
prospective cohort.
2.2.2 Patient Categories
Of those who survived, 103 patients survived to one month with no
neurological impairment or recorded disability, 66 survivors had
detectable hearing loss without complete deafness and 47 patients had
disability (paresis, intellectual impairment, blindness, complete deafness
debility or recurrent seizures). 249 of these patients died, of which 92
survived for 10 days or more but died before 40 days from presentation,
and 157 patients died within 10 days of presentation to hospital. Initial
group definitions included: Survival with no neurological impairment or
recorded disability (n = 103); deaf (n = 66); maimed (n = 47); protracted
death (n = 92); rapid death (n = 157). Recruitment included consent for
diagnostic samples to be used in meningitis pathogenesis research at a
later date.
2.2.3 Diagnosis
Probable bacterial meningitis was defined as a cerebrospinal fluid
specimen containing a cell count of more than 100 per cubic millimetre
with more than 50% neutrophils without identification of an organism
(See appendix A). Recruitment included consent for diagnostic samples
to be used in meningitis pathogenesis research at a later date. CSF
specimens were examined as previously described (2). CSF was
examined by means of microscopy for cell and differential counts. A
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Gram’s stain procedure was performed if the sample was turbid or had
more than 10 white cells per cubic millimeter. Centrifuged CSF deposits
were incubated on sheep-blood agarin a candle- extinction jar at 37°C for
48 hours and isolates were identified by means of standard techniques.
Blood was cultured at 37°C for a minimum of 48 hours (BacT/Alert,
bioMérieux). In the first 51 consecutive CSF specimens for which
Gram’s stain and culture were negative, polymerase chain reaction (PCR)
for meningococcus and pneumococcuswasperformed(2).
Proven bacterial meningitis was defined as identification of an
organism from a CSF specimen by meansof microscopy, culture, or PCR
or from blood culture in the context of a CSF specimen containing a
white-cell count of more than 100 per cubic millimeter with more than
50% neutrophils. Probable bacterial meningitis was defined as a CSF
specimen containing a cell count of more than 100 per cubic millimeter
with more than 50% neutrophils without identification of an organism
(2).
All subjects were HIV positive and all samples were collected
before any treatment commenced. The median CD4 cell count, on
admission for 101 consecutively admitted HIV-positive patients during
recruitment to the trial was 102 per cubic millimeter (interquartile range,
51 to 169). We did not measure CD4 counts on all but one of these
patients as anti-retrovirals were not routinely available until mid 2004 in
Malawi and therefore there was noclinical imperative and no advantage
to the patient to know their CD4 count. None of these patients were on
anti-retroviral therapy. All had WHO stage III or IV disease (1990
criteria). As described previously normal CSF wasobtained from patients
whotested negative for meningitis or any other pathogen. The HIV status
of the normal patients was not known.
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2.3 General Solutions and Reagents
All chemicals were purchased from Sigma Aldrich (Poole, UK),
VWR (Lutterworth, UK) or Fisher (Loughborough, UK) unless otherwise
stated. General solutions used for the analysis were made using HPLC
grade water. The pHofall solutions used in this thesis was adjusted by
the addition of 1 M HCI or NaOH.Solutions used in thesis are presented
in appendix B.
2.4 The Bradford Assay
The concentration of protein was determined using the Bradford
assay. Samples were analysed in triplicate on a standard 96-well plate.
The calibration standard used for the analysis was BSA.If the coefficient
of variation between the replicates was > 5% the assay was repeated.
Protein concentrations were rejected if the BSA standard curve did not
have an R’ value of >0.98.
2.5 SDS Polyacrylamide Gel Electrophoresis (PAGE)of proteins
2.5.1 Gel Electrophoresis
SDS PAGE was undertaken using the PROTEAN II gel
electrophoresis kit (BioRad). The concentration of gels used for the
separation of proteins is shown in table 2.1. The proteins were separated
in SDS supplemented tank buffer.
2.5.2 2D PAGE
This variation of SDS PAGEis discussed in detail in chapter3.
2.5.3 Staining
SDS PAGEgels werestained using colloidal coomassie blue (CBB)
stain. In this methodofstaining gels were incubated overnight in CBB.
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Table 2.1 Gel Concentrations usedfor this analysis
 
Gel concentrations
 Reagents
5% 7.5% 10% 12.5% 15%
30% Acrylamide/bisphosphate 083ml 1.25mi 1.7 ml 2.0 ml 2.5 ml
Trizma base pH 8.8 1.3 ml 1.3 ml 1.3 ml 1.3 ml 1.3 ml
10% SDS 50 ul 50 ul 50 ul 50 ul 50 ul
Ultra-pure HO 2.77mi 2.35mi 1.9 ml 1.6 ml 1.1m
10% APS 50 ul 50 ul 50 ul 50 ul 50 ul
TEMED 2 ul 2 ul 2 ul 2 ul 2 ul
 
The table above shows the quantity of reagents required to prepare the
gel concentration required for separation of protein by SDS PAGE.
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Gels were washed the following day in destaining CBB wash 1 for | min
followed by destaining solution for 2 hrs at RT.
2D gels were stained using silver stain. The use of silver staining
allowed protein quantities as low as 5-7 ng to be detected (106). Gels
were fixed overnight in fixing solution. Fixing solution was washed off
using distilled water for 30 mins. Gels were then incubated in 0.03%
(w/v) sodium hydrosulphite for 2 mins followed by washesin distilled
water. Gels were then incubated in silver nitrate solution for 40 mins
before washing with distilled water. Spot images were developed by the
addition of silver developing solution for 7-12 min. The reaction was
stopped using silver stopping solution for 2 hrs at RT.
The silver nitrate bonds to cysteine groups within the protein. The
silver is darkened by exposure to ultra-violet light. The darkness of the
silver can be related to the amountofsilver and therefore the amount of
protein at a given location on the gel (107). Excessive staining effects
have been surmounted using computational methods for gel matching as
spot normalisation will remove mostofthis effect (108).
2.5.4 2D Gel Comparison
This is discussed in detail in chapter3.
2.5.5 Gel Excision
Following the selection of the spots of interest, they were manually
excised from the stained gels and subjected to in-gel tryptic digestion
(123).
Protein spots of interest were manually excised from the gel using
pen picking. Silver stained samples were destained using a 1:1 mix of
100mM sodium thiosulphate and 30 mM potassium ferracyanide. Spots
were equilibrated in 200 mM ammonium bicarbonate (ambic) and
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dehydrated using a 2:1 acetonitrile (ACN):ambic (25 mM)solution. Spots
were vacuum centrifuged to dryness and a 12.5 ng/ul solution of
sequencing grade, modified trypsin (Promega, Madison, WI, USA) in
ambic (25 mM)wasapplied to the gel spot. In-gel digestion was carried
out overnight at 37°C. Peptide extraction was carried out by sonication
(10 min) followed by centrifugation (10000 RPM) and transfer of
supernatant to a new microcentrifuge tube. Neat ACN wasaddedto the
gel spot and incubated for a further 30 min at 37°C. Peptide extraction
was repeated and the supernatant pooled with the earlier supernatant
(124). Thefinal pooled supernatant was vacuum centrifuged to 3 ul.
2.6 Mass Spectrometry
2.6.1 MALDI-TOF
MALDI-TOF was used for the peptide mass fingerprint analysis
(PMF)of protein spots identified in chapter 3. 0.5 ul of the peptide digest
sample to be analysed was spotted onto the MALDItarget plate. The
remainder was concentrated using a Zip-Tip C18 (Millipore, Billerica,
MA, USA)andalso spotted onto the target plate. 0.5 ul of a-cyano-4-
hydroxycinnamicacid solution was layered over the sample spot. Sample
spots were allowedto air dry before insertion into the MALDI-TOF.
The MALDI-TOF spectra of the peptides were obtained with an
Axima CFR plus mass spectrometer (Kratos analytical, Shimadzu,
Manchester UK) in 2 GHz reflectron mode. Near spot calibration was
performed using a 5 point calibration mix: Bradykinin [1-5] (572.7 Da),
Angiotensin II (1046.2 Da), Neurotensin (1672.9 Da), ACTH [18-39]
(2465.7 Da) and Bovine Insulin chain B (3495.9 Da) (Laserbiolabs,
France). Acquisition and data processing were controlled by Launchpad
software V. 2.4 (Kratos Analytical, Shimadzu, Manchester UK). No
smoothing was applied to the spectra. The positive control used was BSA
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solution and was subject to the same digestion procedure. The negative
control used was a blank gel piece sourced from the same gel under
analysis. Peaks from the negative control along with common
contaminants listed on the Matrix Science website were eliminated from
the raw peaklist to create the final peak list for searching with Mascot.
2.6.2 LC-MS/MS
Digestion was carried out as described for MALDI-TOF. Samples
were mixed with 5% formic acid in 50% ACN. The separation and
analysis of digested peptides were performed using reverse phase (RP)
capillary liquid chromatography (Dionex ultimate 3000, Dionex,
Sunnyvale, CA, USA) directly coupled to a Finnigan LCQ IT mass
spectrometer (Thermofisher, Waltham, MA, USA). A C18 PepMap100
solid-phase extraction m-Precolumn cartridge (particle size 5 mm, pore
size 100 A, 300 mm inner diameter - Dionex) trapping column and Nano-
column PepMap C18 reversed-phase material (particle size 3 mm, pore
size 100A, 75 mm inner diameter, Dionex) resolving column were placed
in-line. Peptides were bound and preconcentrated in the trapping column
using the mobile phase (composition: 0.1% formic acid in 2.5% ACN).
The eluting gradient was 2-90% v/v ACN in 0.1% v/v formicacid for 50
min at a flow rate of 0.3 l/min. Eluent from the capillary column was
directly sprayed into the ion trap mass spectrometer.
All the data were collected in centroid mode using “triple play”
settings (i.e. a full mass scan at mass range of 400— 1500 Da (m2),
determination of the charge states of an ion on zoom scan, and then
acquisition of the MS/MSspectrum of each ion on a full MS/MSscan,
with collision energy preset at a value of 55%). Calibration of the mass
spectrometer was carried before each batch of samples using human
glufibrinopeptide B.
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2.6.3 Mascot® Search
All searches were carried out using in-house Mascot software
(Matrix Science, London, UK, at http://www.matrixscience.com).
Criteria selected in the search field for PMF analysis included: (1)
Database selection - here the PMF obtained for each protein digest was
analysed using the Swiss Prot (High quality, curated protein database)
and MSDB (Comprehensive, non-identical protein database) non-
redundant protein databases against all species, all mammals and all
bacteria, with focused analysis on Homo sapiens and Streptococcus
pneumoniae. (2) Missed cleavages was varied between 0 - 2. (3) Fixed
post translational modifications (PTM) of carbamidomethyl on the
carboxy terminal and variable PTM of oxidation of methionine,
phosphorylation, acetylation and propionamide. (4) The error window on
experimental peptide mass values (peptide tolerance) was varied between
1 — 1.2 Da.
Criteria for the positive identification of the proteins with MALDI
were: (1) Scores above the Mowsestatistical threshold value in Mascot
using the Swiss Prot and MSDB database. (2) Protein must be identified
in at least two of the three replicates by a minimum offive peptides in
MALDI-TOF. (3) Protein sequence must have a minimum of 10%
sequence coverage.
From raw LC-MS/MSfiles, MS/MS spectra were exported as dta
(text format) files using LCQDTA raw file converter software (Matrix
science) using the standard settings. Dta files were mergedinto a single
Mascot generic format (mg/) file. Criteria selected in the search field for
Mascot MS/MSion search analysis included: (1) Database selection -
here the MS/MS ion spectra obtained for each protein digest was
analysed using the Swiss Prot (High quality, curated protein database)
and MSDB (Comprehensive, non-identical protein database) non-
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redundant protein databases against all species, all mammals and all
bacteria, with focused analysis on Homo sapiens and Streptococcus
pneumoniae. (2) Missed cleavages was varied between 0 — 2. (3) Fixed
post translational modifications (PTM) of carbamidomethyl on the
carboxy terminal and variable PTM of oxidation of methionine,
phosphorylation, acetylation and propionamide. (4) The error window on
experimental peptide mass values (peptide tolerance) was varied between
1 — 1.2 Da. (5) The Error window for MS/MSfragment ion mass values
(MS/MStolerance) was set to 0.6 and (6) the precursor peptide charge
state was varied between +2 and +3.
2.6.4 Mascot® Statistics
Criteria for positive identification of the proteins with LC-MS/MS:
(1) Scores above 100 according to the Mowsestatistical threshold value
in Mascot using the Swiss Prot database were considered significant. (2)
Protein must be identified in at least two of the three replicates, by a
minimum of two peptides (unless previous identification with MALDI
TOF). The threshold ions scores suggested by Mascot for confident PMF
identification in Swiss Prot and MSDB databases were 55 and 63 (p <
0.05), respectively. The threshold score for MS/MS data was 31 for
individual peptides (120).
2.7 Western Blot
2.7.1 Preparation ofCSFSamplesfor Western Blot
CSF samples were measured for protein concentration in order to
determine an optimum quantity of protein. A volume (pl) equivalent to
the required weight of protein in CSF was combined with PBS to make a
final volume of 10 pl. To this volume 2x sample buffer was added to
make up final volume of 20 pl. The samples were boiled for 3 min at
95°C to denature the samples before SDS PAGE.
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2.7.2 Western blot ofCSF
Solutions for Western blotting were made up on the day of the
experiment.
2.7.3 Protein Transfer
Transfer of SDS PAGE separated protein to membrane was
undertaken using the Towbin method. Here the protein is transferred
using electric current onto a membrane in Towbintransfer buffer at 4°C.
The membranes used in all the experiments of this analysis were
nitrocellulose paper (NCP, GE lifesciences). AIF and caspase 3 protein
blots were retested using PVDF membranes(GELifesciences)
Depending on the antibody to be used for investigation, the
membraneswere blocked using 5% milk or 5% BSA in TBS-T. Blocking
was carried out overnight at 4°C on a rocking platform. The molecular
weight markers were coloured markers which can transfer onto the
membrane (Full-Range Rainbow Molecular Weight Markers (GE
Lifesciences RPN800E). The protein markers consisted of: 225 kDa
(Blue), 150 kDa (Red), 102 kDa (Green), 76 kDa (Yellow), 52 kDa
(Purple), 38 kDa (Blue), 31 kDa (Orange), 24 kDa (Green), 17 kDa
(Blue) and 12 kDa (Red).
2.7.4 Antibody Detection
Membraneswere then incubated in primary antibody for 2 hrs at RT
on a rotating platform or overnight at 4°C on a rocking platform. Primary
antibody was addedto either 5% milk or 5% BSA in TBS-T (depending
on the primary antibody). Membranes were then washed 3 times for 20
min at RT to remove primary antibody before the addition of the
secondary antibody in either 5% milk or 5% BSA in TBS-T for 2 hrs at
RT on rotating platform. The secondary antibody was then washed 3
times for 20 min at RT.
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Depending on the conjugate attached to the secondary antibody used
the membrane was then either incubated in DAB substrate, BCIP/NBT
(5-bromo-4-chloro-3-indolyl phosphate/ nitro blue tetrazolium, Sigma
Aldrich) or ECL (Enhanced Chemiluminescence, GE lifesciences). Both
DAB and BCIP/NBTproduce precipitated coloured blots directly onto
the membrane surface. ECL emits chemiluminescence whichis detected
using x-ray film (Kodak). The x-ray film was then developed using an
automated x-ray developer (Photon Imaging, Swindon, UK).
2.7.5 Semiquantitative Measure ofProtein Expression
The protein images were captured using a gel documentation camera
(Syngene, Cambridge, UK). The images were converted to TIFF format
before analysis using the open source software ImageJ (V. 1.43, NIH,
Maryland, USA, free download available at http://rsb.info.nih.gov/ij/)
(125). Here the images were initially converted to an 8-bit format to
covert the image to true greyscale. The background was subtracted from
the image before inverting the images to black and grey. The bands of
interest after inverting the colours appear as dense grey bands. The
software then measures the absolute intensity of each band using
pixelated grey density. This can be convertedto a relative intensity ratio
using a standard band asreference. In these Western blots the reference
band used was the positive control for the protein under analysis. The
relative intensity is a unitless value. By calculating a relative intensity
that is tied to the same sample standard on every membrane, we can make
up for variations in the length of film exposure or variations in the
efficiency of the antibodies or other reagents. This can be convertedto an
approximate quantity using a calibration curve generated from the
positive control as shown in figure 2.1. This value was then converted to
a native concentration in CSF using the total preparation volume
ST
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Figure 2.1 Quantification of Western Blot Expression. Each of the
protein controls was serially diluted. Using ImageJ the relative intensity
of the protein band was matched against the quantity ofprotein loaded
onto the gel (R’ = 0.99). This was used to determine approximate values
for the quantity ofprotein expressed.
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multiplied by the total protein concentration expressed as a ratio of
volumeofprotein loaded onto the gel.
The protein images used in chapter 6 were captured with a GS-710
Imaging Densitometer (BioRad, Hemel Hempstead, Hertfordshire, UK).
The images were saved in TIFF file format before semiquantitative
analysis using PDQuest® software v. 6.2.1 (BioRad).
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2D PAGE OF CSF IN PATIENTS WITH
PNEUMOCOCCAL MENINGITIS
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3.1 Introduction
Proteomics offers a novel methodology for the analysis of
complicated biological samples. It also provides a promising approach to
monitor the pathological changes in patients with neurological disorders.
The proteome has been described as all of the proteins produced by an
organism,cell or tissue under defined conditions.
For pneumococcal meningitis, the CSF proteome could provide
unique protein biomarkers for the pathways associated with disease
progression or proteins associated with cell death pathways (126). This
could lead to novel treatment interventions or improvements in current
therapy. Humanbodyfluids, such as CSF and plasma,are rich sources of
proteins andin particular glycoproteins, which are recognised diagnostic
markers of disease (110;127).
Oneofthe basic requirements for proteome studies is the need for a
separation method that is capable of separating very complex protein
mixtures, even many thousandsof proteins in one experiment. At present,
2D PAGEis the simplest method for the separation of complex protein
mixtures in proteomics research. 2D PAGEprovides aninitial basis for
comparing a selection of proteomes for potential diagnosis and instant
proteome comparison. The differentially expressed proteins can be
located on a 2D gel by a comparison of the proteomes contained in the
digitised gel images obtained from the CSF proteomes of controls and
patients (128).
2D PAGE was used to test three hypotheses. (1) There is a
difference between the 2D gelprofile of clinically normal (control) CSF
and clinically diagnosed meningitis CSF. (2) There are differences
between the 2D gel profile of non-survivors and survivors of
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pneumococcal meningitis. (3) The meningitis CSF contains
pneumococcalproteins as well as host responseproteins.
3.2 Materials and Methods
All chemicals were purchased from Sigma Aldrich (Poole, UK),
VWR (Lutterworth, UK) or Fisher (Loughborough, UK) unless otherwise
stated. General solutions used for the analysis were made using HPLC
grade water. The pH ofall solutions used in this chapter was adjusted by
the addition of 1 M HCl or NaOH. Other solutions used in this chapter
include: (1) Rehydration solution (composition: 8 M urea (Sigma), 3%
w/v CHAPS, 0.5% w/v IPG buffer 3-10 NL (GE Lifesciences), 10 mM
DTT, and 0.5 mg bromophenol blue. (2) Equilibration buffer
(composition: 50 mM Tris-HCI pH 8.8, 6 M urea, 30% v/v glycerol, 2%
w/v SDS, and 0.5 mg bromophenol blue). (3) Reducing solution
(composition: 0.1g DTT and 10 ml equilibration buffer), and (4)
Alkylating solution (composition: 0.45 g iodoacetamide in 10 ml of
equilibration buffer).
3.2.1 Patient CSFSample Selection
The 2D PAGEanalysis included patient samples from the rapid
death group (non-survivors, n = 11) and the well group (survivors, n = 9).
‘Normal’ CSF was obtained from patients who had presented with
symptomsand foundto have no evidenceof infection on lumbar puncture
(n = 10). Details of patients used in this analysis are given in table 3.1.
3.2.2 Sample Preparation
CSF Preparation
CSF samples werestored at -20°C within an hour of sampling andat
-80°C from 24 hrs until the time of analysis (See appendix A). Archived
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Table 3.1 Clinical details ofpatients used in pilotproteomics
 
Cerebrospinalfluid sample
 
Normal Non-survivors Survivors
N=10 N=9 N=11
Age-yrs mean (+/- SD) 27.8 (9.5) 28.3 (4.8) 35.0 (14.7)
Male sex - number 3 2 5
Glasgow ComaScore - mean (+/- SD) 9.4 (4.7) 11.6 (2.8) 8.0 (3.0)
SGU Mime (0 PYERENESEON 55.2(12-96)  50(18-72)  86.5(10- 168)(Interquartile range)
Previous antimicrobials - number 2 0 0
Positive CSF culture (%) - 9 (100) 11 (100)
Positive blood culture (%) - 3 (33) 4 (36)
Blood culture unavailable - 1 0
Hemoglobin, g/dL (+/- SD) - 9.8 (1.4) 10.2 (3.3)
Steroid Treatment — number(placebo) - 0 (9) 0 (11)
HIV Positive (% of those tested) - 9 (100) 11 (100)
HIV Not known 10 - -
Survival at day 10 - 0 11
 
The table above shows the patient data for CSF samples used in this
analysis. All meningitis subjects were diagnosed as havingpneumococcal
meningitis caused by Streptococcus pneumoniae, all subjects were HIV
positive andall samples were collected before any treatment commenced.
Normal CSF was obtained from patients who tested negative for
meningitis or any other pathogen. The HIV status of the normalpatients
was not known.
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CSF was thawed on ice and desalted using a centrifugal filter (YM3,
Amicon and Microcon, Millipore). The salt content in CSF must be
removed, or decreased significantly, before 2D PAGE. A high salt
content interferes with the electrophoretic separation of proteins because
of the high electrical current that is carried by the salt load. This reduces
the quality of the 2D PAGE separation.
The concentration of protein was determined using the Bradford
assay as discussed in chapter 2. Samples with protein concentrations
lower than 1 mgml”’ were concentrated by vacuum centrifugation to a
volumesufficient for analysis with 2D PAGE.
Pneumococcal Culture Protein Extraction
In order to compare and confirm the presence of pneumococcal
proteins in meningitis CSF, protein from pneumococci was extracted and
compared against meningitis CSF. The pneumococcal types cultivated
were serotype 1, 6b and 14. The bacteria were cultured on human blood-
agar plates at 37°C in 5% CO overnight. The pneumococci were then
cultivated in Todd-Hewitt media supplemented with yeast extract (TH-Y,
BD sciences) overnight or until mid-log phase (O.D. of 0.4 — 0.6 at 620
nm). Bacterial samples were “snap” frozen in liquid nitrogen. A proteome
extraction kit (Qiagen, Valencia, CA, USA) was used in accordance with
the manufacturer’s instructions to extract bacterial proteins via the freeze
thaw cycle. Protein was separated from the TH-Y media by ice cold
acetone protein precipitation. Protein content was measured using the
Bradford assay as described. The protein yielded from this was analysed
using 2D PAGEwith the same conditions as used for CSF samples.
3.2.3 2D PAGE
For each CSF sample a volume equivalent to 75 pg (for silver
staining) of total protein was brought to a final volume of 260 pl with
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rehydration solution. This solution was added to a dry strip re-swelling
tray. IPG strips (13cm, 3-10 non linear, GE Lifesciences) were placed
into the lanes of the re-swelling tray with the protein/rehydration buffer
mix. In-gel rehydration was carried out for 20 hrs at room temperature
(129).
After rehydration, isoelectric focussing was carried out using a
Multiphor™ II flat bed electrophoresis system (Pharmacia, Uppsala
Sweden). Proteins were focused at 300 V (1 hr), 1500 V (1 hr), and then
3000 V (20 hrs). The IPG strips were equilibrated at room temperature in
reducing solution and then alkylating solution for 15 min each.
After equilibration, the IPG strips were applied to vertical 12.5%
SDS polyacrylamide gels (gel plate size 180 x 160 x 1.5 mm).
Electrophoresis was performed at room temperature using a constant
current of 25 mA per gel using an SE 600 series vertical slab gel
electrophoresis units (Hoefer, Little Chalfont, Buckinghamshire, UK).
For each sample, 2D PAGE was repeated in duplicate. The standard
molecular weight markerproteins consisted of hen egg white conalbumin
(76 kDa), bovine serum albumin (66.2 kDa), Bovine muscle actin (43
kDa), rabbit muscle GAPDH (36 kDa), bovine carbonic anhydrase (31
kDa), soybean trypsin inhibitor (21.5 kDa) and equine myoglobin (17.5
kDa).
2D gels were stained with silver stain because of its high detection
sensitivity (130;131). The smallest protein spot visible with silver
staining generally correlates to one nanogram of protein. That amount
(ca. hundredsof fmol, depending oneachprotein’s Mr) generally suffices
for the mass spectrometric characterisation of the proteins (see chapter 2)
dependingon the sensitivity of the mass spectrometry method.
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3.2.4 2D PAGE Comparison Software
The gels under analysis were silver stained in order to detect low
abundance proteins. The abundance of protein spots on the 2D PAGE
gels was analysed by scanning the spots with a PowerLook 111 scanner
(UMAX, Taiwan). The gels were compared using Progenesis software
PG220 (Nonlinear Dynamics, Newcastle, UK). The gels were analysed in
four groups; normal (control 1), bacteria (control 2), non-survivors and
survivors. The order of analysis included:
Reference Selection
A reference gel was selected which encompassed the greatest
numberofspots. In addition a gel wasselected to represent each group to
produce an ‘averaged reference’ gel for each ofthe four groups.
Spot Filtering
The spots generated were manually filtered to remove erroneous
spots which would have confounded the final result. This was reduced as
much as possible in order to avoid potential adverse effects on the
outcomeofthe analysis. The background wassubtracted using the ‘Mode
of none spot’ method which calculates the background based on the most
commonpixel value in the region aroundthe spot.
Warping andMatching
Warping was performedvia vector alignment. Manual warping was
required for some spots. However this was reduced as muchaspossible.
Manual warping wasused to overcome 2D gel swirling, generated in the
gel during the isoelectric focusing stage of protein separation. In order to
improve matching between the gel spots of the individual gel and the
reference gels, a reduced stringency of matching was used. Spots were
acceptedif present in at least 50% ofthe gels in each group.
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Normalisation
In this analysis normalised volume was used, which is a
computerised construct which creates a 3D visualisation of the protein
spot based on the intensity of the spot as shown in Figure 3.1. All spots
were normalised using the Total spot normalisation method. In this
normalisation method, each spot on a gel image is expressed relative to
the total volume ofall spots on that image. Since this tends to produce
extremely small values, the ratio can be multiplied by a user defined
scaling factor (in this experiment 100). The software performsa t-test on
the normalised volumes. Initially the reference gels are compared within
the individual groupsto their respective reference gel. Next the averaged
gels are compared by comparing the averaged gels with the referencegel.
The ‘Total spot normalisation’ method is the most appropriate
method in situations where images within a single experiment have
widely differing numbers of spots, ensuring that all spots will only be
normalised relative to those spots that are present on all gels within a
group. This method assumes that few protein spots are changing within
the experiment, orifthey are, that the bulk of changes are averaged out. It
also assumes that those spots which are changing don’t contribute to a
large proportion of the total volume of spots (132).
Progenesis Statistics
In the Progenesis software, the Welch t-test for unequal variance
data was used to identify those spots in the two averaged gels that
differed in normalised volume for a spot. The null hypothesis being that
there was no change in the protein’s normalised volume between the
groups.
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C  
Figure 3.1 Comparison of Normalised volume. To accurately compare
the abundance of protein spots across 2D gels, it was essential to
compensate for variations from external sources of interference caused
by suchthings as variations in staining time. Normalisation is the process
ofremoving such variation. In this analysis normalised volume was used.
This is a computerised construct which creates a 3D visualisation of the
protein spot based on the intensity of the spot. For example when two
spots are matched. In gel A, the spot wasfound to have a low normalised
volume compared to the same spot in gel B. This normalised volume can
be compared betweengels in order to determineifthere is a difference in
intensity (representedin the bar chart, C).
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3.3 Results
3.3.1 Cerebrospinal Fluid Sample Information
In the initial experiment, the 2D gel profile of 30 CSF samples was
compared. Analysis was carried out on clinically normal CSF (n = 10)
and clinically diagnosed pneumococcal meningitis CSF (n = 20). These
20 meningitis CSF samples were used as representative of the spectrum
of protein profiles in meningitis CSF. It was observed that protein
saturation occurred in the 2D gel analysis beyond this numberof samples.
Saturation occurred asa result of protein spot themes developing amongst
all the gels and also protein spot metathemes developing i.e. themes
within the groups. This saturation effect was a result of basic spot
patterns caused by endogenousproteins within CSF.
In addition these samples had the largest distribution of
concentrations of proteins found in the collection of CSF. Therefore the
proteins which were present in these 20 samples were most likely to
represent the proteomic profile of the CSF collection as a whole. All
subjects were diagnosed as having pneumococcal meningitis caused by
Streptococcus pneumoniae, all subjects were HIV positive and all
samples were collected before any treatment commenced. Normal CSF
was obtained from patients who tested negative for meningitis or any
other pathogen.
3.3.2 CSF Protein Concentration
The concentration of protein in each sample was measured using the
Bradford assay. The ‘normal’ samples had a protein concentration
ranging from 0.05 — 0.94 mgm!’ (average 0.23 mgml'). The non-
survivors had a protein concentration of 2.33 — 10.40 mgml'' (average
6.94 mgml''). The survivors had a range of protein concentration of 3.16
— 10.89 mgml'' (average 7.07 mgml’, Figure 3.2). The protein
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Figure 3.2 Protein concentrations observed in initial CSF samples
CSF. The total protein concentration ofCSF did vary between survivors
and non-survivors (p < 0.1). However both non-survivor and survivor
CSF had a significantly greater concentration ofprotein compared to
normal CSF (p < 0.01).
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concentration in normal CSF was significantly less than clinically
diagnosed meningitis CSF (p < 0.01).
3.3.3 Progenesis Analysis:
Differences between CSF 2D GelProfiles
For this experiment the gels were analysed in three groups; normal
(control), non-survivors and survivors (Figure 3.3). Initially the normal
CSF gels were comparedagainst the clinically diagnosed meningitis CSF
gels. Normal CSF was found to have an average of 638 protein spots per
gel. The average number of protein spots identified in clinically
diagnosed meningitis CSF gels was 2466. There were 20 protein spots in
normal CSF which were commontoclinically diagnosed meningitis CSF
gel spots as shown in figure 3.4A. Therefore there were over 2400
proteins which were novel to meningitis CSF. All of these 20 spots
matched wereat least five-fold lower in expressed normalised volume in
the normal CSF samples comparedto the clinically diagnosed meningitis
CSF. These data are shown in table 3.2.
The average numberof protein spots identified in the non-survivor
gels was 2386 and the survivor gels had an average of 2546 protein spots
per gel.
The normalised volume data for all spots on the average non-
survivor gel was compared with the normalised volumedata forall spots
on the averaged survivor gel. There were 469 common spots between
non-survivors and survivors (present in a minimum of 50% of gels). This
comparison identified 34 proteins with a minimum 2-fold difference in
normalised volume between non-survivors and survivors as summarised
in table 3.3. All of these proteins identified had a significantly lower
concentration in the normal CSF compared to the clinically diagnosed
meningitis CSF. None of the 20 protein spots which were common to
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Figure 3.3 Representative CSF 2D gels. In this figure four gels were
selected as representative ofthe protein profiles observed in the 2D gels.
The most concentrated 2D gel is shown on the left with the least
concentrated on the right. CSF was separated using 2D PAGE. The gels
were grouped into three groups ofnormal’s, survivors and non-survivors.
2D PAGE separates proteins based on isoelectric point and molecular
weight. The proteins are visualized using silver stain and analysed for
differences. It can be observed that the normal CSF has less protein
compared to the survivors and non-survivors. It can also be observedthat
both groups show a wide range ofappearances. (The entire collection of
gels is shown in appendix C).
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Figure 3.4 Comparison of2D gels of normal and meningitis CSF. The
green arrows represent upregulated protein spots and the yellow arrows
represent downregulated protein spots. Spots were accepted provided
they were present in a minimum of 50% of the gels analysed in that
group. In A the normalised volume ofeach spot identified in normal CSF
was compared to the normalised volume of each spot identified in
diseased CSF. There were 20 protein spots found to be common between
diseased and normal CSF. All 20 proteins were significantly upregulated
in normal CSF. In B there were 34 differential expressed proteins found
between survivors and non-survivors ofmeningitis.
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Table 3.2 Spots in Normal CSF compared to Diseased CSF
 Expression
Spote. warpiikoa/en) medion 5%" median 5% aiterence in
NormalCSF
1 66, 4.50 0.003 0.001 — 0.006 0.017 0.009 — 0.036 -6.0
2 66, 4.50 0.002 0.002 — 0.090 0.016 0.010 — 0.056 -9.2
3 66, 4.50 0.002 0.000 — 0.012 0.018 0.020 —- 0.089 -7.5
4 40, 4.00 0.002 0.000 — 0.034 0.033 0.027 — 0.098 -16.4
5 40, 7.00 0.001 0.001 — 0.078 0.005 0.018 — 0.078 -5.5
6 38, 7.00 0.004 0.001 — 0.034 0.038 0.042 - 0.120 -10.7
7 36, 7.00 0.004 0.007 — 0.013 0.030 0.026 — 0.110 -8.1
8 35, 6.90 0.003 0.004 — 0.016 0.037 0.094 — 0.106 -11.0
9 35, 6.90 0.003 0.000 — 0.085 0.034 0.025 — 0.078 -9.9
10 36, 6.00 0.002 0.002 — 0.013 0.042 0.050 — 0.160 -23.6
11 36, 6.00 0.006 0.001 — 0.023 0.032 0.026 — 0.098 -5.0
12 31, 5.00 0.003 0.000 — 0.078 0.017 0.023 — 0.089 -5.4
13 27, 5.10 0.003 0.000 — 0.010 0.056 0.050 — 0.090 -21.3
14 21, 5.00 0.003 0.000 — 0.034 0.018 0.048 — 0.078 -6.4
15 19, 7.00 0.003 0.001 — 0.067 0.034 0.022 — 0.098 -10.4
16 19, 7.00 0.001 0.000 — 0.012 0.005 0.018 — 0.078 5.5
17 20, 5.50 0.002 0.000 — 0.067 0.031 0.108 — 0.230 -16.7
18 22,5.40 0.004 0.000 — 0.034 0.037 0.094 — 0.120 -9.1
19 22, 5.00 0.004 0.001 — 0.016 0.028 0.065 — 0.130 -7.1
20 22, 4.50 0.001 0.000 — 0.018 0.010 0.046 — 0.120 -14.7
 
The 20 spots found to be common between diseased and normal CSFis
shown above. The median ofthe data and lower to upper 95% confidence
interval (CI) are shown along with the expression value asfold difference
in normal CSF compared to CSFfrom patients clinically diagnosed with
meningitis.
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Table 3.3 Spots in non-survivors comparedto survivors
 
; Non- ; Expression Fold
_ apiel) survivors 95% Cl ee 95% CI Difference in
Median Non-survivors
1 76, 6.30 0.012 0.005 - 0.020 0.059 0.002 - 0.117 -4.8
2 66, 5.90 0.008 0.002 - 0.014 0.022 0.006 - 0.038 -2.8
3 60, 5.90 0.012 0.005 - 0.019 0.047 0.010 - 0.085 -4.9
4 60, 5.80 0.019 0.006 - 0.032 0.083 0.000 - 0.203 -5.0
5 59, 5.60 0.013 0.007 - 0.018 0.052 0.000 - 0.113 -3.6
6 58, 5.30 0.027 0.006 - 0.048 0.070 0.028 - 0.112 -2.5
7 60, 4.70 0.010 0.000 - 0.024 0.021 0.005 - 0.037 -3.0
8 58, 4.90 0.050 0.002 - 0.098 0.025 0.000 - 0.051 2.9
9 48, 5.81 0.130 0.047 - 0.213 0.032 0.000 - 0.066 5.1
10 50, 5.50 0.025 0.015 - 0.035 0.057 0.023 - 0.091 -2.5
11 50, 5.60 0.118 0.038 - 0.197 0.035 0.005 - 0.066 3.3
12 50, 5.60 0.068 0.030 - 0.106 0.026 0.011 - 0.042 2.5
13 50, 5.60 0.027 0.000 - 0.053 0.009 0.004 - 0.014 2.5
14 60, 6.00 0.086 0.010 - 0.161 0.029 0.001 - 0.057 3.6
15 60, 6.00 0.050 0.016 - 0.084 0.018 0.000 - 0.039 2.7
16 50, 6.20 0.053 0.023 - 0.083 0.033 0.017 - 0.049 2.0
17 43, 5.60 0.075 0.028 - 0.122 0.179 0.094 - 0.264 -2.0
18 43, 5.40 0.045 0.004 - 0.086 0.104 0.071 - 0.138 2.7
19 40, 5.40 0.085 0.056 - 0.115 0.195 0.121 - 0.269 -2.2
20 55, 5.20 0.095 0.029 - 0.162 0.039 0.022 - 0.056 3.0
21 40, 5.00 0.027 0.005 - 0.050 0.117 0.057 - 0.178 -5.5
22 40, 4.70 0.055 0.000 - 0.118 0.097 0.000 - 0.210 -2.1
23 40, 4.70 0.032 0.001 - 0.055 0.061 0.029 - 0.093 -2.5
24 40, 5.20 0.083 0.030 - 0.135 0.023 0.009 - 0.038 3.4
25 38, 5.20 0.026 0.009 - 0.044 0.051 0.025 - 0.077 -2.2
26 36, 4.75 0.013 0.005 - 0.021 0.038 0.014 - 0.062 -2.5
27 38, 5.10 0.022 0.006 - 0.037 0.007 0.000 - 0.014 3.1
28 35, 5.40 0.022 0.008 - 0.036 0.061 0.010 - 0.112 -2.9
29 40, 5.70 0.063 0.000 - 0.129 0.035 0.014 - 0.055 2.1
30 37, 7.10 0.022 0.000 - 0.044 0.007 0.002 - 0.013 2.8
31 20, 5.60 0.005 0.000 - 0.010 0.014 0.001 - 0.027 -3.8
32 20, 6.00 0.169 0.000 - 0.346 0.392 0.130 - 0.654 -2.0
33 50, 5.90 0.053 0.022 - 0.083 0.023 0.016 - 0.030 2.7
34 27, 5.90 0.027 0.000 - 0.056 0.007 0.001 - 0.013 4.0
 
The 34 spots found to differ between survivors and non-survivors of meningitis are
shown above. The median of the data and lower to upper 95% confidenceinterval (Cl)
are shown along with the expression value asfold difference in non-survivors compared
to CSFfrom survivors.
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clinically diagnosed meningitis CSF and normal CSF was matched to any
of the protein spots in the list of spot differences found between non-
survivors and survivors.
Pneumococcal Protein Spots in Clinically Diagnosed Meningitis CSF
In this experiment protein was extracted from cultured pneumococci.
The protein yield from the pneumococcal protein extraction was
relatively low and the subsequent expression of protein spots was weak.
The concentration of protein in sp] = 0.23 mgml', sp6b = 0.19 mgm!’
and sp14 = 0.14 mgml”. The gels were analysed as described previously.
The numberofprotein spots identified in SP1 was 815, sp6b was 789 and
spl4. was 737. These gels were used to produce an averaged
pneumococcal gel which had 350 commonprotein spots between the
gels. Of these 350 proteins only three proteins were matched to proteins
in clinically diagnosed meningitis CSF gels as shown in figure 3.5.
3.4 Discussion
3.4.1 Normal CSFProtein Differences
In the initial analysis normal CSF was compared to clinically
diagnosed meningitis CSF. The concentration of protein in normal CSF
wassignificantly lower compared to clinically diagnosed meningitis CSF.
This was visually striking from the 2D gel images. There was a clear
difference between the protein profile in normal CSF gels and the protein
profile in clinically diagnosed meningitis CSF gels.
Over 2400 proteins were unique and present only in the meningitis
CSF. Based on our knowledge of the pathology of this condition it is
highly likely that these proteins are present in CSF as a direct
consequence of meningitis. There are a numberofexplanations that could
explain the observation; they couldpotentially be a result of the
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Figure 3.5 Comparison ofpneumococcal protein lysate with clinically
diagnosed meningitis CSF. Pneumococcal protein was extracted from
cultured pneumococci. This cultured pneumococcal protein was
separated using 2D PAGE. The subsequent 2D gelprofile was compared
to clinically diagnosed meningitis CSF. A - An averaged pneumococcal
protein gel was created using the pneumococcal types, spl, sp6b and
spl4. B - There were three protein spots found to be common in
pneumococcalprotein gels andclinically diagnosed meningitis CSF gels.
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breakdown of the blood-brain barrier: a consequence of the
pneumococcal response: due to a significant upregulation of protein
within CSF itself (host response) or some combination of the above.
There are many proteins which have been discovered to be associated
with meningitis. It is likely that these proteins spots will include host
response proteins including cytokines, chemokines and growth factors
(133). In addition it is likely that pneumococcal proteins will also be
amongst these proteins.
3.4.2 Non-survivors Compared to Survivors
In the second analysis the non-survivor CSF average gel was
compared to the survivor CSF average gel. A numberof the samples had
protein spots which were commonto all the gels. These endogenous
proteins demonstrated that the 2D gels were reproducible. However there
were a large numberofspot differences within individual gels of both the
non-survivor and survivor groups. Also there were a large number of
protein spots that were unique to individual samples. These were
excluded from the analysis. There were commonproteins between non-
survivors and survivors which differed in their total expression.
3.4.3 Pneumococcal Proteins in Clinically Diagnosed Meningitis CSF
In the third analysis pneumococcal proteins were compared against
meningitis CSF proteins. The number of proteins identified from the
pneumococcal protein extraction were similar to spot counts obtained
from other research groups as demonstrated in Enchevaet al (134). The
yield of protein extracted from the pneumococcal culture was low. This
was most likely a result of the extraction procedure which was optimised
to avoid inhibiting the 2D PAGEprocedure.
In this analysis only three protein spots were common between the
pneumococcal protein 2D gel average and the meningitis CSF 2D gel
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average. This would indicate that the proteins in meningitis CSF are
composed predominantly of host proteins with a very small number of
pneumococcalproteins.
Although the pneumococcal proteins were useful in establishing
what proteins were present in the meningitis CSF gel 1.e. either host
response proteins or pneumococcal proteins they were not the ideal
solution. A more accurate control would have involved culturing
pneumococciin an artificial CSF and comparing the proteins produced.
However based on the complexities seen the amount of endogenous
proteins may have confounded the identification of pneumococcal
proteins.
3.4.4 Strengths and Weaknesses of Using 2D PAGE
The technique of separating proteins on a global scale using 2D
PAGEis a complex and labour intensive process despite rapid advances
in the technology associated with this technique. Also the complexity of
Progenesis software wasa rate-limiting factor in the analysis. 2D PAGE,
however, has been successfully used to analyse cerebrospinal fluid for
other diseases such as Alzheimer’s disease and Creutzfeldt-Jakob disease
(135;136). It has been found to be useful in identifying biomarkers in a
numberof diseases, such as cancer and has lead to the development of
drugs used in the treatment of that disease (137). It was for this reason it
was considered a good strategy for identifying proteins of interest
associated with pneumococcal meningitis.
2D PAGEallowed for a substantial number of CSF protein spots to
be separated and observed. The sensitivity of silver staining allowed
many thousandsofproteins to be visualised in the CSF proteome.In our
hands the 2D gels were highly reproducible despite other papers
suggesting otherwise. The process of normalisation in Progenesis tended
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to negate the effect of differences from staining or co-migration of spots.
However the analysis has suggested some interesting areas where
potential biomarkers of interest might be found for further analysis.
3.5 Conclusions
In this chapter it has been shown thatthereis a significant difference
in the protein profile of normal CSF and meningitis CSF. There are also a
numberof differences between non-survivors and survivors. Howeverthe
analysis is complicated by the fact that there are a numberofprotein spot
differences within the individual groupsalso.
It has been demonstrated that meningitis CSF is composed of both
host response proteins and pneumococcal proteins. However the
pneumococcal proteins are largely confounded by the host response
proteins.
The next step for this analysis will require protein spots to be
excised out and formally identified. Identification of the excised spot can
be achieved by subjecting the protein spots to in-gel tryptic digestion.
The trypsin digested fragment can then be analysed by other techniques
in particular, liquid chromatography- tandem mass spectrometry (LC-
MS/MS) or Matrix assisted laser desorption/ ionisation time of flight
(MALDI-TOF) mass spectrometry.
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4.1 Introduction
Massspectrometry is a powerful analytical technique which is used
to analyse small molecules and complex biomolecules, such as DNA,
lipids, carbohydrates and proteins. The scope of the use of mass
spectrometry in the biological sciences has grown enormously with
applicationsto all areas concerned with events occurring at the molecular
and macromolecular level. One of the most impressive aspects of mass
spectrometry is the diversity of the technique itself. It allows an insight
into biological systems because these mass specific devices can make
measurements at the molecular level. In addition it is a bioanalytical
technique with almost unparalleled sensitivity, thus providing an ability
to mine substantially deeper into the serum or plasma proteomesthan has
previously been possible (94).
The technique involves the study of the mass-to-charge ratio (m/z)
of atoms, molecules or fragments of molecular ions (112). Spectral
information can be obtained that produces only molecular species for
molecular mass measurements or fragmentation data of sufficient detail
to allow sequencing andstructure elucidation.
The mass spectrometry methods used in this chapter include matrix
assisted laser/desorption time offlight mass spectrometry (MALDI-TOF-
MS) and liquid chromatography electrospray ionisation tandem mass
spectrometry (LC-MS/MS). MALDI is more sensitive than other laser
ionisation techniques (112). MALDIuses peptide mass fingerprinting of
digested proteins to identify proteins whereas LC-MS/MS uses ion
fragmentation of digested or intact proteins to identify proteins.
This chapter focuses on the formalidentification of the cerebrospinal
fluid protein spots selected in chapter 3 as biologically interesting. This
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identification has been carried out using modern mass spectrometry and
subsequent database searching.
4.2 Materials and Methods
All chemicals were purchased from Sigma Aldrich (Poole, UK),
VWR (Lutterworth, UK) or Fisher (Loughborough, UK) unless otherwise
stated. General solutions used for the analysis were made using HPLC
grade solvents. The pH ofall solutions used in this chapter was adjusted
by the addition of 1 M HCl or NaOH.
4.2.1 Protein Identification
Sample Selection
Protein spots from 2D gels presented in chapter 3 wereselected to
be identified using mass spectrometry (Figure 4.1).
4.2.2 Protein Function Clustering
The proteins identified were analysed using three web based protein
tools; (1) Protein information resource (PIR,
http://pir.georgetown.edu/pirwww/). The data submitted to the PIR was
Swiss Prot accession numbers (Appendix D). This tool analyses all the
proteins against the Gene Ontology databases.
(2) Gene Ontology (GO, http://www.geneontology.org/). The two
main components of the GO that were included in this analysis were
‘molecular function’ and ‘biological process’. Only the GO slim codes
are shown (GO slim codesare cut-down versions of the GO ontologies
containing a subset of the terms in the whole GO. They give a broad
overview of the ontology content without the detail of the specific fine
grained terms).
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Figure 4.1 Spots selected for identification by mass spectrometry. The
34 spots found to be differentially expressed between non-survivors and
survivors above were excised from the 2D gel using a pen picking
method. These spots were then subjected to in-gel tryptic digestion and
identification with mass spectrometry.
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(3) ClustalW  (http://www.ebi.ac.uk/Tools/clustalw2/index.html).
The protein Pearson (FASTA) sequences generated from mass
spectrometry were inputted into ClustalW (122). ClustalW allows the
multiple alignments of protein sequences. The basic information they
provideis the identification of conserved sequence regions. This is very
useful in designing experiments to test and modify the function of
specific proteins, in predicting the function and structure of proteins and
in identifying new members of protein families. A phylogram was
generated (a branching diagram (tree) that is assumed to be an estimate of
a phylogeny). The branch lengths were proportional to the amount of
inferred evolutionary change.
4.3 Results
Protein spots which were found to be differentially expressed in
normal and clinically diagnosed meningitis CSF were excised and
analysed with MALDI TOF and LC-MS/MS.
4.3.1 Common Proteins ofNormal and Meningitis CSF
The majority of proteins identified in normal CSF which matched to
meningitis CSF (n = 20) included immunoglobulin G (IgG, heavy and
light chains, 40%) and serum albumin (20%). Other common proteins
found included, ceruloplasmin, transthyretin, o-1-antichymotrypsin,
apolipoprotein-a-1, apolipoprotein-a-4 and haptoglobin.
4.3.2 Protein Differences between Non-survivors and Survivors
Protein Identification
34 proteins were identified as showing a minimum 2-fold expression
difference in non-survivors compared to survivors. The protein spot
differences identified are given in full in Table 4.1 with corresponding
expression given in appendix E.Protein differences with the largest fold
expression included: Chitotriosidase (CHIT1), Serotransferrin (TRFE),
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Brain-enriched guanylate kinase-associated (BEGIN), Complement C3
precursor (CO3), phosphoglucomutase-like protein 5 (PGMS), Cleavage
stimulation factor 64 kDa subunit tau variant (CSTFT), Beta-2-
glycoprotein 1 precursor (APOH), Solute carrier family 25 (member 16,
GDC), Fascin (Singed-like protein, FSCN1), complement Clq tumour
necrosis factor-related protein 9 (C1QT9), tryptophan/serine protease
(YH004), Rab-37 and glyoxalase domain-containing protein 4 (GLOD4).
Functional Clustering
The proteins were cross-referenced using there UniProtKB/ Swiss-
Prot accession numbers. The accession numbers were inputted into the
PIR database and searched against the GO database. Most of the proteins
identified had multiple processes and functions, which made analysis
complex (Figure 4.2 and 4.3). Thus by cross referencing the proteins with
known aspects of pneumococcal meningitis, the identified protein spots
were functionally clustered into the following groups: Membrane and
skeletal proteins (n = 4), transporters (n = 2), glycoproteins (n = 2), G
proteins of the Ras family (n = 1), metabolic enzymes (n = 4), cellular
defence proteins (n = 3), globins (n = 1), kinases (n = 2), phosphatases (n
= 3), chaperone (n = 1), protease (n = 1), translation proteins (n = 6),
others (n = 3) and proteins of unknown function (n = 1) (Figure4.4).
Evolutionary Clustering
To determineif there was any evolutionary relationship between the
proteins identified a phylogram tree was constructed for the proteins with
ClustalW, as shown in figure 4.5. Here we showed that there were 9
groups of close ancestral links between the protein sequences. These
links included; group 1 (GLOD4, GDC, PPAL and ZIK1), group 2
(CHIT1, ALBU, and A1AT), group 3 (FSCN1, HNRPC, NLF1, 2AAA,
RN112, RXRG, CO3, PRS7, RAB37 and ZA2G), group 4 (FIBB, TRFE,
CIA30 and BEGIN), group 5 (CSTFT, APOH and YH004), group 6
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(3) ClustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html).
The protein Pearson (FASTA) sequences generated from mass
spectrometry were inputted into ClustalW (122). ClustalW allows the
multiple alignments of protein sequences. The basic information they
provide is the identification of conserved sequence regions. This is very
useful in designing experiments to test and modify the function of
specific proteins, in predicting the function and structure of proteins and
in identifying new members of protein families. A phylogram was
generated (a branching diagram (tree) that is assumedto be an estimate of
a phylogeny). The branch lengths were proportional to the amount of
inferred evolutionary change.
4.3 Results
Protein spots which were found to be differentially expressed in
normal and clinically diagnosed meningitis CSF were excised and
analysed with MALDI TOF and LC-MS/MS.
4.3.1 Common Proteins ofNormal and Meningitis CSF
The majority of proteins identified in normal CSF which matched to
meningitis CSF (n = 20) included immunoglobulin G (IgG, heavy and
light chains, 40%) and serum albumin (20%). Other commonproteins
found included, ceruloplasmin, transthyretin, a-1-antichymotrypsin,
apolipoprotein-a-1, apolipoprotein-a-4 and haptoglobin.
4.3.2 Protein Differences between Non-survivors and Survivors
Protein Identification
34 proteins were identified as showing a minimum 2-fold expression
difference in non-survivors compared to survivors. The protein spot
differences identified are given in full in Table 4.1 with corresponding
expression given in appendix E. Protein differences with the largest fold
expression included: Chitotriosidase (CHIT1), Serotransferrin (TRFE),
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Brain-enriched guanylate kinase-associated (BEGIN), Complement C3
precursor (CO3), phosphoglucomutase-like protein 5 (PGMS), Cleavage
stimulation factor 64 kDa subunit tau variant (CSTFT), Beta-2-
glycoprotein 1 precursor (APOH), Solute carrier family 25 (member 16,
GDC), Fascin (Singed-like protein, FSCN1), complement Clq tumour
necrosis factor-related protein 9 (CIQT9), tryptophan/serine protease
(YH004), Rab-37 and glyoxalase domain-containing protein 4 (GLOD4).
Functional Clustering
The proteins were cross-referenced using there UniProtKB/ Swiss-
Prot accession numbers. The accession numbers were inputted into the
PIR database and searched against the GO database. Mostof the proteins
identified had multiple processes and functions, which made analysis
complex (Figure 4.2 and 4.3). Thus by cross referencing the proteins with
known aspects of pneumococcal meningitis, the identified protein spots
were functionally clustered into the following groups: Membrane and
skeletal proteins (n = 4), transporters (n = 2), glycoproteins (n = 2), G
proteins of the Ras family (n = 1), metabolic enzymes (n = 4), cellular
defence proteins (n = 3), globins (n = 1), kinases (n = 2), phosphatases (n
= 3), chaperone (n = 1), protease (n = 1), translation proteins (n = 6),
others (n = 3) and proteins of unknown function (n = 1) (Figure 4.4).
Evolutionary Clustering
To determine if there was any evolutionary relationship between the
proteins identified a phylogram tree was constructed for the proteins with
ClustalW, as shown in figure 4.5. Here we showed that there were 9
groups of close ancestral links between the protein sequences. These
links included; group 1 (GLOD4, GDC, PPAL and ZIK1), group 2
(CHIT1, ALBU,and A1AT), group 3 (FSCN1, HNRPC, NLF1, 2AAA,
RN112, RXRG, CO3, PRS7, RAB37 and ZA2G), group 4 (FIBB, TRFE,
CIA30 and BEGIN), group 5 (CSTFT, APOH and YH004), group 6
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Unknownproteins Membrane andskeletal proteins
3% 9%
Others
9%
 
   
   
  
Transporters and channels
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Glycoproteins
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Translation
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G proteins of Ras family and
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9% Cellular defence proteins
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Figure 4.4 Functional Clustering of Proteins Identified by Mass
Spectrometry. Clustering of the proteins identified was made simpler
using literature relating possible functions associated with meningitis to
the proteins.
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Figure 4.5 Phylogram of Proteins Identified by Mass Spectrometry. A
phylogram is a branching diagram (tree) that is assumed to be an
estimate of a phylogeny. The branch lengths are proportional to the
amountofinferred evolutionary change. There were 9 groups ofproteins
with close ancestry. These ancestry links were based on the amino acid
sequence homology ofthe proteins identified.
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(ANR42 and DESM), group 7 (CAGE1, KPYM and PGMS), group 8
(CIQTY, TCPZ and EIF2S2) and group 9 (HPT and STYLI1).
In this analysis 34 protein differences were observed between non-
survivors and survivors of pneumococcal meningitis. These 34 proteins
were subsequently identified with mass spectrometry.
4.4.1 Functional Clustering
Clustering of the proteins revealed that most of the proteins
transcription and translation. The GO analysis was able to provide an
accumulation of the current information available on the proteins
protein with meningitis. GO revealed that many of the proteins have
multiple functions. Therefore the groupings were reduced using a
letruentuien anaenh tn Frnig in nn ney aganniatinan nf thn wnentaing «unth
LILWWIALULL SLAIVLIL W LULUDS Ll UlL ally ASSUUIALLIVIL UL LLIL pliyut AS VWVLULL
pneumococcal infection, meningitis or CSF.
4.4.2 Protein Functions
Naat nf tha nentaing idantifGiad wara lilraly; tr ha a raailt af thadviayovre Ul LUI piyveeiiyo JUWVLILILIVNGU WNL LIN w urw a invouit vi Liv
breakdown of the BBB and may bepresent in blood plasma. Noclear
abnormal pathway looked to be altered based on clusters of proteins from
Poet oe?2 34 an a Axx Th xx,Qa VULIUIIULL py Lqa. + A +“up Vi UUW.r x es Oe © = 5
—
OY
proteins identified in the list of differences between non-survivors and
survivors. Surprisingly there were no cytokines also found amongst the
large host endogenous proteins in the CSF. A brief discussion of the
proteins identified is given below (fold difference values were for non-
wae rae2 aAea\:SULVIVULDS).
oo Oo
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be associated with filamentous actin condensation during invasion of the
CNSbyE. coli (161). Therefore it was possible that a similar mechanism
c : Ou ea : in rE r ¢ Y ¢ = QO Q O £2, ES w o> e Cu me Ww 2
muscle cells. It has been detected in CSF before as it is found in the
endothelialcells of the wall of the meninges (162).
Fibrinogen (FIBB, 2-fold downregulated in non-survivors) has a
double function; yielding monomers that polymerise into fibrin and
have been shown to adhere to or invade tissues by utilizing fibrinogen
(160). The downregulation of this protein in non-survivors was most
£ Glaeinagan din taL LIVINOEREU UUL LU
vragulatian in nnnlensetunra\y ia ao mambhor of a cranny of orotoing whichivpeul LULULL LHL 1LUdIMOULVIVUL Ss) 19 @ WIVIUeL Vid Bivuyp VL privet 1S WVU
contain an ankyrin repeat. It was first discovered as a repeated sequence
in yeast cell-cycle regulation proteins. Ankyrin repeats are common in
association with protein binding during the cell cycle.
Metabolic Enzymes
Phosphoglucomutase like protein 5 (PGMS or Aciculin,
cell-cell and cell-matrix junctions (164). It has not been previously
identified in the brain, however, PGMSispart ofthis dystrophin—utrophin
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epithelium and vascular endothelial cells. The short C-terminal isoform
of dystrophin (Dp71) is localized in the glial end-feet surrounding blood
N Dath wnentaing <A} DvVul plylwiiis dave
neurons in the brain and were most likely to be the source of PGMS in
CSF either as a result of breakdown of the BBB or direct neuronal
damagn LPrnoumatiu ALABY. LiiLy LIAL
established therefore the reason for the downregulation of this protein
was not known.
Glyoxalase domain-containing protein 4 (GLOD4, downregulated 3-
fold in non-survivors) was found during the cloning and characterisation
£Lo
17p13.3 in hepatocellular carcinoma (176). It is a member of the
glyoxalase system, a set of enzymesthat play a role in detoxification of
motheloleaval and thea other reacHCULyYIELyYUAGL alu Wie UIT LeaL
metabolism (177). The protein methyl glyoxal has been shown to induce
neurotoxicity through the impairment of detoxification pathways and
The 26S protease regulatory subunit 7 (PRS7, upregulated 2 fold in
wad 3 tha A TD Aanandantvea if wit AL MULPULIUELIL RhaAgradatinn onVEL auallvull VU
ubiquitinated proteins. The regulatory (or ATPase) complex confers ATP
dependencyandsubstrate specificity to the 26S complex.It is involved in
apoptosis, and DNArepair (166).
NADHdehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9,
2 5
~ O° O° a n Mn °
a
a c o e 5 of ° a + s oO 5 as ° O° >
S
© 5 Qa. ss, 2. 5 o 3 Ss —= 9 5 o lon o Nn Ss = S. ° 2 ° > 2 rs
e+ 3 7 ar
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the respiratory chain. The immediate electron acceptor for the enzymeis
believed to be ubiquinone. This molecule has been shown to be expressed
ming UAH infaotian her OC nvpmnning (17QNdit LIU upy 1 JULI uy WD. PIEUMmuinlue es f oO).
Transcription and Translation Proteins
Datinain anid V rrnanetar camma (DYDO IOLFRIA daumeaAgulatinn inJNULULLIVIL AUIU “a LEUULPVLUL Bau ila LIMUIANU, 271ylu UVUWIES JALIVIL LiL
non-survivors) is a member of the retinoid X receptor (RXR) family.
These receptors are involved in the expression of anti-inflammatory
anctiinty iu immuno anacuvity oY immune ce
compounds (144). In mice, vitamin A deficiency is associated with
increased T-cell production of IFN-y and decreased production of IL-4
aA TTUd 1N Th. vali Liv. ii 12)
A deficiency and survival of meningitis.
Cleavage stimulation factor 64 kDa subunit, tau variant (CSTFT
polyadenylation and is directly involved in binding to pre-mRNAs.
Upregulation in non-survivors was most likely due to a rapid increase in
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRPC,
wnragulataduprCEuiawwu 2-10
assembly of 40S hnRNP particles. It plays a role in the early steps of
spliceosome assembly, pre-mRNA splicing and interacts with poly-U
DY FAIA in niu i r e = Q r 1 w ¢ r < pl <1 © = w YY
5 ct _ > 2 —_ 4 “3 0 ar SITITD Af wDNA oJIN UL YTU LIN UL LUNINSA ALL
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associated with neuronal differentiation. It has been implicated in a
variety of functions such as transcriptional regulation, DNA repair, site-
this protein in non-survivors was mostlikely a result of neurogenesis as
result of neuronal cell death (179).
Zinc finger protein 1 (ZIK1, upregulated 2-fold in non-survivors)
has been found to be associated with transcriptional repression (148). It
f +hain KY (LINIRDY ann aMi IS UGA INJ, ULI U nie
major pre-mRNA-bindingproteins.
Eukaryotic translation initiation factor 2 (EIF2S2, 2-fold
NON-SUTVIVOTS) iS TCSponsi
steps in the initiation of protein synthesis. The upregulation in survivors
may be due to an association with an increase in protein production
Auring tha dignagn (1A0NUUs UI ULSLAD \ TO
Phosphatases
Teranganmal Anid Dhaanhatagn (DDAT wnrnoulatad OFAlA in nanLysvoviltal w i LUSpialase (Ad An, UpiLEUL wu 2°71U1U Li lluil
survivors) is a member of a family of distinct isoenzymes which
hydrolyse orthophosphoric monoesters to alcohol and_ phosphate.
radical lipid peroxidation (152).
Serine/Threonine" Phosphatase (2AAA, upregulated 2-fold in non-
rquire:Surv
2AAA hasbeen shown to be associated with neuroprotection (181).
awrara\ weAVULS} Was
Serine/threonine/tyrosine-interacting-like protein 1 (STYLI,
2-fold i
phosphatase-like protein (153) has been found to associate with the innate
immune responses. MAP kinase cascadesare crucial in the biosynthesis
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of proinflammatory cytokines (157). MAP kinase phosphatase has been
found to reguiate MAP kinase in a numberofceili signaiiing pathways,
thara at av ha neanrnding a 4nntix fFAnt againgt MAAD Li gwius it May oC providing a NAcuroproiwciive CiiCCt against iis Kinase
Transport Proteins
Solute carrier protein 25 member 16 (upregulated 3-fold in non-
survivors) is a mitochondrial carrier protein. Mitochondnial carrier
proteins, which are localized in the inner membrane,facilitate the rapid
teanannet and anvohancn anUdalisSpuil alu CAULIALEY VU
mitochondrial matrix space. Membersofthe solute carrier family play an
importantrole in the efflux transport of the blood brain barrier, especially
a detoxification system in the brain (143). Its upregulation may be
associated with the release of the pore forming toxin pneumolysin from
thank ia Ile x tan A aAn1 nown wo acgraacag ax tha witanhan1-1S AGLOWIL UaUe Lit
responsible for the transport of iron from sites of absorption and haem
degradation to those of storage and utilization. TRFE may also have a
Faethae eala inLULUIEL LULL L = w
BBB wasthe most likely source. However, the downregulation ofthis
protein suggest an association with iron which is essential for the nutrient
growth of
conditions is related to the virulence of a variety of bacterial pathogens.
The CSF is a low region of iron therefore Streptococcus pneumoniae
PiA and PiU. Therefore it was possible that pneumococci were utilizing
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transferrin as a source of iron in CSF leading to its reduction in non-
survivors(183).
Glycoproteins
1eta-2-giycoprotein I (a. a)Two giycoproteins were discovered;
most likely upregulated (3-fold) in non-survivors as a direct result of
biood ciotting during the breakdown of the biood-brain barrier (150).
Zine a-2-glycoprotein (2-fold downregulation in non-survivors) is
1secreted in various body fluids where it is invoived preferentiaiiy in
Analatinn nf fath: anida Fram adinnan teoagieg anhananontl namod aqUvplieuvdvil VL tatty MIMO LIU aULpusLe tinsues, Ssuvovyurliuy daLLINU AD
lipid-mobilising factor (151).
-Kinases
Tru leinagaq (wera) fannd:  Demreoate kinaga (KDVN & _falaAi vwvyu DALLIAID Welle LUULIU, L yt uvaly DALLAS (uM Livi yvq1yuiUu
Auring nauralagizral dianage (140)uu ALE UVULVUIVEIvAL ULDLAaADSL \1iv7).
Brain-enriched guanyiate kinase-associated protein (BEGIN,
anracgalatad O_FfAlA tn nan loirutynare’ wad fire identified hy DNeonchi ot alUple ULALLU L2mLULU IIE LIULIT SOUL VEIVUL os) VAO LILO LULL vy eS Vili VE Al.
in 1998 (158) as a novel post synaptic density componentassociated with
he PSD-95/synapse associated protein 90 (i184). it is found in manyas
reduced expression in non-survivors suggests it may have an aiternate
wanlnaum ealaJINTIU Wil LULL.
Other Proteins
T-complex protcin 1 subunit zeta (TCPZ, 2-fold downrcgulation in
a Q Ww
Upati R. Gooneiilieke Chapter 4
al. in 1992 and identified as the human equivalent of the bacterial groEL
detrimentai effect on survivai.
Alpha 1 antitrypsin precursor (ALAT, downregulated 2-fold in non-
survivors) is an inhibitor of serine proteases. its primary target is elastase,
hy + alan hag a madarata offini nlaamin and theambhin (1Q4\ TtU tL alov liad a LlluULlLaul aiiiiiity AVL piaositiiit ALIU LULIULIIUILL \ i OV). At
Inhibits trypsin, chymotrypsin and plasminogen activator, and the
aberrant form inhibits insulin-induced Nitric Oxide synthesisin piateiets,
dAnnenaana anagilatinn time and hag neotenletic activity agcaingt inanlinULLLLADSDLD vuagZul UULLE ULI Mu Has plu Vlylly ALLIVIL apalliot Lt JOULLIL
and plasmin. It is associated with inflammation, and this particular
+protein has been found to be upreguiated in the jungs of humans and mice
Nuciear iocaiized factor i (NLFi, downreguiated 2-foid in non-
anewuiwara\’ idantified he Wartan ot al DNNA aw nlawa rale in pndathaelialOSULVIVUL S)> IUVLIULLIOU uy VYQALLVILI UL AL LUT, m ry. pt @ 1VUIle 1 VHUUVUILad
awarnaand tn andAnthalial nelle and te uRcenoulated hy weclinflammatanyVCAVLUELSSEU LIL CLIUVULIILLIAL ULSD iu 1D UpTives LAWU uy plyriiiii ALILIICALY. 2y
cytokines
Human Serum Aibumin (ALBU, downreguiated 2-foid m non-
thyroid hormones, fat soluble hormones, fatty acids to the liver,
unconjugated bilirubin. It also competitively binds calcium ions (Ca**)
aA.and buffers pH (170)
Haptogiobin (HPT, upreguiated 2-foid in non-survivors) combines
Upali R. Goonetilleke Chapter 4
kidneys and protecting the kidneys from damage by haemoglobin, while
4making the haemogiobin accessibie to degradation enzymes. it may have
£4YU S
o=Awe eanannnan (VULY LUESPULLY
ryptophan/serine protease (YHOO4, upreguiated 3-foid in non-
aueoiara\) ta an prugumn that plaawnd legiarg and argigor hande TtSULVIVULDS) ID all Llizylliv Ullal Vil Ves lysvmale alu alEq-oUl uvuliuDs. Lb
activates, in a reciprocal reaction, factor xii after its binding to a
negatively charged surface. it has functions which are very simiiar to
termain and nchumatremamn (15A\Niby pout aliu’ Vil ALluul y polit \ivT)
Cancer associated gene i (CAGEi, downreguiated 2-foid in non-
wemunra\y wad Aiannuared he GCanwaung Dark at al in DNND ag nart of oVivUlys) VaoO ULVUVEILU U VayYUULLE Lain wl al ill LUYUVUL AD pare via
serological analysis of cDNA expression library (SEREX) to identify
cancer-associated genes from sera of with jung cancer The exact
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e oniy G protein of the Ras family identified was the Ras-reiated
dD AVA aa Awawirivnen\’ DAD-1010 iff HON-SUFVIVOr SJ. INDUDS ~
is a protein which belongs to the small GTPase superfamily which
reguiates ceiiuiar functions inciuding signai transduction, cytoskeietai
to identify a protein, with a success rate of about 70-80% using samples
of humanorigin. ESI was more time consuming than PMF butit provided
a better analysis for protcin mixtures (188). LC-MS/MS can provide a
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PMF instantaneously (188). The limiting factor in the analysis was the
digestion efficiency. Once this was optimised the data was generated
pg quantities of proteins with Mw up to 300 kDa (112). ESI allows
analysis of proteins above 130 kDa with a detection limit of 1 pmol.
hL
(114). Howeverone of the major issues occurred when the protein spots
consisted of more than one protein as it was difficult to identify the
fea own ant Twil L2 2 the aac of MAATTIILTOCLQBUICIIUS. 1 Ue Las UL AVIAYIMtT,
it was necessary to use peak deduction to determine the identity of
proteins which could have affected the outcome of the search. This was
f thiahy aeriterUv AVity UL UllSet ronnat tha nanan in TO_LAC/NMG wan th tha hig gonaUIUL UI Ladue Lb LUMLVLO/IVLO, ui Wo UIY LieID SLL
technique, proteins in the CSF such as immunoglobulin and albumin
tended to confound spectra.
In this analysis the spectral data was searched using Mascotas it
provided a clear and objective system for protein identification through
+hul£ Manns Gaga 1L iMajUL LssouesoOmA Alice VU
< &scores which were obtained in the analysis in MALDI-TOF. It
difficult to
¢ g
g Oo oo; © Nn QO g @) z. é to 0 rr 4 O° Lo a.2. Oo Q
o
e “< > mn 2 —
'
oO DN Sc —s , s Nn
create the final peak list for searching. This may have lead to unnecessary
modifications in the identification.
Theidentified peptides are compiled into a protein ‘hit list’, which is
the output of a typical proteomic experiment. Because protein
proteomics is currently restricted largely to those species for which
comprehensive sequence databases are available. Therefore it is possible
3 + 3 + = 3 oait Ayta a tn thauy Ww iLAi
inferior amount of protein data compared to the human database, many of
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the pneumococcal proteins will have been confounded by host protein.
There is also a potential for false positive recognition rates. This remains
an open problem as how to validate database search results (119). A
further confirmation through Western blotting may be required to
validate the proteins identified as well as confirm any clinical
significance to the proteinsidentified.
4.5 Conclusions
In this chapter it was found that the use of mass spectrometry was
able to discriminate proteins identified in non-survivor and survivor
cohorts. These consisted mostly of cellular defence proteins, protein
transcription and translation molecules and metabolic proteins. There are
a number of proteins which require further analysis to validate the
analysis by mass spectrometry and to determine anyclinical significance.
The next step in this analysis will be to confirm the fold difference in
protein levels found by testing a new set of CSF samples by the
alternative protein analysis method of Western blot.
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5.1 Introduction
The aim of this chapter was to validate the presence of 9 proteins as
potential biomarkers associated with survival from pneumococcal
meningitis using Western blotting. The proteins selected for analysis
were based on literature regarding cell death associated with
pneumococcal disease and the protein identification results from chapters
3 and 4.
Three apoptosis markers were selected for analysis. The apoptosis
markers analysed included caspase 3, apoptosis inducing factor (AIF) and
the marker of necrosis, creatine kinase BB (CKBB).
Six proteins from the list of proteins identified in chapter 4 were
selected for Western blot validation. These six proteins consisted of three
proteins which were potentially of CSF origin. These three proteins
included; retinoic acid X receptor gamma, zinc finger protein 179 and
chitotriosidase. The three proteins which were most likely proteins
originating from serum included; B-2-glycoprotein, complement C3 (C3)
and transferrin.
SDS PAGEand Western blotting are two important and well-known
methods for protein characterisation. Although classical Western blotting
is typically used for qualitative purposes, it also can be used for
quantitative analysis of proteins.
This chapter will aim to test three hypotheses; (1) Classical cell
death protein markers can be detected in CSF. (2) The proteins
discovered in chapter 3 and 4, and their expression profiles can be
validated with Western blotting. (3) These proteins have a predictive
value in explaining the outcome of pneumococcal meningitis.
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5.2 Materials and Methods
All chemicals were purchased from Sigma Aldrich (Poole, UK),
VWR (Lutterworth, UK) or Fisher (Loughborough, UK) unless otherwise
stated. General solutions used for the chapter were made using HPLC
grade water. The pH ofall solutions used in this chapter was adjusted by
the addition of 1 M HCl or NaOH.
5.2.1 Patient information
CSFfor this Western blot analysis included samples from the rapid
death group (n = 40) and the “well” group (n = 40). Control ‘normal’
CSF wasobtained from patients who had beenclinically diagnosed as not
having meningitis (n = 10). Details on patient data are provided in table
5.1.
5.2.2 Antibodies and Control Markers
Antibodies
Primary antibodies used in this analysis were directed against
caspase 3 (9665 and sc-22140), apoptosis inducing factor (AIF, 4642 and
sc-9416) from Cell Signaling (Danvers, MA, USA) and Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Creatine kinase BB (CKBB,
ab38212), zinc finger protein 179 (ab42499), retinoic acid X receptor
gamma (ab15518), chitotriosidase (ab72574) and transferrin (ab1223)
from Abcam (Cambridge, UK). Beta-2-glycoprotein (MCA2114, Abd
Serotec, Oxford, UK) and complement C3 (C7761-1 VL, Sigma Aldrich).
Secondary antibodies were purchased from Dako (Cambridge, UK), and
Nordic Immunology (Tilburg, Netherlands). A summary of the antibodies
used in this chapter are listed in Table 5.2.
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Table 5.1. Clinical Details ofPatients Used in the Host Western Blot
 
 
Analysis
Cerebrospinalfluid sample
Normal Non-survivors Survivors
N=10 N = 40 N=40
Age-yrs mean (+/- SD) 27.8 (9.5) 30.1 (8.4) 33.3 (11.2)
Male sex - number 3 23 16
GCS - mean(+/- SD) 9.4 (4.7) 10.9 (3.2) 8.4 (3.3)
Meantimeto presentation (IQR, hours) 55.2(12-96) 60.2(15-336)  78.6(10-192)
Previous antimicrobials - number 2 7 6
Steroid Treatment — number(placebo) - 17 (23) 21 (19)
HIV Positive — number(% of those tested) - 35 (100) 37 (100)
HIV Not known 10 5 3
Survival at day 10 (%) 100 95 98
 
The table above showsthe clinical data collectedfrom patients providing
CSF samples that were usedin this analysis. All meningitis subjects were
diagnosed as having pneumococcal meningitis caused by Streptococcus
pneumoniae, all subjects were HIV positive and all samples were
collected before any treatment commenced. Normal CSF was obtained
from patients who tested negative for meningitis or any other pathogen.
The HIVstatus ofthe normalpatients was not known.
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Table 5.2 Antibodies Used in Host Western Blot Analysis
 
 
Antibody . AntibodyA fics ; 5piiase ntibody iype Specificity Host Detection Supplier
Zinc finger .protein 179 Polyclonal Human Rabbit ECL Abcam
Human,
RXR Gamma Polyclonal mouse, Rabbit ECL Abcam
hamster
Chitotriosidase Polyclonal Human Mouse ECL Abcam
-2-
B . Monoclonal Human Mouse’ BCIP/NBT AbDSerotecglycoprotein
Primary Transferrin Polyclonal Human Rabbit DAB Abcam
Complement Polyclonal Human Goat DAB Sigma Aldrich
AIF Polyclonal Human, Goat ECL Santa Cruemouse Biotechnology
AIF Polyclonal Human Rabbit ECL Cell Signaling
Caspase 3 Polyclonal Human Rabbit ECL Santa CruzBiotechnology
Caspase 3 Polyclonal Human Rabbit ECL Cell Signaling
eeanliae Polyclonal Human Rabbit ECL Abcamkinase BB
HRP conjugate . kgacondany IgG Antigoat Don ey ECL/DAB Dako
HRP conjugate IgG Anti Goat ECL/DAB Nordic
secondary rabbit immunology
Secondary HRP conjugate _ Anti Goat ECL/DAB Nordic
secondary g mouse immunology
nPrenhyages IgG Ape Goat  BCIP/NBT SigmaAldrichsecondary mouse 
The table above shows the antibodies used in this analysis along with the
corresponding conjugate used in the analysis i.e. either Horseradish
peroxidise (HRP) or alkaline phosphatase (AP).
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Control markers
The positive control lysate used for caspase 3 was Jurkat apoptosis
cells treated with etoposide (9663, Cell Signaling). For AIF, CKBB and
RXR gammathe positive control cell lysate was HeLa whole cell lysate
(sc-2200, Santa Cruz Biotechnology). For zinc finger protein 179 the
positive control lysate used was HepG2cell lysate (sc-2227, Santa Cruz
Biotechnology). For CHIT1 a recombinant CHIT1 protein was used
(3559-GH,R and D systems, Minneapolis, MN, USA).
Blood plasma (obtained from a healthy volunteer) was used as a
control for complement C3, transferrin and beta-2-glycoprotein. In
addition for transferrin a recombinanttransferrin protein was also used as
a positive control (Sigma Aldrich, 90190).
In addition to using the normal CSF as a negative control the other
negative control used was a normal Western blot of the meningitis CSF
samples with the secondary antibody only i.e. without any primary
antibody under the same conditions as used in the normal Western blot
experiments.
5.2.3 CSFSample Preparation
Preparation of CSF samples is described in detail in chapter 2.
Briefly CSF samples were stored at -20°C within an hour of sampling and
at -80°C from 24 hrs until analysis.
5.2.4 Western Blot ofCSF
The concentration of protein was determined using the Bradford
assay as described in chapter 2. Samples were measuredin triplicate. CSF
was separated and analysed using SDS PAGE followed by Western blot.
This method is described in detail in chapter 2. The concentration of
protein calculated in this chapter was based off the total protein content
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and therefore a more accurate measure would involve the use of purified
recombinant proteins for each of the proteins under analysis. For the
comparative analysis this had no effect on the final comparison between
normal, non-survivors and survivors.
5.2.5 CKBB Confirmation
Following the selection of protein bands of interest, these bands
were manually excised from the stained gels and cut into Imm?’slices.
The sections were then subjected to in-gel tryptic digestion and analysed
with MALDI-TOF and LC-MS/MSasdescribed in chapter 2.
5.2.6 Statistics
Pairwise comparisons were performed using an unpairedt-test with
Welch’s correction. This was calculated using Prism software (v. 5.0,
GraphPad, La Jolla, CA, USA) and R software (R project for statistical
computing, free download from http://www.r-project.org/). Charts were
plotted using SigmaPlot (v.10, Systat Software Inc, Chicago, IL, USA)
and Prism Software.
5.3 Results
5.3.1 Sample Information
80 subjects wereselected for analysis. 40 of these CSF samples were
from patients who had an excellent recovery and short clinical course.
These subjects all survived with no neurological impairment (median
duration of symptomsetc). The remaining 40 subjects had very poor
outcomeandall died (median duration of admission = 30 days).
5.3.2 CSF Protein Concentration
The concentration of protein in each sample was measured using the
Bradford assay. CSF from patients clinically diagnosed with meningitis
had a meanprotein concentration of 5.92 mgm! compared to normal
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CSF (mean 0.23 mgmI", p < 0.0001). The CSF from non-survivors had a
protein concentration of 2.20 — 11.30 mgm!’ (mean 6.38 mgm). The
CSF from survivors had a protein concentration of 1.12 — 10.89 mgm!’
(mean 5.46 mgmI'). The mean protein concentration was higher in CSF
from non-survivors compared to CSF from survivors but was not
significantly different (p = 0.09). This is shown infigure 5.1.
5.3.3 Expression ofProtein Markers Associated with Apoptosis
CSF Western Blot to Detect Caspase 3
In the CSF Western blot for caspase 3 none of the 90 CSF samples
expressed a protein band which correlated with caspase 3 as shown in
Figure 5.2A. Caspase 3 wasdetectable in the positive control at levels of
protein as low as 100 ngul'. This positive control band appeared at
approximately 35 kDa which corresponds to the Caspase 3 protein. The
17 kDa cleavage product of caspase 3 wasalso visible in the positive
control but was also not detected in the analysis of the 90 CSF samples.
This Western blot was repeated with two primary antibodies directed
against different regions of the caspase 3 protein structures with the same
outcome. Specificity of the antibodies was confirmed using an antigenic
blocking peptide. The blocking peptide binds to the active site of the
antibody which inhibits the antibody activity leading to quenching of
protein expression.
CSF Western Blot to DetectAIF
In the CSF Western blot to detect AIF none of the 90 CSF samples
had a band which correlated with AIF as shown in Figure 5.2B. AIF was
detectable at levels of protein as low as 100 ngul'. This positive control
band appearedat a level consistent with the 77 kDa AIF protein as shown
in figure 5.2B.
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Figure 5.1 Protein concentrations in larger CSF sample size groups.
‘Normal’ CSF samples had a protein concentration rangingfrom 0.05 —
0.94 mgmt" (average 0.23 mem"). The non-survivors had a protein
concentration of 2.20 — 11.30 mgm! (average 6.38 mgmt!). The
survivors had a range ofprotein concentration of 1.12 — 10.89 memt!
(average 5.46 ment!). The protein concentration in control CSF was
significantly less than meningitis affected CSF (p < 0.0001). The average
protein concentration was higher in non-survivors compared to survivors
but was notstatistically different (p = 0.09).
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35 kDa
17 kDa
77 kDa  
Figure 5.2 Western blot analyses of apoptosis associated proteins
caspase 3 and AIF. A Western blot of Caspase 3 resulted in negative
detection in CSF. Both the 35kDa caspase 3 and cleaved subunits were
visible in the positive control. B Western blot ofAIF resulted in negative
detection ofthe protein in CSF. The 77kDaprotein was visible in the lane
containingpositive control.
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This Western blot was repeated with two primary antibodies
directed against different regions of the AIF protein structures with the
same outcome. Specificity of the antibodies was confirmed using an
antigenic blocking peptide. The blocking peptide binds to the active site
of the antibody which inhibits the antibody activity leading to quenching
of protein expression.
CSF Filtration to Expose AIF
WhenCSFwasanalysed with SDS PAGE,a significant quantity of
protein was also present at the same molecular weight region as AIF. To
determine if AIF expression was being inhibited by another protein, a
filtration experiment wascarried out. Here CSF was spiked with different
concentrations of the AIF positive control(5 ul, 2.5 pl and 0 pl of HeLa
cell lysate). Half of the samples werefiltered using a spin column for
proteins above 60 kDa. These samples were then Western blot as
described earlier. There was no effect on the outcome of the analysis
which indicated that AIF was not being confounded by anotherprotein as
demonstrated in figure 5.3.
5.3.4 Expression ofMarkers Associated with Necrosis
CSF Western Blot to Detect Creatine Kinase BB
Creatine kinase BB (CKBB) was not detected in normal CSF
samples. However, CKBB was discovered in over 40% of meningitis
CSF samples at varying concentrations as shown in figure 5.4. The mean
concentration of CKBBin non-survivors (mean 0.89 mgml”) was higher
than the mean concentration of CKBB in survivors (mean 0.19 mgml”).
Howeverthere was nostatistically significant difference (p = 0.16) as
shown in figure 5.5.
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Figure 5.3 Filtration experiment for AIF. A Coomassie stained SDS
PAGE ofthe filtered and unfiltered CSF samples spiked with differing
concentrations ofthe HeLa cell lysate. The AIFprotein is indicated by a
red arrow. B Western blot of the filtered and unfiltered CSF spiked with
differing concentrations ofthe HeLa cell lysate. There appeared to be no
confounding effect on the detection ofAIF.
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Figure 5.4. Western blot analysis of CKBB. A Western blot ofCKBB in
non-survivors. B Western blot of CKBB in survivors. C SDS PAGE of
non-survivor CSF samples. D SDS PAGE ofsurvivor CSF samples. The
suspected CKBB protein band is indicated by red arrows. The bands
matched in the SDS PAGE and Western blot were excisedfrom the gel
and subject to in-gel tryptic digest followed by mass spectrometry. This
confirmedthepresence ofCKBB.
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Figure 5.5 CKBB levels in CSF. There was no statistical difference
between the levels of CKBB in non-survivors and survivors (p = 0.16).
Howeverthe level ofCKBB was higher in non-survivors (average of0.89
mem!) than the amount ofCKBBin survivors (average of 0.19 mem!").
CKBB was notfound in normal CSF.
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Mass Spectrometry Confirmation ofCKBB
The positive control marker was HeLacell lysate spiked in normal
CSF. In the Western blot CKBB was expressed at region of 43 kDa
consistent with the molecular weight of CKBB (43 kDa). Despite a band
appearing which wasat a level commonto the positive marker, there was
significant cross-reactivity to cast doubt on the band observed being
CKBBas shown in figure 5.4. Thus the band in each CSF sample was
excised and sequenced using mass spectrometry. The protein was
confirmed as CKBBthrough both MALDI-TOF and LC-MS/MSanalysis
with Mascot.
5.3.5 Expression ofProteins ofCSF Origin
CSF Western Blotfor Retinoic AcidXReceptor Gamma (RXRG)
In the previous 2D PAGEanalysis, RXR gamma wasidentified as
being downregulated 2-fold in non-survivors. In this Western blot
analysis there was a significant difference observed between the mean
concentration of RXR gamma in the non-survivor CSF samples (mean
0.69 mgm!) and the mean concentration in survivors CSF samples
(mean 1.38 mgm!) used in the initial 2D PAGE analysis. A 2-fold
downregulation in non-survivors was observed. This wasidentical to the
fold difference observedin the initial 2D PAGEanalysis.
In the analysis of RXR gammain a larger sample size, RXR gamma
was not found in normal CSF. However RXR Gammawasfound in 73%
of non-survivor CSF samples (mean 0.50 mgml') and 83% of survivor
CSF samples (mean 0.36 mgm’). Although the RXRG concentration
was higher in non-survivors, there was nostatistically significant
difference between non-survivors and survivors (p = 0.48) as shown in
figure 5.6.
122
Upali R. Goonetilleke Chapter 5
 CSF  
B
et1 S j
= l
 
0.01 a an Protein Concent
rat
ion
/ m
gm
l
© nm
S 8 =
Figure 5.6 Retinoic acid X receptor gamma levels in CSF. A Western
blot of CSF samples with Retinoic acid X receptor gamma detection. B
RXR gamma was not detected in normal CSF. There was nostatistically
significant difference between non-survivors and survivors (p = 0.48).
However the amount ofRXRG in non-survivor CSF samples (average =
0.50 mgm) was higher than that in survivor CSF samples (average =
0.36 mgmt").
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CSF Western Blotfor Zinc Finger Protein 179
In the 2D PAGEanalysis, zinc finger protein 179 was previously
identified as being upregulated 2-fold in non-survivors. In this Western
blot analysis there was a significant difference observed between the
mean concentration of zinc finger protein 179 in the non-survivor CSF
samples (mean 0.22 mgml’') and the mean concentration in survivors
CSF samples (mean 0.06 mgmI’') used in the initial 2D PAGEanalysis.
A 2-fold upregulation of this protein in non-survivors was observed. This
fold difference wasidentical to the fold difference observed in the initial
2D PAGEanalysis.
In the analysis of Zinc finger protein 179 in a larger sample size,
zinc finger protein 179 was not found in normal CSF however it was
found in 98% of non-survivor CSF samples (average = 0.52 mgml') and
70% of survivor CSF samples (mean 0.41 mgml'). Although its
concentration was higher in non-survivors, there was no statistically
significant difference between non-survivors and survivors (p = 0.59) as
shown in figure 5.7.
CSF Western Blotfor Chitotriosidase
Chitotriosidase was previously identified as being upregulated 5-
fold in non-survivors. In this Western blot analysis there was a significant
difference observed between the mean concentration of chitotriosidase in
the non-survivor CSF samples (mean 1.19 mgml') and the mean
concentration in survivors CSF samples (mean 0.23 mgmI’') used in the
initial pilot proteomics analysis. A 5-fold upregulation of chitotriosidase
was observed in non-survivors. This fold difference observed was
identical to the fold difference observedin the initial 2D PAGEanalysis.
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Figure 5.7 Zinc finger protein 179 levels in CSF. In this analysis zinc
finger protein 179 was notfound in normal CSF. Zincfinger protein was
found in higher amounts in non-survivor CSF samples (average = 0.52
mem') than survivor CSF samples (average = 0.41 mgmt"). However,
there was no statistically significant difference between non-survivors
and survivors (p = 0.59).
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In the analysis of chitotriosidase in a larger sample size
chitotriosidase was not found in normal CSF. Chitotriosidase was found
in 50% of non-survivor CSF samples (mean 0.88 mgm!) and 75% of
survivor CSF samples (mean 0.47 mgml”). Although the chitotriosidase
concentration was higher in non-survivors, there was no statistically
significant difference between non-survivors and survivors (p = 0.09) as
shown in figure 5.8.
5.3.6 Expression ofProteins ofPlasma Origin
CSF Western Blotfor B-2-glycoprotein
In the initial 2D PAGEanalysis, beta-2-glycoprotein was previously
identified as being upregulated 3-fold in non-survivors in chapter 4. In
this Western blot analysis there was no significant difference observed
between the mean concentration of beta-2-glycoprotein in the non-
survivor CSF samples (mean 0.97 mgml'') and the meanconcentration in
survivors CSF samples (mean 0.86 mgm’) used in the initial 2D PAGE
analysis. Although there wasnosignificant difference observed, the trend
of beta-2-glycoprotein being higher in non-survivors was similar to the
expression observedin the initial pilot proteomicsanalysis.
When Beta-2-glycoprotein was analysed in the larger CSF
collection, beta-2-glycoprotein was found in normal CSF (mean 0.13
mgml''), non-survivor CSF samples (mean 0.83 mgml') and survivor
CSF samples (mean 0.69 mgm!) as shown in figure 5.9. Although the
mean concentration of beta-2-glycoprotein was higher in non-survivors
than survivors, there was nostatistically significant difference between
the groups (p = 0.10). There was however a significant difference
between the beta-2-glycoprotein levels in clinically diagnosed
pneumococcal meningitis CSF in comparison to normal CSF (p <
0.0001). There was no statistically different expression of beta-2-
glycoprotein between non-survivors and survivors. The mean expression
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Figure 5.8 Chitotriosidase levels in CSF. Chitotriosidase was notfound
in normal CSF. Chitotriosidase was found in higher amounts in non-
survivor CSF samples (average = 0.88 mgmt") than survivor CSF
samples (average = 0.47 mgml'). There was no statistically significant
difference between non-survivors and survivors (p = 0.09).
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Figure 5.9 Beta-2-glycoprotein levels in CSF. Beta-2-glycoprotein was
found in normal CSF (average = 0.13 mgmt). Beta-2-glycoprotein was
found in non-survivor CSF samples (average = 0.83 mgml') and
survivor CSF samples (average = 0.69 mem"). There was no
statistically significant difference between non-survivors and survivors (p
= 0.10). There was a significant difference between meningitis CSF
compared to normal CSF (p < 0.0001).
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levels of beta-2-glycoprotein were higher in non-survivors indicating a
trend which followed the expression identified by proteomics.
CSF Western Blotfor Complement C3 (C3)
In the pilot 2D PAGE analysis, C3 was previously identified as
being downregulated 4-fold in non-survivors. In this analysis there was a
significant difference observed between the mean concentration of
complement C3 in the non-survivor CSF samples (mean 0.04 mgm!’)
and the mean concentration in survivors CSF samples (mean 0.21 mgmI”
') used in the initial pilot proteomics analysis. C3 was found to have a 5-
fold downregulation in non-survivors. This fold difference observed was
identical to that identified in the initial 2D PAGEanalysis.
In the analysis of Complement C3 in the larger CSF sample
collection, complement C3 was not found in normal CSF. However C3
was found in non-survivor CSF samples (mean 0.04 mgml') and survivor
CSF samples (mean 0.21 mgml''). There was statistically significant
difference between non-survivors and survivors (p < 0.0001) as shown in
figure 5.10. Non-survivor CSF had 5-fold less C3 compared to survivors
indicating a high dependence on C3 during pneumococcal meningitis.
This increased level of C3 in survivors could indicate that C3 is not
present in CSF of non-survivors or it is being rapidly used in non-
survivors. This level of C3 correlated with the levels identified from the
proteomic analysis.
CSF Western Blotfor Transferrin
Transferrin was previously identified as being downregulated 5-fold
in non-survivors. Whenthe samples used in the initial 2D PAGEanalysis
was analysed using Western blot it was observed the there was a 2-fold
reduction in the mean concentration of transferrin in non-survivors
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Figure 5.10 Complement C3 levels in CSF. C3 was notfound in normal
CSF. C3 was found in non-survivor CSF samples (average = 0.04 mgml
') and survivor CSF samples (average = 0.21 mgmt"). There was a
statistically significant difference between non-survivors and survivors (p
< 0.0001). Non-survivor CSF had 5-fold less C3 compared to survivors.
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(mean 0.72 mgml”') compared to survivors (mean 1.42 mgml''). This was
comparable to the mean concentration observed in the pilot 2D PAGE
analysis.
Whentransferrin was analysed in the larger sample size, transferrin
was found in normal CSF (mean 0.08 mgml'), non-survivor CSF
samples (mean 1.25 mgm!) and survivor CSF samples (mean 0.67
mgm’). There wasa statistically significant difference between non-
survivors and survivors (p < 0.0004) as the expression of transferrin in
non-survivors was 2-fold higher than in survivors as shown in figure
5.11. There was also statistically significant difference between
meningitis CSF and normal CSF (p < 0.0001).
5.4 Discussion
In this chapter the technique of Western blot was used to validate
and identify protein targets in CSF. These proteins targets included
proteins associated with cell death and proteins identified in previous
chapters.
5.4.1 Analysis ofProteins Associated with Cell Death
The data obtained from the analysis of apoptosis proteins indicate
that since caspase 3 and AIF are not present in this CSF collection there
was no leakage of cell death material into CSF. This was surprising
considering the level of data in animal models which suggest these
proteins would be identified in CSF (33;189). The sensitivity of detection
was increased by the use of polyclonal antibodies directed against
caspase 3 and AIFat optimum levels of concentration and exposureto the
CSFproteins.
The limit of detection was determined by serial dilution of the
positive control. Both AIF and caspase 3 were detectable in the positive
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Figure 5.11 Transferrin levels in CSF. Transferrin was found in some
normal CSF (mean = 0.08 mgmt’). Transferrin was found in non-
survivor CSF samples (mean = 1.25 mgm') and survivor CSF samples
(mean = 0.67 mgml'). There was a Statistically significant difference
between non-survivors and survivors (p < 0.0004). Non-survivor CSF
had 2-fold higher Transferrin compared to survivors. There was a
statistically significant difference between meningitis CSF and normal
CSF (p < 0.0001).
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cell lysate at protein concentrations as low as 100 ngul'. The
visualisation of the proteins in CSF upon spiking normal CSF with the
control lysate would suggest that the proteins are not being confounded
by larger proteins in CSF. It was possible that small foci of apoptosis did
not result in a large increase of caspase 3 or AIF and this could be
confirmed with suitable post mortem material.
There are alternative explanations for the lack of measurable
apoptotic proteins. An increase in metabolic proteins was previously
identified in chapter 4. Thus an increased metabolic rate may have led to
an increase in AIF and caspase 3, undergoing rapid proteosomal
degradation. These degradation pathways mayoccurvia an ubiquitination
process such as that mediated by X-linked inhibitor of apoptosis (XIAP)
utilizing E3 ubiquitin ligase activity. This enables apoptosis inhibitors to
catalyse ubiquination ofitself, caspase-3, caspase 7 and AIF (190).
Alternatively other cell death pathways may be associated with
pneumococcal meningitis in humans. The existence of multiple programs
of cell death is strongly supported by the vast amount of information
disclosed in recent years. Such pathways may include matrix
metalloproteinases (MMPs) such as MMP9 and reactive oxygen species
(ROS) which contribute to brain damage (191;192). Other pathways for
apoptosis have also been described including; antiribosomal-P
autoantibodies (193), brain-derived neurotrophic factor (BDNF) which
blocks activation of caspase-3, reduces translocation of apoptosis-
inducing factor (AIF), attenuates excitotoxicity of glutamate and
increases antioxidant enzyme activities (34). Also Calpains (cysteine
proteases activated by calcium during apoptotic processes) are known to
activate proteins such caspase-12 after Ca’* overload (194). Caspase-12
has been linked to neuronal degeneration in neurotoxicity animal models
(195). Finally, STATsare a family of latent cytoplasmicproteins that are
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involved in transmitting extracellular signals to the nucleus. Among the
STATs, STAT3 has been shown to be involved in apoptosis (196).
In the meantime, however, the study has implications regarding
treatment with caspase inhibitors and citicoline. These cannot, on the
basis of these data, be expected to improve outcome in patients with
pneumococcal meningitis.
Creatine kinase is a cytoplasmic protein released during tissue
necrosis and CK-BBis the brain specific isotype of the protein. The
presence of CKBB in CSF wasanindicator that there was a low level of
cortical necrosis in the CSF of patients (197). In this analysis the level of
CKBB was expected to show a trend towards being higher in non-
survivors based on other studies of CKBB in meningitis (44;198). In this
analysis, however, the expression of CKBB was low which mayhave had
an effect on the pairwise comparison. A more sensitive technique may be
required to give a more accurate quantification and comparison. It is
unclear whether oxidative modification may have had an effect on the
outcome ofthe analysis (199). However there was noclear association of
CKBBlevels with clinical outcome.
In addition the expression of CKBB did not correlate with the
expression of complement C3. This may indicate that the activities of
these proteins were independent of each other.
5.4.2 Analysis ofProteins ofCSF Origin
Three proteins that were found in chapter 4 were analysed as
proteins of CSF origin. These included RXR gamma,zinc finger protein
179 and chitotriosidase. The concentrations ofall three of these proteins
varied significantly between patient samples.
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It was expected that chitotriosidase would have a high expression in
clinically diagnosed pneumococcal meningitis CSF but the expression
was very low or absent. This protein has been identified as being a
marker of macrophageactivity (200). The lack ofstatistical difference in
the mean concentration of chitotriosidase between non-survivors and
survivors would suggest that there is no clear association of this protein
with macrophageactivity and outcome.
RXR gammaandzinc finger protein 179 are associated with protein
transcription. As they are located primarily in the nucleus their low
expression may be due to an incomplete leakage of cell material into the
CSF. Howeverthe similar levels of these proteins suggest similar levels
of transcription in non-survivors and survivors (144;147).
All three proteins were expressed in higher quantities in non-
survivors than survivors but were not statistically significant. This
expression trend corresponded with the 2D gel expression identified in
chapter 3 for zinc finger protein 179 and chitotriosidase. However RXR
gamma was found to have an opposite expression to that identified in
chapter 3. This difference in expression maybea result of errors from the
2D PAGEanalysis or from the mass spectrometry data.
5.4.3. Analysis ofProteins ofPlasma Origin
Three proteins identified in chapter 4 were selected as proteins of
plasma origin. These three proteins included beta-2-glycoprotein,
complement C3 and transferrin. Unexpectedly the three proteins had
differing results. The mean level of beta-2-glycoprotein expressed was
higher in non-survivors, but there was no statistically significant
difference between non-survivors and survivors. However the mean
levels of C3 were significantly lower in non-survivors (5-fold), whereas
the mean level of transferrin was foundto be significantly higher in non-
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survivors (2-fold). The level of C3 found in ‘normal’ blood plasma
ranges from 0.75 mgm!" to 2.55 mgml”. The levelof transferrin found in
blood plasma ranges from 2.04 mgmI' to 3.06 mgml'. Therefore the
levels of both C3 and transferrin found in CSF were significantly lower
than the levels found in normal plasma. In this analysis the expression
trends of C3 and beta-2-glycoprotein corresponded to the 2D gel
expression identified in chapter 3. Howevertransferrin was found to have
an opposite expression to that observed in chapter3.
Beta-2-glycoprotein (implicated in processes such as coagulation
and atherosclerosis) had a higher mean concentration in non-survivors.
The similar levels between non-survivors and survivors of this protein,
which is associated with the blood clotting cascade, may indicate any
effect on blood clotting during the breakdown of the blood-brain barrier
by beta-2-glycoprotein may not have an association with outcome (150).
Thefirst evidence for a functional role of the complement system in
limiting pneumococcal outgrowth within the CNS was described by
Tuomanenet al (201). In rabbits depleted of C3 by cobra venom factor,
intracisternal inoculation of S. pneumoniae resulted in higher bacterial
titres than in complement-sufficient control animals (202). Thus the
lower levels of C3 in non-survivors may have been due to a greater need
for C3 due to the severity of the illness. Angel et al, however,
demonstrated that type 3 pneumococci express C3-degrading activity
associated with the cell wall (67;203).
In addition pneumolysin can activate the classical complement
pathway. High levels of pneumolysin in CSF may allow pneumococcito
evade opsonophagocytosis by consuming the limited supply of
complementfactors (25).
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Transferrin is a blood iron transport protein. The upregulation of this
protein in non-survivors was most likely acting as an indicator of the
degree to which the blood-brain barrier has leaked. The greater
concentration oftransferrin identified in non-survivors may be associated
with blood-brain barrier damage. This blood brain barrier damage may in
turn be a contributing factor to death from pneumococcal meningitis.
Alternatively transferrin is commonly referred to as a negative acute
phase protein. This is because transferrin levels tend to reduce during
inflammation (204). Therefore an alternative theoretical explanation
could be that survivors have an inflammatory process which is different
to non-survivors. This unknown inflammatory process may be having an
effect on outcome.
5.4.4. Western Blot as a Validation Tool
Although Western blotting is often considered qualitative, it also can
be advantageous as a quantitative method. Quantitative Western blotting
can be used for biological samples where no ELISA is available.
Quantitative Western blotting could also be applied in situations where
certain components in a biological sample may interfere with an ELISA.
Often antibodies directed against one protein may interact with equal
specificity with another closely related protein. In such situations an
ELISA may generate false positives or overestimation of the target
protein abundance. Because Western blotting involves gel
electrophoresis, variations in molecular weight can be exploited to
distinguish and quantify the target protein alone. Even though both
Western blotting and ELISA rely upon immunodetection, they are
different methods and as such are developed using specific antibodies and
recombinant controls. Therefore, variation in absolute protein amounts
may be caused by differences in the recombinant protein used for
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controls, primary antibody specificity, and variations in protein
interactions within each technique.
5.5 Conclusions
Western blot was able to confirm the presence of proteins identified
previously in chapter 4 as well as confirm the presence of 1 of the 3
hypothesised proteins. Western blot however was only able to correlate
the expression data identified from the initial proteomics analysis for the
protein complement C3. The trend identified in the Western blot analysis
appeared to correlate with the expression data identified in the initial
proteomics analysis in 4 of the 6 proteins analysed. In addition to
complement C3, the only other protein which appeared to give a
significant difference between non-survivors and survivors was
transferrin.
The lack of standard apoptosis markers would suggest that standard
apoptotic pathways may be not occurring in this group ofpatients.
Howeverthe presence of CKBBindicates cortical necrosis is present in
some patients with pneumococcal meningitis.
Transferrin levels may indicate that blood-brain barrier damage is
more severe in non-survivors. This may be having an effect on survival
from meningitis. Thus future treatment may need to focus on protecting
the blood-brain barrier from damage. This chapter has also shown that
complement C3 may beplaying a role in survival from pneumococcal
meningitis. Future analysis of corresponding blood samples may provide
confirmation of these results.
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HIGH LEVELS OF PNEUMOLYSIN
AND NEURAMINIDASEAIN CSF OF
PATIENTS WITH PNEUMOCOCCAL
MENINGITIS
Upali R. Goonetilleke Chapter 6
6.1 Introduction
The aim of this chapter was to determine if CSF samples obtained
from patientsclinically diagnosed with pneumococcal meningitis contain
the pneumococcal proteins pneumolysin and/or neuraminidase A.
Asdescribed earlier in Chapter 1, pneumolysin (hemolysin or Ply) is
a 53-kDaprotein producedbyall clinical isolates of S. pneumoniae.It is
a pore forming toxin that requires activation by the addition of thiol-
reducing agents (50). Ply can activate the complement pathway; however,
immunoglobulin is required for Ply to bind to immunoglobulin G
fragmentcrystallizable region (IgGF,). Ply is able to induce leakage of
solutes from erythrocytes, nucleated cells, liposomes, and conductance
through planarlipid bilayers. It is presumed that the pores allow an influx
of waterleading to cell lysis, referred to as colloid-osmotic lysis.
Neuraminidases are a group of enzymes present in pneumococci
which can cleave terminal sialic acid residues from a wide variety of
glycolipids, glycoproteins, and oligosaccharides on cell surfaces or in
body fluids (56). Coma and bacteraemia have been shown to occur
significantly amongst patients with pneumococcal meningitis when the
concentration of N-acetyl neuraminic acid in the cerebrospinal fluid is
high. Pneumococci produceat least 2 distinct neuraminidases; NanA and
NanB (205). NanA is the major neuraminidase and removes terminal
sialic acid from glycoconjugates found on the surfaces ofhost cells (206).
This is believed to expose cryptic receptors for the pneumococcus. There
are several conflicting publications on the precise role of NanA in
pneumococcal disease. However NanA-deficient pneumococci are
significantly less able to colonise and persist in the nasopharynx and
middle ear than NanA-sufficient wild-type pneumococci (57).
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In this chapter four hypotheses were tested; (1) Pneumolysin is
present in CSF, (2) NanA is present in CSF, (3) Poor outcome in
pneumococcal meningitis is associated with the presence of either
pneumolysin or NanA in CSF and (4) Ply and NanA expression levels
changeafter antibiotic treatment.
6.2 Materials and Methods
All chemicals were purchased from Sigma Aldrich (Poole, UK),
VWR (Lutterworth, UK) or Fisher (Loughborough, UK) unless otherwise
stated. General solutions used for the analysis were made using double
distilled water.
6.2.1 Patient Sample Information
The Western blot analysis was of CSF from non-survivors and
survivors. After the initial lumbar puncture (to), a follow up lumbar
puncture was carried after 48 hrs of treatment (tsg). The Western blot
analysis was performed on CSF samples from the non-survivors to
samples (n = 5), non-survivors tg samples (n = 5), the survivors to
samples (n = 24) and the survivors tg samples (n = 24). The Western
blots were conducted at the University of Leicester (Samia Hussain) in
collaboration with the Liverpool School of Tropical Medicine. The low
numberof non-survivor CSF samples was due to the low numberof non-
survivors which survived to the second lumbar puncture. Normal CSF
was obtained from patients who had presented with symptoms and were
found to have no evidence of infection on lumbar puncture (n = 10).
Information regarding the patients is given in table6.1.
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Table 6.1 Clinical Details ofPatients Used in Pneumococcal Protein
 
 
Analysis
Cerebrospinalfluid sample
Control Non-survivors Survivors
N=10 N=5 N=25
Age-yrs mean (+/- SD) 27.8 (9.5) 30.8 (12.7) 31.7 (10.6)
Male sex - number(%) 3 (30) 1 (20) 12 (48)
GCS- mean(+/- SD) 9.4 (4.7) 10.0 (3.5) 11.8 (3.4)
Meantimeto presentation (IQR, hrs) 55.2(12-96)  58.4(18-158) 78.1 (12 — 240)
Previous antimicrobials - number(%) 2 (20) 0 (100) 9 (36)
Microbiologic diagnosis - number(%)
Provenbacterial
S. pneumoniae - 5 (100) 25 (100)
Not meningitis 10 (100)
HIV Positive (% of those tested) - 4 (80) 21 (84)
HIV Not known 10 (100) 1 (20) 4 (16)
Steroid Treatment — number(placebo) - 2 (3) 17 (8)
Survival at day 10 (%) - 5 (100) 25 (100)
 
The table above shows the patient details for the CSF samples analysed
in the Western blot analysis for the presence of Ply and Nand. GCS
Glasgow comascore, IQR interquartile range.
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6.2.2 Antibodies and Control Markers
The antibodies for pneumolysin and NanA were supplied by the
laboratory of Dr. Aras Kadioglu (University of Leicester). Work was
carried out in collaboration between the Liverpool School of Tropical
Medicine and the University of Leicester.
Antibodies
Pneumolysin and NanA antibodies were raised in mice at the
University of Leicester. A summary of the antibodies used in this chapter
are listed in Table 6.2.
Control Markers
Each of the proteins under investigation required a positive protein
marker to confirm the identity of the protein under investigation. Purified
pneumolysin and NanA wasusedasthe positive control markerprotein.
The positive markers were recombinant proteins synthesised at the
University of Leicester.
6.2.3 CSFSample Preparation
CSF samples were stored at -20°C within an hour of sampling andat
-80°C from 24 hrs until analysis.
6.2.4 Western Blot ofCSF
Solutions for Western blotting were made up on the day of the
experiment. The Western blot technique applied in this chapter is
discussed in detail in chapter2.
6.2.5 Statistics
Statistics were calculated using Prism software (v. 5.0, GraphPad,
La Jolla, CA, USA) and R software (R project for statistical computing,
free download from http://www.r-project.org/). Pairwise comparisons
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Table 6.2 Antibodies Used in Pneumococcal Protein Analysis
 
Antibody . Antibody eins . isAntibod Specificit Host Detection Supplierphase y ‘pe pecificity p
Pneumolysin Polyclonal Streptococcus Rabbit ECL Miteeatty etpneumoniae Leicester
Primary
NanA Polyclonal Sireploceneis Rabbit ECL University ofpneumoniae Leicester
Hi? SigmaSecondary conjugate IgG Mouse Goat ECL g .Aldrichsecondary 
The table above shows the antibodies used in this analysis along with the
corresponding conjugate usedin the analysis.
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were performed using an unpairedt-test with Welch’s correction. Charts
were plotted using Prism software.
6.3 Results
6.3.1 CSF Western Blotfor Pneumolysin
The level of pneumolysin was measured in the CSF of non-survivors
and survivors. There wasnostatistical difference between the levels of
Ply in non-survivors and survivors (p = 0.90). There wasnostatistically
significant difference between the levels of Ply in the survivor’s to
samples (mean 0.08 mgml”) and survivor’s tyg samples (mean 0.03
mgml”, p = 0.08). There was also nostatistical difference between the
non-survivors to samples (mean 0.07 mgml'') and the non-survivors t4g
samples (mean 0.07 mgml”, p = 0.97). No pneumolysin (Ply) was
detected in normal CSF as shown in figure 6.1. Ply has been shown to
induce cytotoxicity of the dentate gyrus at a concentration of 0.006 mgml”
' (207). Spreer et al have discovered widespread toxicity of Ply at a
concentration of between 85 ngml” and 180 ngml' (208). The expression
mean discovered in these CSF samples wassignificantly higher than the
concentrations seen in these previousstudies.
6.3.2 CSF Western blotfor NanA
The level of NanA was measured in the CSF samples of non-
survivors and survivors. There wasnostatistical difference between the
levels of NanA in non-survivors and survivors (p = 0.31). There was no
statistically significant difference between the levels of NanA in the
survivor’s to samples (mean 0.48 ugml') and survivor’s tyg samples
(mean 0.33 ugml’, p = 0.30). There wasalso nostatistical difference
between the non-survivors to samples (mean 0.3 ugml’) and the non-
survivors tyg samples (mean 0.28 ugml’, p = 0.91). No NanA was
detected in normal CSF as shown in figure 6.2.
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Figure 6.1 Comparison ofpneumolysin in non-survivors and survivors.
There was noStatistically significant difference between the levels ofPly
in the survivor’s tg samples (mean 0.08 mem!) and survivor’s t4s
samples (mean 0.03 mgmt"). There was also no statistical difference
between the non-survivor’s to samples (mean 0.07 meml') or the non-
survivor's ty; samples (mean 0.07 mgml'). Ply has been shownto induce
cytotoxicity of the dentate gyrus at a concentration of 0.006 mgmt!
represented by the red line A. (207). Spreer et al have discovered
widespread toxicity of Ply at a concentration of between 85 nem! and
180 ngmI' represented by the green line B (208). The expression mean
discovered in these CSF samples was significantly higher than the
concentrations seen in previous studies.
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Figure 6.2 Comparison ofNanA in non-survivors and survivors. There
was no Statistically significant difference between the levels of NanA in
survivor’s tg samples (mean 0.48 ugml') and survivor’s t4g samples
(mean 0.33 ugml). There was also no statistical difference between the
non-survivors to samples (mean 0.3 ugml') and the non-survivors tig
samples (mean 0.28 ugmt").
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6.4 Discussion
In this chapter we have shown that the proteins pneumolysin (Ply)
and neuraminidase A (NanA)are present in CSF of patients clinically
diagnosed with pneumococcal meningitis. Antibiotic therapy provided to
patients successfully sterilised CSF.
6.4.1 Pneumolysin in CSF
There wasnosignificant difference in the mean concentration of Ply
in both non-survivor and survivor CSF samples at initial lumbar
puncture. The mean concentration of Ply identified in these CSF samples
was high compared to Ply concentrations identified in a previous study of
pneumolysin in CSF from patients treated for meningitis (208).
After 48 hrs of treatment the level of Ply in non-survivors remained
consistent with levels of Ply observed in the initial lumbar puncture. In
the CSF samples, taken from patient survivors after 48 hrs of treatment,
there was a reduction in the mean concentration of Ply observed in the
CSF samples from theinitial lumbar puncture. This wasnota statistically
significant reduction.
6.4.2 NanA in CSF
There was no significant difference in the mean concentration of
NanA in both non-survivor and survivor CSF samples at initial lumbar
puncture.
After 48 hrs of treatment the level of NanA in non-survivors
remained consistent with levels of NanA observed in the initial lumbar
puncture. In the CSF samples, taken from patient survivors after 48 hrs of
treatment, there was a reduction in the mean concentration of NanA
observed in the CSF samples from the initial lumbar puncture. This was
not a statistically significant reduction.
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6.4.3 Implicationsfor Therapy
The implications of pneumococcal proteinspersisting in CSF despite
antibiotic therapy might suggest that there is a requirement for treatments
aimedat neutralising toxins in order to improve outcome.
In previous chapters we have demonstrated that the host response is
responsible for proteins with an association with survival. The presence
of pneumococcal proteins in CSF, however, suggests that any future
treatment may benefit from a focus on pneumococcal proteins. This may
indicate that vaccine development targeting specific proteins of
pneumococci may provide a greater protection than host specific target
therapy.
In addition, in chapter 4 it was observed that there was a significant
increase in the level of metabolic proteins present in CSF at the initial
lumbar puncture. The observation that these pneumococcal proteins
remain at a consistent level after 48 hrs would also suggest that these
proteins are evading the standard metabolic pathways associated with
protein degradationas a result of metabolism.
6.4.4 Effect ofPneumolysin on the Host Response
Although the pneumococcal proteins observed in this analysis may
not be predictive of outcome, they are likely to be influencing the host
response. Ply in particular has been significantly linked to neuronalcell
death in animal models. In chapter 3 we were unable to find evidence of
cell death markers in CSF. The presence of Ply could potentially be an
explanation for the widespread levels of neuronal injuries despite no
evidence of cell death markers. The mean expression of Ply was
significantly higher than cytotoxicity levels discovered in previous
studies ofPly.
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The site of Ply production before detection in CSF remains
unknown.It can be hypothesised that Ply is either produced externally of
the blood brain barrier and the toxin aids entry of pneumococciacross the
blood brain barrier. Alternatively Ply may be produced in CSF by
pneumococci leading to the host immune response and neuronal cell
death.
6.4.5 Effect ofNeuraminidase A on the Host Response
It is still not clear what specific role NanA has during pneumococcal
infection. NanA was found to promote pneumococcal brain invasion in a
recent murine model of meningitis (209). However it was not shown to
be an important factor for invasion in another murine model of meningitis
(210).
The lack of effect on outcome observed in this analysis strongly
correlate with O’Toole and Stahl which states that pneumococcal
neuraminidase played no significant role in the pathogenesis of
neurologic dysfunction or death of dogs and, to the extent that findingsin
this modelare applicable in the death of man (211).
The major effects of NanA are most likely associated with earlier
processes of pneumococcal infection such as colonisation of the
nasopharynx and with the spread of the pneumococcus from the
nasopharynx to the lungs. Therefore the presence of NanA in CSF was
most likely a result of the breakdown of the blood brain barrier. It is
likely that NanA has an effect on the host inflammatory response. The
extent of this effect remains to be determined.
6.5 Conclusions
Ply and NanA are present in CSF in high quantities. These proteins
do not appear to be predictive of outcome from pneumococcal
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meningitis. The mean concentration of Ply and NanA appear to remain
constant in CSF from patients of non-survivors after 48 hrs of treatment.
There is trend of reduction of the mean concentration in CSF of both Ply
and NanA in survivors. But the mean concentration of both Ply and
NanA remain high.
The implications of this are that despite surviving meningitis there is
a risk of further complicationsat a later time point. Therefore host protein
targets may not provide an adequate target for therapy. Thus there is a
need to reduce the effect of these pneumococcal proteins. This will most
likely be through developmentofprotein specific vaccines.
None of these proteins were discovered in the previous proteomic
analysis. This could potentially support the finding that there was no
statistical difference in the level of expression of ply and NanA found in
both non-survivors and survivors.
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7.1 Introduction
The information generated in this study implies that there are protein
differences between CSF patient samples who are non-survivors and
survivors. 2D PAGE research has illustrated that several 1000’s of
proteins are present in CSF. These proteins identified may yet form the
basis of clinical point assays to assess the presence and activity of
inflammation in meningitis, with a particular emphasis being placed on
disease monitoring.
The technique of Western blot was used for both hypothesis testing
and validation of mass spectrometry generated target proteins.
Western blot analysis was able to validate the incidence in CSF of
the six proteins selected from the pilot proteomics analysis. Only
complement C3 had a Western blot expression profile which correlated
with the protein expression data observed in the 2D gel comparison
analysis. However4 of these proteins had an expressiontrend in line with
the expression data from the 2D gel analysis.
Transferrin and complement C3 showedstatistically different levels
between non-survivors and survivors. Any association of transferrin and
complement C3 with survival may allow new alternative treatment
strategies for treating meningitis. The breakdown of the blood brain
barrier appears to allow large influx of proteins into the CNS which has
a significant impact on the host inflammatory response. Thusindicating
that protecting the blood brain barrier may improve outcome.
Cell death pathways found in animal models do not appear to
correlate with the human forms of meningitis. Evidence ofthe classical
apoptosis pathway was absent in CSF suggesting that treatment with
apoptosis inhibitors will not have any impactas a treatment strategy. This
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data from Western blot has been unable to support the use ofciticoline
and other methods of treatment. New hypotheses however have been
generated leading to new studies which may suggest future treatment
targets.
The presence of CKBB in CSF may indicate that neuronal necrosis
occurs in meningitis at low levels. The low levels of CKBB suggest that
necrosis may not be a major contributing factor to outcome.
The significant quantities of pneumolysin and NanA in CSFand the
constant levels after 48 hrs of treatment indicate that therapy should be
developed to minimise the efficacy of these pneumococcal proteins. This
data is evidence that protein specific vaccines may prevent further
complications from meningitis.
7.2 Differences between 2D PAGE and Western Blot Expression
Sample variability may account for differences observed in the
expression data from proteomics and Western blot. Variability may be
due to technical “procedural noise” or biological “genetic” variation.
Understanding the degree of variation present in an experimentis central
to all quantitative proteomic investigations. The degree of technical
variation inherent to the 2D gel analysis was assessed using two-methods.
Simple, pair-wise comparisons of spot volumes from two replicate 2D
gels yielded a correlation coefficient (R’), while for numerous repeat 2D
gels the coefficient of variation (CV) (SD/ mean x 100) for all spot
volumes on a gel was determined. Biological variation was measured
using correlation coefficient (R’) and the coefficient of variation (CV)
(SD/ mean x 100) for all spot volumes on a gel from experiment- to-
experiment repeats (inter-experimental replicates). The CV data for both
technical and biological variation was high in both non-survivors and
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survivors. There were extensive protein spots detected that overlap
between survivors and non-survivors which highlights the complexity of
the pathology of meningitis. This will have caused the coefficient of
variation of the protein spots between samples to be high, which is a
possible explanation for the lack of concordance observed between
Western blot and 2D PAGEexpression. Asa result it is probable that this
data underestimated the numbers of small proteins which differ between
the groups due to technical limitations of 2D PAGE. Therefore an
alternative approach may have beento fractionate the CSF and run 2D
PAGEofthe individual fractions. However the volume of CSF which can
be collected from a lumbar puncture is low and this would have been
impractical to carry out as a result. The results of this initial analysis
suggest that improvements to the initial separating method will improve
the level of detection of low abundantproteins in CSF.
There were also technical limitations of the Western blot technique
applied. Western blot analysis is limited by the sensitivity of antibody
detection. The data generated was semi-quantitative and only extreme
differences in protein expression levels were discernable. Quantitative
methods of mass spectrometry such as Isotope coded affinity tagging
(ICAT) and iTRAQ massspectrometry may provide an alternative to the
use of Western blot.
7.3 Absence of Classical Inflammatory Markers
7.3.1 Classical Inflammatory Proteins
Previous protein analysis in meningitis and pneumococcal disease
has often focused on the analysis of proinflammatory proteins including
cytokines, chemokines and other inflammatory proteins. In particular
previous analysis has identified the proteins: IL-1B, IL-6, IL-10, MIF, and
TNF-a, CXC chemokines (ENA-78, GRO, IL-8, IP-10, and NAP-2), CC
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chemokines (MCP-1, MCP-2, and MIP-3a and the growth factors HGF,
IGFBP-1, and MCSF as being significant in the progression of
pneumococcal disease towards fatal outcome from meningitis (133).
Similarly, work on CSF from patients with malaria have previously
identified similar proteins: IP-10, IL-1ra, IL-8, IP-10, PDGFbb, MIP-1B,
Fas-L, sTNFR1 and sTNF-R2 in Ghanian children (100). None of these
proteins were identified in our list of protein differences between non-
survivors and survivors.
7.3.2 Possible Explanationfor the Absence ofInflammatory Proteins
These proteins have previously been identified in a cytokine analysis
of the CSF samples used in this study. Therefore the absence of these
proteinsis unlikely to have a biological cause and is more likely to be due
to technical reasons. Long term storage of samples and inadequate
collection methods required for future proteomics analysis could
potentially account for the absence of cytokine data. Alternatively the
differences in expression of these proteins could be below the limits of
detection for 2D PAGE spotanalysis. It has been demonstrated that a
single spot on a 2D gel of a yeast proteome consists of a minimum of 6
proteins. In humans this number will be much higher. Therefore it is
possible that these proteins were confounded by large quantities of other
endogenousproteins present in CSF from patients clinically diagnosed
with meningitis such as albumin and immunoglobulin. This may also
have influenced the data generated by mass spectrometry. The final
peptide spectra is normalised to the highest abundant peak present in a
peptide mixture. Therefore more abundant peptide ion species present in
a spot digest mixture at the time of mass spectrometry will have inhibited
the final database search. Alternative approaches to global scale protein
analysis such as 2-Dimensional LC-MS/MS may overcome this
limitation.
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7.4 Fixed-Time Point Analysis
There is potential for these techniques to be applied to various time
points in the disease. As discussed, the CSF used in this study was
collected from patients at two time points. CSF was collected by lumbar
puncture from the patient after initial diagnosis and again after 48 hrs of
antibiotic therapy. Protein levels constantly rise and fall. The time
between the patient showing symptoms and presentation may have
influenced the concentration of protein found in CSFatthe initial lumbar
puncture. Analysis at more time points would therefore provide greater
accuracy in the analysis. However this would be difficult and unethical to
obtain.
7.5 Mode of Death in Pneumococcal Meningitis
In this analysis proteins in CSF were analysed for an association
with outcome. This analysis was limited by only using two phenotypes
for comparisoni.e. survival and death. The overall concluding analysis
suggested there was no clear association with outcome of the proteins
analysed in the larger CSF collection other than complement C3 and
transferrin.
In many cases, the clinical outcome at the end of primary
hospitalisation was not definitive and evolved in subsequent weeks and
months.In the initial clinical trial study, the predefined primary outcome
was mortality at 40 days from randomization by intention to- treat
analysis. Secondary outcomes were time to death, combined disability
and death as defined by the Glasgow Outcome Score (1, death; 2,
vegetative state; 3, severe disability; 4, moderate disability; 5, mild or no
disability) at day 40, hearing impairmentat day 40, death at 10 days, and
death at 6 months(2).
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Therefore the conclusion of this study suggests a need to increase
the phenotype groupings used in the comparison analysis. The
phenotypes included in any future studies may include measured
neurological sequelae including hearing deficiency, paresis,
encephalopathy, vestibular syndrome, mental disease, severe headache,
epilepsy and more severe sequelae including vegetative state apallic
syndrome (212).
In other case studies of meningitis which have looked at outcome
(213); the following variables were found to be associated with an
increased risk of unfavourable outcome: age, predisposing infectious
focus, internal comorbidity, > 48 hrs to treatment, coma (low GCSscore),
general compromise (high APACHE II score), hypotension, convulsions,
high CSF protein, low glucose ratio, pneumococcal and Gram-negative
aetiology, and non-meningococcalaetiology.
Independent predictors of unfavourable outcome: internal
comorbidity, > 48 hrs to treatment, coma, hypotension, high CSF protein,
low glucoseratio, and non-meningococcalaetiology (213).
7.6 Hypothetical Example of a Potential Treatment Strategy
The level of transferrin and complement C3 require quantification in
the corresponding plasma samples of the CSF samples used in this study
to confirm the origin of protein expression data observed. This work is
ongoingin the laboratory.
A hypothetical example of how therapy may be developed using the
transferrin data may involve providing treatment to improve the
resistance of the blood brain barrier if transferrin data correlates with
blood brain barrier damage. It may be possible to reduce mortality
associated with pneumococcal meningitis by protecting the blood brain
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barrier. An example of a treatment strategy could involve inhibiting
initial blood brain barrier insults associated with apoptosis of endothelial
cells. Therefore although anti-apoptotic drugs may not have any benefit
in treating pneumococcal disease at the stage of meningitis as discussed
in chapter 5, they may have a beneficial role in providing protection to
the blood brain barrier. It must be noted, however, that blood brain
barrier leakage may allow entry ofcritical defence molecules and cells
such as IgG and neutrophils.
In another hypothetical example of how therapy may be designed
from complement C3 data. Low levels of C3 may require an artificial
method of increasing the levels of C3 to increase pathogenic resistance.
One such method may involve the artificial use of estradiol which has
been demonstrated to induce C3 gene expression (214).
7.7 Future Experiments
Initial protein separation methods are inhibited by the presence of
large endogenous proteins. Therefore in order to detect low abundance
proteins, alternative techniques are required. Such techniques include:
7.7.1 2D LC-MS/MS
To analyse a complex protein sample by LC-MS/MS, a so
called "shotgun sequencing" approach is often used. The sample under
analysis e.g. CSF is digested directly with a suitable protease, commonly
trypsin, and the resulting peptides are separated by HPLCintofractions
(the 1° dimension). These fractions can then be re-separated (the 2m
dimension) by HPLC and characterised by tandem MS. This effectively
increases the detection of low abundanceproteins. Proteins are identified
by matching the MS fragmentation patterns with predicted information
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from genomics or proteomics databases. More peptides can be loaded
and comprehensively analysed with 2D LC-MS/MS(215).
7.7.2 Alternatives to Western Blot
iTRAO
Isobaric tagging of peptides enables high-throughput proteomic
analysis. iTRAQ reagents allow simultaneous identification and
quantitation of proteins in four different samples using tandem mass
spectrometry (MS) (216).
ICAT
Isotope-coded affinity tags (ICAT) is a method which involves
labelling amino acids with chemical probes. These chemical probes
consist of 3 general elements: a reactive group capable of labelling a
defined amino acid side chain (e.g. iodoacetamide to modify cysteine
residues), an isotopically coded linker, and a tag (e.g. biotin) for the
affinity isolation of labelled proteins/peptides. For the quantitative
comparison of two proteomes, one sample is labelled with the
isotopically light (dO) probe and the other with the isotopically heavy
(d8) version (217).
7.7.3 Fourier-Transform (FT) Mass Spectrometry
FT mass spectrometry allows increased sensitivity for the detection
of low abundance proteins. There are two key FT mass spectrometers
available:
LTQ Orbitrap
The linear trap quadrupole (LTQ) orbitrap is the upgradeto the ion
trap system used in this analysis. The benefit of this system is for
database searching and PTM assignment. The Orbitrap is able to identify
many more proteins. High mass accuracy is achieved with the Orbitrap
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mass analyser which has a direct benefit on the quality of protein
identifications. Many more predicted ions are matched in the Orbitrap
spectrum which significantly improves Mascot scores for these peptides
(218).
FTIon Cyclotron Resonance (ICR)
FT mass spectrometers are expensive, but they have a much
improved signal-to-noise ratio (S/N), higher sensitivity and higher
resolution than most other mass analysers (113). FT ICR mass
spectrometers contain a type of ion-trap within which ions are allowed to
circulate in defined orbits over extended periods of time. The behaviour
of the ions is described by the ICR phenomenon(219).
7.7.4 Metabolomics/Metabonomics
Metabolomics is the systematic study of the unique chemical
fingerprints that specific cellular processes leave behind with mass
spectrometry. Metabonomics utilises NMR for the same analysis (220).
Thepresence of large amounts of metabolic proteins would suggest that a
metabolomic analysis of the CSF may provide new answers to
differences in the physiology of CSF with pneumococcal meningitis.
7.8 Final Conclusion
Proteomics has not delivered the expected insights that might drive
the next treatment for pneumococcal meningitis. However 3500 proteins
were found to be different between CSF from patients with
pneumococcal meningitis and CSF from ‘normal’ patients. This would
indicate a high probability that there are moreproteins to be validated and
analysed in pneumococcal meningitis CSF as specific for the disease. In
addition manyofthe proteins that have been discoveredin this sampleset
have yet to be analysed further. Thus they may still provide new
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information regarding the protein biology of CSF during pneumococcal
meningitis.
This global scale analysis of proteins in CSF has a potential
advantage over targeted measurements of proteins in CSF as analysis of
single proteins is both rate-limiting and unlikely to reveal information
regarding the collective protein associations found in pneumococcal
meningitis. Howeveruntil all technical limitations are overcome,targeted
analysis of proteins using Western blot provides the most adequate
method for CSF research. Therefore proteomics in biomarker discovery
in CSF meningitis studies still has some way to go before it becomes a
truly informativetool.
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Appendix A
CSFExamination
Day 1
Appendices
1. Numberthe sample and enter the patient details in the CSF daybook.
2. Appearance (note the appearance of the CSF on front of form):
a) Clear and colourless
b) Hazy
c) Cloudy/ turbid
d) Bloodstained/ clotted
e) Frankly purulent
f) Xanthochromic
3. Samples should be treated as follows:
 
  
Cell . Indian ; .
Appearance Protein Glucose Gram Differential BA CHOC BHIcount Ink
Clear v v v v* v v
Cloudy v v v v* v v v v v
Bloodstained
|
¥ v** v v% ve ve v v
Clotted / y : o
(Blood)          
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* All adult samples and paediatric samples on request ** If not heavily
bloodstained “ If indicated by the cell count
4. Cell Count
a) Using sterile pipette, fill a Modified Fuchs Rosenthal chamber with
CSF
b) Allow the chamberto stand for a few mintoallow anycells to
settle.
c) Count the numberofwhite andred blood cells present in 5 large
squares (see Fig.1, below), under x 40 magnification
 
Fig 1. Modified Fuchs Rosenthal Counting Chamber
d) Note the numberofwhite and red cells as:
i) No cells seen - report 0
ii) Cells seen - report (The number seen)/ mm’e.g. 240/ mm?
e) If there are >40 cells per large square count a single square and
multiply the answerby 5.
f) If there are >40 cells per small square count a single square and
multiply the answerby 80.
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g) If there are too many WBCcells to count accurately, dilute the CSF
1:10, 1:20, 1:50, or 1:100 (as appropriate) in saline. Adjust the count
using the appropriate dilution factor.
h) If the sampleis heavily bloodstained/ clotted report “Not available’
against the RBC countand prepareslides for Gram stain.
5. Protein and Glucose
Using a sterile pipette put a drop of CSF onto the protein and glucose
sections of a urine dipstick. Report as indicated by the dipstick
instructions.
NB: Heavily bloodstained/ clotted samples are should not be
tested as the high RBC content interferes with interpretation
of the strip.
6. White Cell Differential
a) To be carried out on all CSF samples where >20 WBC’sare seenin
the cell count.
b) Make film direct from the CSF if cloudy, or from the spun deposit.
c) Allow to air dry or dry on the edge of a hotplate to avoid cell
distortion.
d) Stain with Wright’s stain (see Identification Tests for method)
e) Examinethe slide under X100, oil immersion and count the number
of polymorphs and lymphocytes present, expressing the result as a %.
7. Gram Stain
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a) To be carried out on all CSF samples where >20 WBCor organisms
are seen in the cell count.
b) Makea film either direct, if cloudy, from the CSF, or from the spun
deposit.
c) Dry the film on a hot plate and Gram stain, (see Identification Tests
for method).
d) Examinethe slide under X100,oil immersion and report the presence
of any organisms and quantify as below:
4 1- 10 organisms/ High Power Field (HPF)
++ 10- 100/ HPF
+++  >100/ HPF
8. Indian Ink Stain
a) Carried out routinely on adult CSF samples; on paediatric samples
only on request.
b) Using a sterile pipette put a drop of CSF onto
a
cleanslide.
c) Put a drop of Nigrosin stain onto the sameslide.
d) Mix the two together and cover with a coverslip.
e) Examinethe slide at x40 magnification.
f) If any capsulated yeast cells are seen, report as Positive and quantify
as below:
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+ 1 per 10 fields
++ 1-10/ field
+++ >10/ field
NB:Report all positive microscopyresults to the ward using the
preliminary result sheets.
9. Ziehl Neilson (To be carried out if advised by theclinical
microbiologist)
a) CSF Culture
i) Spin all CSF’s at 3000rpm for 15min
ii) Decant the supernatantof samples requiring storage,into sterile
labelled cryotube tube and store at —20°C, (see list on wall in MRP
Lab). If there is any doubt about which samples should be stored
discuss with the senior microbiologist.
iii) Discard supernatant of negative samplesinto a discard jar
containing disinfectant.
iv) Culture the deposit as indicated below:
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MEDIA
Y% CHOC %BA “%SAB BHI ISC Y% CLED ISB ISO
(COz) (CO2) (Oz) (Oz) (CO2) (O2) (CO2) (O2)
Allsamples |¥ v
gnr v v ve v v
gpdc " v
gndc v v v
Yeast v v v
nos v v v        gnr-Gram negative rod; gpdc- Gram positive diplococci; gnde- Gram negative diplococci; nos- No
organisms seen
*Only paediatric samples
b) ISC, ISO, and ISB are whole plates used for antibiotic sensitivity
testing (see below)
10. Direct sensitivity Testing
a) Direct antibiotic sensitivity testing should be carried out onall
samples where >++ organisms are seen on the Gram stain.
b) Use the appropriate plate indicated in the table above.
c) Using a sterile pipette put a drop of CSF into the middle ofthe plate.
d) Spread the drop evenly over the surface ofthe plate, in 3 directions
using a sterile cotton wool swab.
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e) After ensuringthat the plate is dry, apply the appropriate antibiotic
sensitivity discs, see table below.
f) Incubate as indicated by BSAC SOP.
 
 
GNR- ISO GNR- ISC GNDC-ISB GPC- ISB
(coliform) (? HD (? Strep)
Ampicillin 10 Ampicillin 2 Tetracycline 10 Tetracycline 10
Ceftriaxone 30
Gentamicin 10
Co-trimoxazole
Chloramphenicol 30
Ciprofloxacin 1  
Tetracycline 10
Gentamicin 10
Co-trimoxazole
Chloramphenicol 10
Ceftriaxone 30  
Co-trimoxazole
Ceftriaxone 30
Chloramphenicol 10
Ciprofloxacin 1
Penicillin 1  
Co-trimoxazole
Erythromycin 5
Chloramphenicol 10
Oxacillin 1
Ceftriaxone 30
Day 2
1. Plates
a) All plates should be examinedafter 24 hours and any growth
identified, see organism identification SOP.
b) If significant organism isolated carry out antibiotic sensitivity testing
for the appropriate organism.
c) Re-incubate for a further 24 hrs if no growth occurs.
NB: Saveall isolates as indicated in Sample storage SOP
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Day 3
1. Plates
a) Examine all re-incubated plates and identify any growth.
b) If no growth and <20 WBC’sreport as: No growthafter 48hrs.
2. BHI Broth
a) Incubate the BHIbroth at 37°C in CO) for 48hrs.
b) If the direct culture plates show no growth after 48hrs, subculture the
BHI. BHI samples should be sub cultured to 4 CHOC and % BA.
Day 4
1. Examine BHIsubculture plates and identify any growth.
2. If no growth occurs re-incubate the plates for a further 24hrs.
Day 5
1. Examine BHIsubculture plates and identify any growth.
2. If no growth report as: No growth after 4 days
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Appendix B
Solutions Used
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
Tris HCl was prepared using 6% Trizma base with the pH
adjusted to 6.8.
1.5 M Tris base was prepared with pH adjustedto 8.8.
PBS was prepared by dissolving 1 tablet of PBS in 200 ml
distilled water.
Tank buffer (composition: 3% w/v Tris base, 14.4% w/v glycine
and 1% w/v SDS).
CBB (composition: 0.125% (w/v) CBB G250, 10% (w/v)
ammonium sulphate, 2% (v/v) orthophosphoric acid and 25%
methanol).
CBB destaining solution 1 (composition: 10% (v/v) acetic acid in
25% (v/v) methanol).
CBB destaining solution 2 (composition: 25% (v/v) methanol).
Fixing solution (composition: 5% (v/v) acetic acid, 40% (v/v)
absolute ethanol).
Silver nitrate solution (composition: 0.2% (w/v)silver nitrate and
0.000025% (v/v) formaldehyde).
Silver developing solution (composition: 3% (w/v) sodium
carbonate, 0.000025% (v/v) formaldehyde and 0.00005% (w/v)
sodium thiosulphate).
Silver stopping solution (composition: 5% (w/v) Trizma base and
2% (v/v) acetic acid).
2x sample buffer (composition: 25% (v/v) Tris-HCl pH 6.8, 40%
(v/v) 10% SDS, 20% (v/v) glycerol, 20% (w/v) Bromophenolblue
and 10% (v/v) 2-mercaptoethanol).
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(13) Towbin transfer buffer (composition: 25mM Tris pH 8.3
consisting of 3% w/v Tris base, 14.4% w/v glycine (192mM)and
20% v/v methanol).
(14) TBS-T (composition: 0.12% w/v Tris base, 0.88% w/v Sodium
Chloride and 0.1% v/v Tween-20 adjusted to pH 7.0).
(15) DAB substrate (composition: 200 ml 1x PBS, 0.05% w/v
diaminobenzadine tetrachloride and 0.03% v/v hydrogen
peroxide).
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Appendix C
Survivor gels
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Appendix D
Additional Information ofMALDIIdentified Downregulated Proteins
 Theoretical Experimental . Sequence: Mascot AccessionProtein name Score >55 Mr/pl Mr/pl Number coverage
(kDa/pH) (kDa/pH) (%)
Phosphoglucomutase-like 63, 6.81protein 5 (PGM5] 57 60, 5.90 Q15124 13
Cancer associated gene 1(CAGE1) 58 64, 6.51 58, 5.30 Q8TC20 23
Chain A, Solution Structure
Of Domain 3 From Human 56 23, 8.22 20, 6.00 P02768 34
Serum Albumin (ALBU)
T-complex protein 1subunit zeta (TCPZ) 81 58, 6.23 66, 5.90 P40227 17
Brain-enriched guanylate
kinase-associated protein 56 65, 5.40 60, 5.80 Q9BUH8 12
(BEGIN)
Glyoxalase domain-
containing protein 4 57 35, 5.40 59, 5.60 Q9HC38 21
(GLOD4)
Retinoic acid receptorRXR-gamma(RXRG) 58 51, 7.55 50, 5.50 P48443 15
Zin: flanger protein’ 59 45, 9.53 43, 5.60 Q3SY53 25(ZIK1)
Serine/Threonine
phosphatase 2-alpha 65K 65 45, 6.13 43, 5.40 P30153 18
regulatory chain (2AAA)
Serine/threonine/tyrosine-
interacting-like protein 1 61 25, 5.44 40, 5.40 Q9Y6J8 45
(STYL1)
Nuclear localized factor 1 57 40, 11.28 40, 4.70 Q8NCU7 21
(NLF1)
Ankyrin repeat domain-
containing protein 42 59 44, 6.01 40, 4.70 Q8N9B4 17
(ANR42)
Eukaryotic translation 38, 5.60
initiation factor 2, subunit 63 — 38, 5.20 Q6IBR8 25
2 beta (EIF2S2)
Ressepatent Emad 56 24, 5.96 20,5.60 Q96AX2 30(RAB37)
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Additional Information ofMALDIIdentified Upregulated Proteins
 
Protein name
Cleavage stimulation
factor (CSTFT) 64 kDa
subunit, tau variant
(CSTFT)
Heterogeneous nuclear
ribonucleoproteins
C1/C2 (HNRPC)
26S protease regulatory
subunit 7 (PSR7)
Brain finger protein
BFP/ZNF179 - human
JC7155
(RING finger protein
112, RN112)
Fascin (Singed-like
protein) (55 kDa actin-
bundling protein) (p55),
FSCN1
Complement C1q tumor
necrosis factor-related
protein 9 (CIQT9)
Tryptophan/serine
protease (YHOO4)
Pyruvate kinase
(KPYM)
NADH dehydrogenase
(ubiquinone) 1 alpha
subcomplex, assembly
factor 1 (Complex
intermediate associated
protein 30) (CIA30)
Mutant desmin (DESM)
Solute carrier family 25
member16) (GDC)
Mascot
Score >55
60
59
60
64
74
64
62
58
57
56
58
Mr/pl
(kDa/pH)
64, 6.79
33, 4.95
49, 5.71
69, 8.88
54, 6.81
31, 7.88
39, 7.95
58, 7.96
37, 7.11
53, 5.21
36, 9.84
Theoretical Experimental
Mr/pl (kDa/pH)
50, 5.60
50, 5.60
50, 5.60
50, 6.20
55, 5.20
40, 5.20
38, 5.10
40, 5.70
37, 7.10
50, 5.90
27, 5.90
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Accession
Number
Q9HOL4
PO07910
P35998
Q9ULX5
Q16658
POC862
Q6UWB4
P14618
Q9Y375
Q549R9
P16260
Sequence
coverage
(%)
12
20
25
21
26
29
28
22
22
18
35
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Additional Information ofLC-MS/MSIdentified Upregulated Proteins
 Theoretical : . Sequence; Experimental AccessionProtein name Mascot Mr/pl Mr/pl (kDa/pH) No coverage
(kDa/pH) (%)
Haptoglobin(HPT) 213 45, 6.13 58, 4.90 P00738 12
Chitotriosidase(CHIT1) 209 50, 6.29 48, 5.81 Q13231 10
Beta-2-
glycoprotein 1 171 40, 8.34 60, 6.00 P02749 10
precursor (APOH)
Lysosomal Acid
Phosphatase 55 48, 7.07 60, 6.00 P11117 18
(PPAL)
 
Additional Information ofLC-MS/MSIdentified Downregulated
Proteins
Theoretical : ,Pravaia name Mascot Mr/pl Experimental Accession Sequence
1 H %(kDa/pH) Mr/pl (kDa/p ) No coverage ( )
ComplementC3 2909 188, 6.02 76, 6.30 P01024 24precursor (CO3)
Alpha 1
antitrypsin 406 58, 4.79 60, 4.70 P01009 16
precursor (A1AT)
Serotransferrin 7 81 0, 5.0 P02787 13(TRFE) 512 9,6 40 5.00
Fibrinogen (FIBB) 809 56, 8.54 36, 4.75 P02675 32
Zinc alpha 2-
glycoprotein 73 a4, S51 35, 5.40 P25311 15
precursor(ZA2G)
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Appendix E
Table ofCombined Mass Spectrometry Data with Gel Spot Data
Fold F 5 , .. Up or . Expression Median Confidence intervalFunctional . Expression
category Protein Bewn in Non- Non-regulation . Survivors ff Survivors Non-survivorssurvivors survivors
Cc | t C3salinl di 477 0.059 0.012  0.002-0.117 (0.005 - 0.020precursor
Cellular ve etodefense Chitotriosidase + 5.14 0.032 0.130 0.000 - 0.066 0.047 - 0.213
proteins Complement C1q
tumor necrosis factor- + 3.42 0.023 0.083 0.009 - 0.038 0.030 - 0.135
related protein 9
Chaperoneg 9“>™PR Proteind V 2.75 0.022 0.008 0.006-0.038 0.002 -0.014subunit zeta
Phasphingeameiass= L 4.87 0.047 0.012 0.010-0.085 0.005 - 0.019like protein 5
Glyexslass aomtalr L 3.57 0.052 0.013 0.000-0.113 0.007 -0.018containing protein 4
Metabolic 265 protenzymes protease 4 2.46 0.009 0.027 0.004-0.014 0.000 - 0.053regulatory subunit 7
NADH dehydrogenase
[ubiquinone] 1 alpha nN 2.76 0.007 0.022 0.002-0.013 0.000 - 0.044subcomplex subunit 9,
mitochondrial
Retineic weld reveptor L 2.46 0.057 0.025 0.023-0.091 0.015 - 0.035RXR-gamma
Cleavage stimulation
factor (CSTFT) 64 kDa * 3.30 0.035 0.118 0.005 - 0.066 0.038 - 0.197
subunit, tau variant
Heterogeneous nuclear
. ribonucleoproteins + 2.46 0.026 0.068 0.011-0.042 0.030 -0.106Translation c1/c2
Zinc finger protein 179 + 2.02 0.033 0.053 0.017 - 0.049 0.023 - 0.083
Zinc finger protein 1 Vv 2.02 0.179 0.075 0.094 - 0.264 0.028 - 0.122
Eukaryotic translation
initiation factor2, JL 2.18 0.051 0.026 0.025 - 0.077 0.009 - 0.044
subunit 2 beta
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Table continued.
. Up or Fold Expression Median ConfidenceintervalFunctional . Expression incategory Protein Down Non- survi Non- survi N: s 7regulation saniivers urvivor: survivors urvivors on-survivors
Serotransferrin \v 5.47 0.117 0.027 0.057 - 0.178 0.005 - 0.050
Transporters Solute carrier
family 25 a 3.97 0.007 0.027 0.001 - 0.013 0.000 - 0.056
(member16)
Beta-2-
glycoprotein 1 sh 3.61 0.029 0.086 0.001 - 0.057 0.010 - 0.161
Glycoproteins precursor
Zinc alpha 2-
glycoprotein VY 2.87 0.061 0.022 0.010 - 0.112 0.008 - 0.036
precursor
G proteins of Ras-relatedthe Ras family protein Rab-37 Y 3.82 0.014 0.005 0.001 - 0.027 0.000 - 0.010
Globins Haptoglobin a” 2.91 0.025 0.050 0.000 - 0.051 0.002 - 0.098
Brain-enriched
guanylate kinase-Kinases accoclatad protein Vv 5.01 0.083 0.019 0.000
-
0.203 0.006 0.032
(BEGAIN)
Pyruvate kinase + 2.06 0.035 0.063 0.014 - 0.055 0.000 - 0.129
protwaseg -"/PHBHHEH/Senne a 3.07 0.007 0.022  0,000-0.014 0.006 - 0.037protease
tysazarnal Mela a 2.68 0.018 0.050  -0.000-0.039 0.016 - 0.084Phosphatase
Serine/Threonine
Phaspbatess 2- 1 2.68 0.104 0.045 0.071-0.138 0.004 - 0.086Phosphatases alpha 65K
regulatory chain
Serine/threonine/
__ fyrosine= ne 2.24 0.195 0.085 0.121-0.269  0,056-0.115interacting-like
protein 1
Fibrinogen y 2.51 0.038 0.013 0.014 - 0.062 0.005 - 0.021
Membraneand Fascin 3.02 0.039 0.095 0.022 - 0.056 0.029 - 0.162
skeletal
proteins Mutant desmin 2.71 0.023 0.053 0.016 - 0.030 0.022 - 0.083
Ankyrin repeat
domain-containing \v 2.51 0.061 0.032 0.029 - 0.093 0.001 - 0.055
protein 42
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Fold Expression Median Confidenceinterval
Functional . Up or Down ExpressionProtein . ‘category regulation in Non- Survivors Non- Survivors Non-
survivors survivors survivors
h titrypsiAlpha 1 antitrypsin Vv 2.97 0.021 0.010  0.005-0.037 0.000 - 0.024precursor
Nuclear localizedethers actor 1 i 2.09 0.097 0.055 0.000-0.210 0.000 -0.118
uusnan Sercrn V 2.01 0.392 0.169  0.130-0.654 0,000 -0.346Albumin
Unknown “moePessceleted ol. 2.45 0.070 0.027 0.028-0.112 0.006 - 0.048gene 1
The table above shows the functional clustering ofthe proteins identified
from mass spectrometry. The expression ofeach protein was based on the
normalized volume of each of the protein spots when identified as a
match in all the gels. This was then usedto create an averaged gel which
involved comparing the non-survivors to the survivor gels. The median of
each normalized volume of the proteins from the samples is shown along
with the 95% confidence intervalsfor the normalized volumes.
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